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communities. The book is designed to be a first step for better practice in the 
treatment of beta thalassemia. Basic and up-to-date knowledge are included in 
this book.
Six contributors and two editors participated in writing this book. The book 
is divided into four sections: Introduction to Beta Thalassemia, Updates of 
Beta Thalassemia, Pathophysiology of Beta Thalassemia and Diagnosis of Beta 
Thalassemia. Many tables and illustrations are included for quick reference in the 
clinical setting.
Section I focuses on the general introduction and a quick overview of beta 
thalassemia. Section II highlights the updates in diagnosis and treatment of beta 
thalassemia. Section III illustrates the pathophysiology dilemma of this disease. 
Section IV displays the diagnostic tools and work up of this disease.
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1. What we need to know about β-thalassemia
Thalassemia is a hereditary, autosomal recessive blood disorder due to partial 
or complete deficiency in the synthesis of or β-globin chains (β-thalassemia) or 
α-globin chains (α-thalassemia) that compose the major adult hemoglobin resulting 
in chronic hemolytic state.
β-Thalassemia is caused by mutations in the HBB gene resulting in decrease of 
the production of β chain leading to excessive accumulation of unpaired α chains 
that aggregate and precipitates along the red cell membranes, causing their damage 
and resulting in intravascular hemolysis. Also, premature destruction of erythroid 
precursors results in intramedullary death and ineffective erythropoiesis and a 
short lifespan of mature RBCs in the circulation. Frequent RBC transfusion is the 
main supportive therapy, leading to excessive accumulation of iron (iron overload), 
a condition that is exacerbated by excessive hemolysis and the increased iron 
reabsorption secondary to ineffective erythropoiesis.
Excessive iron is toxic and catalyzes the generation of reactive oxygen species, 
which in excess are toxic, causing damage to numerous body organs such as the 
heart and liver as well as the endocrine system. Herein, we represent an overview 
on thalassemia regarding the underlying pathophysiology of the disease, clinical 
presentations, and potential therapeutic modalities for the amelioration of its 
complications, as well as new modalities that may provide a cure for the disease. 
Thanks to the significant improvement in therapy, patients with β-thalassemia may 
reach an advanced age.
1.1 β-Thalassemia: types and clinical presentation
In the homozygous state of β-thalassemia which is known as thalassemia major 
represented with severe, transfusion-dependent anemia within the first 2 years of 
life. Also associated with skeletal abnormalities and poor growth, in the hetero-
zygous state of β-thalassemia (trait or minor) causes mild to moderate microcytic 
anemia and not require any specific management. On the other hand, patients in 
whom clinical severity of the disease lies between that of thalassemia major and 
thalassemia trait are classified as having β-thalassemia intermedia and require only 
periodic blood transfusions under special circumstances [1]. Numerous different 
genotypes are associated with β-thalassemia intermedia, such as HbE which is a 
common Hb variant found in Southeast Asia, and this variant is included in the beta 
thalassemia category of diseases. Also, HbS (sickle cell disease) can be presented 
clinically with severe anemia [2].
Repeated blood transfusions resulting in excessive iron deposition and genera-
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1.2 Removal of excess iron
Removal of blood (phlebotomy) is used to remove excess iron in patients with 
normal Hb levels, such as in patients with hereditary hemochromatosis, where iron 
overload is caused by mutations in the iron homeostasis system [4].
Most other patients with iron overload are anemic (Hb < 10 g/dL) and, there-
fore, particularly those who are transfusion dependent, phlebotomy would not be 
optimum and will require iron chelation therapy to decrease iron overload [5].
1.3 Iron chelators
Each unit of transfused red blood cells contains approximately 200 mg of 
elemental iron. In addition to anemia and ineffective erythropoiesis down-regulates 
the synthesis of hepcidin, so the use of iron chelators is mandatory to remove excess 
iron from the plasma as well as from tissues through binding the cheatable, labile, 
iron form and enhancing its excretion through the body excreta.
Three chelation agents are approved for use in the United States. Deferoxamine, 
the first to be used, is given by continuous intravenous infusion or slow subcutane-
ous, infusion through a portable pump. Its main disadvantage is poor compliance 
secondary to its mode of administration [6].
Deferiprone is an oral iron chelator effective in removing excess iron from the 
organs and mainly from the heart. The main potential complication is neutropenia 
that may rarely be followed by agranulocytosis. A liquid formulation has been 
recently introduced [7].
Deferasirox is available as oral dispersible tablets and is considered as an effec-
tive oral chelator, and it reduces liver iron concentration and serum ferritin levels. 
Deferasirox binds iron with high affinity in a 2:1 ratio. Its main side effects are GIT 
upsets in the form of abdominal pain, nausea, diarrhea, liver, and kidney dysfunc-
tion as well as skin rash. A new formulation of film-coated tablets are now available 
with better compliance, as it can be taken with a light meal [8].
1.3.1 Shuttle mechanism
The efficacy of chelation may be improved by the use of a combination of chela-
tors. For example, deferiprone may mobilize iron from tissues into the circulation, 
where deferoxamine binds and facilitates its excretion in the urine this is what is 
called (the “shuttle mechanism”) [9].
1.4 Dyserythropoiesis
Chronic anemia in addition to associated hypoxia in β-thalassemia stimulates 
excessive RBC production which is mediated through release of erythropoietin, 
the main erythropoietic stimulating hormone. This attempt is called “stress 
erythropoiesis” that passes through four steps: expansion of erythroid progeni-
tors, accelerated erythroid differentiation, maturation arrest, and apoptosis. 
Many other factors, for example, transforming growth factor-β and activin 
receptor-II trap ligands contribute to this phenomenon. Binding of EPO to 
its surface receptor on erythroid precursors activates transduction pathways, 
including Jak2/Stat5, which inhibit apoptosis and stimulates proliferation as well 
as differentiation of the new cells. However, this operation is futile termed inef-





Recent advances in understanding the molecular mechanism involved in two 
critical steps of dyserythropoiesis are paving the way to new alternative therapeutic 
targets.
1.5 Novel therapeutic modalities
Several therapeutic modalities aimed at reducing the dyserythropoiesis in thal-
assemia are currently under research. For example, activin receptor-II trap ligands, 
JAK2 inhibitors, induction of the Hsp70 chaperone machinery, reducing α-globin 
synthesis, and stimulation of HbF production [11–15].
1.5.1 Gene modification approach
The hematopoietic stem cells of the affected individual are subjected to gene edit-
ing techniques ex vivo and then reinjected again to the patient for reconstitution [16].
To increase the production of γ-globin lentiviral vectors that express a zinc 
finger protein has been used in order to carry microRNAs that silence its repressors 
or interacts with the promoter of the γ-globin gene 80 [17].
Genome editing of the promoter of BCL11A can be accomplished by several 
nucleases, such as engineered zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and clustered regularly interspaced short palin-
dromic repeats linked to Cas9 nucleases (CRISPR-Cas9) (Figure 1) [18]. Recently, 
it has been shown that ZFN-driven BCL11A enhancer ablation leads to increased 
production of HbF in erythroid progenitors derived hematopoietic stem cell from 
β-thalassemia patient which could be used for autologous transplantation [19]. 
Similarly, CRISPR-Cas9-mediated BCL11A enhancer inactivation in a human adult-
stage erythroid cell line can achieve the same results [20].
Figure 1. 
Mechanism of gene editing.
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Currently, gene therapy represents a novel therapeutic promise, after many 
years of extensive preclinical research for the optimization of gene transfer 
regimen. This is mediated through autologous transplantation of genetically 
modified hematopoietic stem cells, clinical trials being held worldwide have 
revealed that, by re-establishing effective hemoglobin production, patients may 
be rendered transfusion- and chelation-independent and escapes the immu-
nological sequel that normally accompany allogeneic hematopoietic stem cell 
transplantation.
The approach of gene therapy has focused on two mechanisms: first, increasing 
the production of β-globin by the addition of a normal gene or correction of the 
mutated gene; and second, increasing the production of γ-globin by the addition 
of its gene, overexpression of its endogenous activating transcription factors, and 
silencing of its repressors. Studies of gene therapy have utilized mainly lentivirus 
vectors in experimental systems, including cultured CD34 HSCs from β-thalassemia 
patients and β-thalassemia mouse models. Yet the safety profile of such technologies 
is still uncertain [16].
Genomic editing has been demonstrated to modify the β-globin gene. 
Thus, TALEN-mediated gene correction has been used in induced HSCs from 
β-thalassemia patients [21].
1.5.3 Allogeneic hematopoietic stem cell transplantation
Currently, allogeneic stem cell transplant [allo-SCT] remains the only curative 
option for the majority of patients with β-thalassemia major before development of 
iron overload complications [22].
Patients with β-thalassemia major who have good risk features are reasonable 
to anticipate a greater than 90% chance of successful transplant outcome, even 
patients with high risk features, success rates are approaching 80%.
Challenging in allo-HSCT in high-risk patients is mainly related to graft rejec-
tion and risk of transplant-related mortality but nowadays novel modified or 
reduced-intensity conditioning regimens are used to improve the transplantation 
outcome in β-thalassemia patients with cheerful results [23].
Traditionally, completely matched human leukocyte antigen identical siblings 
have been used as donors, and on the other hand, matched unrelated donors have 
also been tried in patients with low risk. Bone marrow has been known as the 
preferred choice of stem cells in non-malignant hematological disorders to reduce 
the risk of GVHD but peripheral blood stem cell graft and cord stem cell when used 
have been reported to be associated with faster engraftment, lower requirement of 
blood product support in the peri-transplant period, and a low incidence of graft 
rejection in patients with low-risk [24, 25].
1.6 Preventive strategies for thalassemia
Despite the great advances in management tools used in β-thalassemia to 
improve the cure rate of the disease, yet the incidence rate of the disease is increas-
ing especially in underdeveloped countries where the prevalence of consanguineous 
marriage is high and low level of standard and sometimes shortage in medical 
resources and supply that limit the early detection of carrier state. Therefore, the 




including prenatal diagnosis, carrier detections, molecular diagnosis, and genetic 
counseling is strongly needed.
1.6.1 Prenatal diagnosis
Recently, prenatal diagnosis is carried out for couples at risk, either in first 
trimester through obtaining fetal material by chorionic villus sampling or in the 
second trimester through cordocentesis or amniocentesis.
One of the main successful procedures in prenatal diagnosis is to study the 
fetal erythroid cells and detection of globin gene mutations. As the first primitive 
erythroblasts appear in embryonic bloodstream around the 4–5 weeks gestations, so 
obtaining fetal material by aspiration of coelomic fluid (celocentesis) followed by 
selection of embryo-fetal erythroid precursors by an anti-CD71 microbeads method 
or by direct micromanipulator pickup of the cells has been extensively improved 
and used by several groups [26, 27].
Nowadays, the possibility of cheaper and safer prenatal diagnosis facilities has 
emerged. Fetal-derived genetic material (cells or cell free DNA) can be obtained 
from the maternal blood and analyzed, which is considered a non-invasive maneu-
ver with no risk of miscarriage and needs neither complicated procedures nor 
highly trained personnel for sampling. This allows future screening for thalassemia 
as well as other genetic diseases [28].
Detection or exclusion of inherited fetal mutations is one of the most important 
approaches that focuses on detection of mutation that are absent from mother’s 
Figure 2. 
Beta-thalassemia: causes, symptoms, and therapeutic modalities. Causes and symptoms are marked in red; and 
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have been used as donors, and on the other hand, matched unrelated donors have 
also been tried in patients with low risk. Bone marrow has been known as the 
preferred choice of stem cells in non-malignant hematological disorders to reduce 
the risk of GVHD but peripheral blood stem cell graft and cord stem cell when used 
have been reported to be associated with faster engraftment, lower requirement of 
blood product support in the peri-transplant period, and a low incidence of graft 
rejection in patients with low-risk [24, 25].
1.6 Preventive strategies for thalassemia
Despite the great advances in management tools used in β-thalassemia to 
improve the cure rate of the disease, yet the incidence rate of the disease is increas-
ing especially in underdeveloped countries where the prevalence of consanguineous 
marriage is high and low level of standard and sometimes shortage in medical 
resources and supply that limit the early detection of carrier state. Therefore, the 




including prenatal diagnosis, carrier detections, molecular diagnosis, and genetic 
counseling is strongly needed.
1.6.1 Prenatal diagnosis
Recently, prenatal diagnosis is carried out for couples at risk, either in first 
trimester through obtaining fetal material by chorionic villus sampling or in the 
second trimester through cordocentesis or amniocentesis.
One of the main successful procedures in prenatal diagnosis is to study the 
fetal erythroid cells and detection of globin gene mutations. As the first primitive 
erythroblasts appear in embryonic bloodstream around the 4–5 weeks gestations, so 
obtaining fetal material by aspiration of coelomic fluid (celocentesis) followed by 
selection of embryo-fetal erythroid precursors by an anti-CD71 microbeads method 
or by direct micromanipulator pickup of the cells has been extensively improved 
and used by several groups [26, 27].
Nowadays, the possibility of cheaper and safer prenatal diagnosis facilities has 
emerged. Fetal-derived genetic material (cells or cell free DNA) can be obtained 
from the maternal blood and analyzed, which is considered a non-invasive maneu-
ver with no risk of miscarriage and needs neither complicated procedures nor 
highly trained personnel for sampling. This allows future screening for thalassemia 
as well as other genetic diseases [28].
Detection or exclusion of inherited fetal mutations is one of the most important 
approaches that focuses on detection of mutation that are absent from mother’s 
Figure 2. 
Beta-thalassemia: causes, symptoms, and therapeutic modalities. Causes and symptoms are marked in red; and 





Faculty of Medicine, Zagazig University, Zagazig, Egypt
*Address all correspondence to: marwazakaria12@yahoo.com
genome that requires DNA quantifications with high sensitivity. Even when the 
parents have the identical mutation, the relative mutation/haplotype approach 
might detect this fetal mutation [29].
1.6.2 Pre-implantation genetic diagnosis
One of the promising approaches is pre-implantation genetic diagnosis of 
cells (PGD) usually single cells, which had been biopsied from oocytes/zygotes or 
embryos obtained by in vitro fertilization and testing it for specific genetic abnor-
mality. PGD assists couples to avoid birth of an affected child and limit the needs 
for abortion. This maneuver aims at delivery of an unaffected newborn. PGD helps 
to identify unaffected embryos for transfer to the uterus [30].
Lastly to conclude, the most likely approach to reduce the patients’ load is effi-
cient prevention, carrier detection, prenatal diagnosis, and genetic counseling, and 
here, we summarize causes, symptoms, and therapeutic modalities in β-thalassemia 
as illustrated in Figure 2.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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Beta-thalassemia is a genetic disease caused by mutations in the β-globin 
gene, resulting in partial or complete deficiency of β-chain. Deficiency of 
β-chain was accompanied by excess unmatched α-globin chains with subsequent 
dyserythropoiesis, oxidative stress, and chronic anemia. The main therapeutic option 
is blood transfusion that improves the anemic status but unfortunately exacerbates 
iron overload status. Till now, the only curative measure is allo-hematopoietic stem 
cell transplantation. New diagnostic and therapeutic modalities are now available. 
These include the preimplantation genetic diagnosis and new tools in the assessment 
of iron overload. Also, new therapeutic options aimed at different targets are being 
developed; for example, therapies that stimulate the synthesis of γ-globin and reduce 
the synthesis of α-globin, as well as the iron excess, dyserythropoiesis, and oxidative 
stress. However, the most likely ideal approach is efficient prevention, through 
genetic counseling, carrier detection, and prenatal diagnosis.
Keywords: β-thalassemia, genetic diagnosis, gene therapy, gene editing, new iron 
chelators, HSCT
1. Introduction
1.1 Updates in diagnosis
1.1.1 Preimplantation genetic diagnosis
Prenatal diagnosis (PND) services are the best practices to control prevalence of 
disease. Wide spread practicing of PND proved effective in reducing the number of 
new cases but on the other hand high abortion rate is hided, which ethically unaccepted 
and for many couples is not a suitable choice. Preimplantation genetic diagnosis is 
considered in a similar fashion to prenatal diagnosis (PGD) and is a strong alternative 
to conventional PND. PGD means genetic profiling of embryos prior to implantation 
(embryo profiling). Its main advantage is that it avoids selective pregnancy termination 
as the method makes it highly likely that the baby will be free of the disease under 
consideration. At present PGD is the only abortion free fetal diagnostic process [1].
The most important indications of PGD [1] are:
• monogenic disorders, e.g., Thalassemias;
• HLA matching (savior baby);
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Technical aspects (Figure 1) [2]:
1. obtaining embryos (assisted reproductive technology)
• controlled ovarian stimulation (COH) to obtain large number of oocytes and
• ICSI/IVF;
2. obtaining biopsy (blastomere or blastocyst biopsy);
3. genetic analysis techniques (PCR, FISH); and
4. embryo transfer and cryopreservation of surplus embryos.
Mutation testing:
PGD method to diagnose beta thalassemia was initially reported in 1998 and 
used either denaturing gradient gel electrophoresis or restriction enzyme digestion 
methods to perform the mutation analysis. The possibility of misdiagnosis due to 
allele drop out (ADO) and DNA contamination is considered to be the major prob-
lems associated with preimplantation genetic diagnosis [3]. Recently, the European 
Society of Human Reproduction and Technology (ESHRE) recommends doing 
both direct and indirect mutation testing using short tandem repeat (STR) linkage 
analysis to achieve the highest accuracy rate [4].
1.1.2 Assessment of iron overload in thalassemia
a. Well established methods for assessment of iron overload in thalassemia [5]:
• serum ferritin;
• liver biopsy for liver iron content (LIC);
• echocardiography, MUGA for cardiac iron; and
• MRI T2* for LIC and cardiac iron.
b. New methods—monitoring of liver iron overload by SQUID:
• Superconducting QUantum Interference Device (SQUID) has been recently 
introduced as an integral part of thalassemia care in few centers worldwide. 
The SQUID allows the thalassemia team to monitor iron concentration in the 
livers of patients and gives them a reliable tool to help adjust medication in 
order to avoid serious complications [6].
Figure 1. 




Mechanism of action of SQUID:
SQUID has high-power magnetic field. Iron interferes with the field and changes 
in the field are detected [6].
Advantages and disadvantages of SQUID:
Advantages and disadvantages of SQUID are listed in Table 1 [6].
1.2 Updates in treatment
1.2.1 Gene therapy
The first obstacle against gene therapy was the extremely complex regulation of 
the globin genes. The second and equally important obstacle has been the lack of an 
optimal vector for gene transfer into quiescent hematopoietic stem cells (HSC) [7].
The first successful gene therapy for β-thalassemia major was in 2007. The 
process is as follow: autologous HSCs are harvested from the patient and then 
genetically modified with a lentiviral vector expressing a normal globin gene. After 
the patient has undergone appropriate conditioning therapy to destroy existing 
defective HSCs, the modified HSCTs are reintroduced to the patient [8].
Two large clinical trials have been recently conducted. The first one was entitled 
“ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells 
Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human 
ß-Globin Gene.” This trial was sponsored by Memorial Sloan Kettering Cancer 
Center. The second one was entitled “A Study Evaluating the Efficacy and Safety of 
the LentiGlobin® BB305 Drug Product in Subjects with Transfusion-Dependent 
β-Thalassemia, who do Not Have a β0/β0 Genotype.” It was sponsored by bluebird 
bio. Expected success awaits these clinical trials (Figure 2) [9].
1.2.2 Gene editing
A newer approach employs genome editing techniques, such as transcription 
activator-like effectors nucleases (TALEN), zinc finger nucleases (ZFN), or the 
clustered regularly interspaced short palindromic repeats (CRISPR) with Cas9 nuclease 
system. They replace the target single-mutation sites with the correct sequence, 
restoring the functional gene configuration. Producing a sufficiently large number of 
corrected genes is the major challenge with this new approach (Figure 3) [7].
1.2.3 Targeting ineffective erythropoiesis
A large number of preclinical and early clinical studies investigating 
erythropoiesis modulators are currently studied. These modulators include 
Advantages Disadvantages
Linear correlation with LIC assessed by liver biopsy Indirect measure of LIC
May be repeated frequently Limited availability
High cost
Highly specialized: needs dedicated technician
May underestimate LIC levels
Table 1. 
Advantages and disadvantages of SQUID.
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Technical aspects (Figure 1) [2]:
1. obtaining embryos (assisted reproductive technology)
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2. obtaining biopsy (blastomere or blastocyst biopsy);
3. genetic analysis techniques (PCR, FISH); and
4. embryo transfer and cryopreservation of surplus embryos.
Mutation testing:
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used either denaturing gradient gel electrophoresis or restriction enzyme digestion 
methods to perform the mutation analysis. The possibility of misdiagnosis due to 
allele drop out (ADO) and DNA contamination is considered to be the major prob-
lems associated with preimplantation genetic diagnosis [3]. Recently, the European 
Society of Human Reproduction and Technology (ESHRE) recommends doing 
both direct and indirect mutation testing using short tandem repeat (STR) linkage 
analysis to achieve the highest accuracy rate [4].
1.1.2 Assessment of iron overload in thalassemia
a. Well established methods for assessment of iron overload in thalassemia [5]:
• serum ferritin;
• liver biopsy for liver iron content (LIC);
• echocardiography, MUGA for cardiac iron; and
• MRI T2* for LIC and cardiac iron.
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• Superconducting QUantum Interference Device (SQUID) has been recently 
introduced as an integral part of thalassemia care in few centers worldwide. 
The SQUID allows the thalassemia team to monitor iron concentration in the 
livers of patients and gives them a reliable tool to help adjust medication in 
order to avoid serious complications [6].
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TGF-β-like molecules or inhibitors of JAK2, Foxo3 activators, HRI-Eif2ap 
stimulators, Prx-2 activators, HO-1 inhibitors, Hsp-70 chaperone induction 
and pyruvate kinase activation. These modulators could soon revolutionize the 
treatment of β-thalassemia and related disorders [10].
Activins, members of TGF-β family signaling, are crucial regulators of 
hematopoiesis and modulate various cellular responses such as differentiation, 
proliferation, migration, and apoptosis. They were observed to ameliorate hematologic 
parameters and improve hematopoiesis in preclinical and early clinical studies [11].
JAK2 plays an important role in the progression and worsening of ineffective 
erythropoiesis. Drugs inhibiting JAK2 activity could reverse ineffective 
erythropoiesis and splenomegaly [12].
1.2.4 Manipulating iron metabolism
Hepcidin is the central regulator of iron homeostasis. Hepcidin inhibitors, 
e.g., ERFE inhibitors are now extensively studied as a possible future treatment 
of iron overload. Induction of iron restriction by means of transferrin infusions, 
minihepcidins, or manipulation of the hepcidin pathway prevents iron overload, 
redistributes iron from parenchymal cells to macrophage stores, and partially 
controls anemia in β-thalassemic mice [13].
1.2.5 New formulation of iron chelators
Patients with transfusional iron overload usually require iron chelation therapy 
(ICT) to help decrease the iron burden and to prevent and/or delay long-term 
complications associated with iron deposition in tissues [14]. There are currently 
three available iron chelators.
1.2.5.1 Deferoxamine
DFO is a hexadentate iron chelator that binds iron in 1:1 complexes. It is given 
subcutaneously using a pump or intravenously as it is not absorbed orally. The dose 
ranges from 20 to 50 mg/kg/day. Though it is an effective drug, limited compliance 
was reported due to the inconvenience of parenteral administration as well as 
infectious complications [14].
1.2.5.2 Deferiprone
DFP was the first oral iron chelator to be used for transfusional iron overload. 
DFP is a bidentate iron chelator that forms 3:1 complexes. The dose ranges from 75 
to 100 mg/kg/day divided over three doses. Treatment with DFP was associated 
with lower myocardial iron deposition compared to deferoxamine. The most 
common adverse effects of DFP include GIT disturbances, elevated liver enzymes 
and arthropathy. The most serious adverse event was neutropenia that was 
recovered after temporary discontinuation of treatment [14].
1.2.5.3 Deferasirox
DFX is another iron chelator. It is a tridentate that forms 2:1 complexes. The 
dose ranges from 20 to 40 mg/kg/day. DFX is a long acting iron chelator. It is given 
once daily which is convenient to most patients. It lacks the DFP’s potentially life-
threatening adverse effect of agranulocytosis. Patient Compliance and adherence to 
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long-term chelation therapy in patients with transfusion-dependent β-thalassemia 
Beta Thalassemia
20
is challenging and critical to prevent iron overload-related complications. Thanks to 
oral iron chelators formulations that allow better compliance and improve patients 
and parents’ adherence to the drugs. Once-daily deferasirox dispersible tablets (DT) 
have proven long-term efficacy and safety in patients ≥2 years old with chronic 
transfusional iron overload. However, barriers to optimal adherence remain, 
including palatability, preparation time, and requirements for fasting state. A new 
film-coated tablet (FCT) formulation was developed, swallowed once daily (whole/
crushed) with/without a light meal [15]. Key differences between deferasirox 
dispersible and film coated tablets are listed in Table 2.
1.2.5.4 Combined iron chelators
Combined DFO and DFP chelation therapy was introduced to manage iron overload 
in patients with suboptimal chelation with maximum DFP doses. A shuttle mechanism 
was proposed to explain the synergistic effect of DFP and DFO. DFP enters cells due to 
its low molecular weight and removes iron, and then passes it on to DFO to be excreted 
in urine and stool. Other combinations like DFX & DFO and DFX & DFP were used to 
maximize efficacy, improve compliance and minimize the side effects [14].
1.2.6 Fetal hemoglobin induction
The main pathophysiological determinant of the severity of β-thalassemia 
syndromes is the extent of α/non-α globin chain imbalance. Thus in β-thalassemia, 
pharmacologically induced increase in γ-globin chains would be expected to 
decrease globin chain imbalance with consequent amelioration of clinical manifes-
tation. Increased production of the fetal γ-globin can bind the excess α-chains to 
produce fetal hemoglobin and hence improve α/β-globin chain imbalance leading 
to more effective erythropoiesis. This partly explains the more favorable phenotype 
in some patients with β-thalassemia intermedia and hemoglobin E/β-thalassemia 
compared with transfusion-dependent β-thalassemia major [16].
Several pharmacologic compounds including: 5-azacytidine, decitabine, 
hydroxyurea (HU), butyrate (short-chain fatty acids), erythropoietin and short 
chain fatty acid derivatives (SCFAD) as fetal hemoglobin-inducing agents had 
encouraging results in clinical trials [16].
1.2.7 Haploidentical hematopoietic stem cell transplantation
Haploidentical transplant approach have a crucial clinical significance in 
patients with beta thalassemia major as it provides a graft source to almost all 
patients who do not have an HLA-matched donors. Haploidentical HSCT is always 
available and parents of children are highly motivated. Haploidentical means 50% 
identity and the problem is the subsequent high risk of graft versus host disease 
(GVHD) caused by donor T cells. Successful haploidentical HSCT depends on 
effective removal of donor T cells [17].
Methods of T-Cell depletion [17]:
1. CD34+ positive selection with immunomagnetic separation which leads to 
enrichment of stem cells;
2. CD3 depletion with immunomagnetic separation which leads to specific 
 reduction of T cells; and
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Dispersible tablet [EXJADE] Film-coated tablet [JADENU]
Dosage forms and 
strengths




• Film-coated blue oval tablet
 ◯ 90 mg (light blue)
 ◯ 180 mg (medium blue)
 ◯ 360 mg (dark blue)
Administration • Once daily on an empty stomach 
≥30 minutes before a meal
• Stir to disperse in water, orange 
juice or apple juice
 ◯ 3.5 oz. liquid for <1 g
 ◯ 7.0 oz. liquid for ≥1 g
• Consume the suspension
• Resuspend residue in small 
amount of liquid and consume 
immediately
• Tablets should not be chewed or 
swallowed whole
• Once daily on an empty stomach 
or with a light meal (<7% fat; ~250 
calories)
• Swallow whole or crush and mix with 
soft foods such as yogurt or apple 
sauce immediately before use
Starting dose • Transfusion-dependent iron 
overload: 20 mg/kg/day
• NTDT: 10 mg/kg/day
• Transfusion-dependent iron overload: 
14 mg/kg/day
• NTDT: 7 mg/kg/day
Titration increments • Transfusion-dependent iron 
overload: 5–10 mg/kg/day
• NTDT: 5–10 mg/kg/day
• Transfusion-dependent iron overload: 
3.5–7 mg/kg/day
• NTDT: 3.5–7 mg/kg/day
Maximum dose • Transfusion-dependent iron 
overload: 40 mg/kg/day
• NTDT: 20 mg/kg/day
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Transcriptional Repressors of Fetal 
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Abstract
During development the human β-globin gene cluster undergoes two switching 
processes at the embryo-fetal and fetal-adult stages, respectively, involving changes 
in chromatin remodeling and in transcriptional regulatory networks. In particular, 
during the perinatal period, the switch from fetal-to-adult globin gene expression 
leads to fetal globin genes silencing and progressive decline of fetal hemoglobin 
(HbF). Impaired hemoglobin switching is associated with hereditary persistence 
of HbF (HPFH), a condition in which the fetal globin genes fail to be completely 
silenced in adult red blood cells. This condition, when co-inherited with hemoglo-
binopathies, has great therapeutic potential because elevated HbF levels can amelio-
rate β-thalassemia and sickle cell anemia. Therefore, there is a growing interest 
about the complex network of factors that regulate fetal globin genes expression. 
Here we discuss the activity of transcriptional repressors of fetal globin genes and 
their potential role as novel therapeutic targets in β-thalassemia.
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1. Introduction
The human β-globin locus consists of five functional genes, HBE, HBG2, HBG1, 
HBD, and HBB, positioned on chromosome 11 in the same order in which they are 
expressed during ontogenesis. This fascinating process that regulates changes in 
the globin gene expression, referred to as globin gene switching, is programmed in 
order to produce different hemoglobin molecules able to meet the changing oxygen 
demand of the developing organism [1]. According to this process, up to the eighth 
week of pregnancy, the embryonic globin gene (HBE) is predominantly expressed 
in the primitive erythroblasts, large nucleated erythroid cells originating in the yolk 
sac. Approximately between the sixth and eighth week of pregnancy, fetal liver 
assumes the hematopoietic role and produces small, enucleated erythroid cells. The 
transition of hematopoiesis from the yolk sac to the fetal liver coincides with the 
switch from the embryonic HBE gene to the fetal globin genes (HBG1 and HBG2). 
At the perinatal period, the bone marrow becomes the principal site of hematopoiesis 
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and generates mature red blood cells. In conjunction with the transition from liver to 
bone marrow hematopoiesis, the second globin gene switch occurs from the fetal-to-
adult globin genes (HBD and HBB) in which fetal hemoglobin (HbF) production 
gradually declines to be replaced by the adult type (HbA) [2].
In the last decades, large research efforts have been devoted to disclose the 
molecular mechanisms underlying this switching process, thus revealing how it 
is under the tight control of complex interactions involving dynamic changes 
in chromatin remodeling as well as in transcriptional regulatory networks. 
Nevertheless, it is rather common that residual amount of fetal globin genes contin-
ues to be expressed throughout adult life with the majority of adults having traces 
of HbF (approximately 1% of total hemoglobin). Impairment of this fetal-to-adult 
hemoglobin switching process, whose molecular basis has been associated with a 
heterogeneous group of inherited defects, leads to hereditary persistence of fetal 
hemoglobin (HPFH) in adult life. Based on clinical and genetic observations that 
HPFH has ameliorative effects in β-thalassemia and in sickle cell anemia (SCD), 
interest has been growing regarding the therapeutic potential of fetal globin gene 
reawakening for these disorders [3–5]. Therefore, much effort is currently under-
way in order to further clarify the molecular basis of hemoglobin switching and 
persistence of high HbF levels in adult life.
Fetal hemoglobin levels are regulated by complex mechanisms involving factors 
linked or not to the β-globin gene (HBB) locus. Several genetic determinants in cis 
to the HBB cluster, including large deletions in the HBB cluster or single nucleotide 
sequence variations in the regulatory regions of the fetal globin genes, are known 
to influence HbF levels [6, 7]. Also, HPFH quantitative trait loci (QTL) unlinked to 
the HBB cluster have been so far identified as being involved in the transcriptional 
control of fetal globin genes. In particular, in the last years, great attention has been 
focused on two genetic determinants, the HBS1L-MYB intergenic region located 
on chromosome 6q23 and the gene coding for the oncogenic transcriptional factor 
BCL11A on chromosome 2p16 that act as main QTLs in influencing HbF levels [8].
Below we discuss the contribution of some of the main cis- and trans-acting 
determinants so far identified in silencing fetal globin gene expression and the most 
recent therapeutic advances based on fetal globin gene reactivation in the treatment 
of hemoglobinopathies.
2.  Regulatory elements and transcriptional factors involved in fetal 
globin gene silencing
2.1  The role of the locus control region (LCR) in chromatin remodeling and 
globin gene switching
The locus control region (LCR), located upstream of the HBE gene, represents 
the major regulatory element in the β-globin gene locus. It plays a key role in the 
switching process by controlling the transcription state of the locus as well as 
the transcription activity of each gene, thus conferring tissue- and stage-specific 
expression of the globin genes [9, 10].
The LCR contains five DNAse I hypersensitive sites (HS 1–5), four of which 
(HS1–HS4) acting as erythroid cell-specific enhancers that are required for proper 
order of activation of the globin genes during ontogeny. However, differently from 
classical enhancer elements, LCR activity is both orientation- and distance-depen-
dent and prevents position effects, therefore also indicating an insulator function 
for this regulatory region [9]. The last hypersensitive site (HS5) has a different role, 
acting as a structural and insulator element. Indeed, in erythroid cells it is closely 
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positioned to another hypersensitive site located at the opposite end of the HBB 
locus (3′HS1) to form an active chromatin hub that allows highly efficient globin 
gene transcription [10, 11].
It is now generally accepted that globin gene switching can occur through not 
mutually exclusive mechanisms involving direct competition between stage-spe-
cific gene promoters for LCR enhancer elements, gene expression activation, and/
or silencing mechanisms promoted by specific activators and repressors as well as 
by epigenetic modifications. By chromatin conformation capture (3C) experiments, 
it has been shown that LCR exerts long-distance transcriptional enhancement 
through dynamic organization of the locus in stage-specific chromatin loops that 
allow the LCR enhancers to be positioned in close proximity of the genes that are 
to be activated [12]. This mechanism is also consistent with the evidence that the 
LCR can interact with only one promoter at a time. These interactions also strictly 
depend on the availability of specific trans-acting factors, non-DNA-binding fac-
tors linked to transcription factors and chromatin facilitators bound to regulatory 
regions of genes to be transcribed (Figure 1).
It has also been shown that epigenetic mechanisms at the HBB locus are involved 
in gene expression control. One of these mechanisms involves DNA and histone 
methylation processes that are generally associated with the repression state of 
globin genes in non-erythroid cells as well as with the erythroid stage-specific 
silencing of globin gene expression within the activated chromatin hub [13]. 
Recently, HS4 in LCR was found to regulate another important stage-specific 
epigenetic mechanism of gene expression control by contributing to drive the 
recruitment of different histone acetylation/deacetylation enzymatic activities 
at specific regulatory regions, with acetylation being a general hallmark of gene 
Figure 1. 
Different molecular mechanisms proposed for LCR long-distance transcriptional enhancement through 
dynamic organization of the locus in stage-specific chromatin loops that allows the LCR enhances to be 
positioned in close proximity of the genes that are to be activated [9–12]. (A) The looping model is based on 
the concept that LCR acts as a holocomplex to stimulate gene expression by looping through the chromatin to 
activate the transcription machinery of a single gene at any given time. In this model, individual globin gene 
promoters are thought to compete for LCR activity. (B) The linking model requires the presence of a continuous 
protein chain from the LCR to the gene to be transcribed involving sequential stage-specific binding of 
transcriptional factors as well as of chromatin modifiers to define the chromatin region to be transcribed. (C) 
The tracking model is based on the idea that a signal such as an enhancer-bound protein complex comprising 
RNA polymerase II or histone modifiers is able to scan the DNA until a promoter is encountered to activate 
gene expression, with inactive genes looped out. (D) In the facilitated-tracking model, concepts of both the 
looping and tracking models are incorporated. In this model, enhancer-bound complexes track along DNA and, 
when the promoter of a to-be-transcribed gene is encountered, a stable DNA loop structure is formed.
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locus (3′HS1) to form an active chromatin hub that allows highly efficient globin 
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It is now generally accepted that globin gene switching can occur through not 
mutually exclusive mechanisms involving direct competition between stage-spe-
cific gene promoters for LCR enhancer elements, gene expression activation, and/
or silencing mechanisms promoted by specific activators and repressors as well as 
by epigenetic modifications. By chromatin conformation capture (3C) experiments, 
it has been shown that LCR exerts long-distance transcriptional enhancement 
through dynamic organization of the locus in stage-specific chromatin loops that 
allow the LCR enhancers to be positioned in close proximity of the genes that are 
to be activated [12]. This mechanism is also consistent with the evidence that the 
LCR can interact with only one promoter at a time. These interactions also strictly 
depend on the availability of specific trans-acting factors, non-DNA-binding fac-
tors linked to transcription factors and chromatin facilitators bound to regulatory 
regions of genes to be transcribed (Figure 1).
It has also been shown that epigenetic mechanisms at the HBB locus are involved 
in gene expression control. One of these mechanisms involves DNA and histone 
methylation processes that are generally associated with the repression state of 
globin genes in non-erythroid cells as well as with the erythroid stage-specific 
silencing of globin gene expression within the activated chromatin hub [13]. 
Recently, HS4 in LCR was found to regulate another important stage-specific 
epigenetic mechanism of gene expression control by contributing to drive the 
recruitment of different histone acetylation/deacetylation enzymatic activities 
at specific regulatory regions, with acetylation being a general hallmark of gene 
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Different molecular mechanisms proposed for LCR long-distance transcriptional enhancement through 
dynamic organization of the locus in stage-specific chromatin loops that allows the LCR enhances to be 
positioned in close proximity of the genes that are to be activated [9–12]. (A) The looping model is based on 
the concept that LCR acts as a holocomplex to stimulate gene expression by looping through the chromatin to 
activate the transcription machinery of a single gene at any given time. In this model, individual globin gene 
promoters are thought to compete for LCR activity. (B) The linking model requires the presence of a continuous 
protein chain from the LCR to the gene to be transcribed involving sequential stage-specific binding of 
transcriptional factors as well as of chromatin modifiers to define the chromatin region to be transcribed. (C) 
The tracking model is based on the idea that a signal such as an enhancer-bound protein complex comprising 
RNA polymerase II or histone modifiers is able to scan the DNA until a promoter is encountered to activate 
gene expression, with inactive genes looped out. (D) In the facilitated-tracking model, concepts of both the 
looping and tracking models are incorporated. In this model, enhancer-bound complexes track along DNA and, 
when the promoter of a to-be-transcribed gene is encountered, a stable DNA loop structure is formed.
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activation and, on the contrary, deacetylation being associated with gene repression 
mechanisms. More recently, it has also been found that histone acetylation, besides 
activating high-level gene transcription, also contributes to the formation of 
specific chromatin looping leading to an open chromatin configuration at the HBB 
locus. Furthermore, it has also been proved that loss of histone acetylation increases 
methylation both in the LCR and in fetal globin genes, thus reinforcing the silenc-
ing mechanisms of these epigenetic modifications [11].
Chromatin looping, transcriptional protein complexes, and epigenetic modifica-
tions require a large array of protein factors whose list grows continuously, thus 
providing deeper insights into these mechanisms. The role of some of the most 
relevant of them will be herein discussed.
2.2 Cold-shock domain protein A (CSDA)
Cold-shock domain (CSD) proteins have been reported to be largely involved in 
a variety of gene expression regulation processes such as transcriptional activation 
and repression or posttranscriptional mechanisms including mRNA packaging, 
transport, localization, and stability. In these proteins the CSD domain does not 
bind to unique DNA sequence motifs, but it is able to recognize intramolecular 
triplex H-DNA structures, commonly generated by CT-rich sequences. The cold-
shock domain protein A (CSDA), also known as DNA-binding protein A (dbpA), is 
a protein with a molecular weight of about 60 kDa [14]. The CSDA gene is located 
at position 12p13.1 and comprises 10 exons spanning a 24-kb genomic region. CSDA 
consists of three structural domains: an alanine/proline (AP)-rich N-terminal 
domain followed by a central cold-shock domain (CSD) and a C-terminal domain, 
containing four alternating clusters of basic and acid amino acids. The DNA-
binding domain is encoded by exons 1–5. Within this region, the cold-shock 
domain, comprising about 70 amino acid residues, is encoded by exons 2–5 [14]. 
A RNP1 motif [GA] – [FY] – [GA] – [FY] – [IVA], conserved in this protein fam-
ily [15], is present in the 3′ end of exon 2. The exon 6, encoding 69 amino acids, 
is alternatively spliced. The C-terminus (exons 6–9) C-terminal domain mediates 
protein-protein interactions [16]. Alternative splicing of exon 6 results in two main 
isoforms, namely, CSDA isoform a and isoform b, respectively, showing differ-
ent C-terminal domains and thus potentially able to take part to specific protein 
complexes [14, 16].
Figure 2. 
Binding of the transcriptional repressor CSDA to the −200 promoter region of HBG2 in adult erythropoiesis is 
impaired by HPFH mutations [18–22].
29
Transcriptional Repressors of Fetal Globin Genes as Novel Therapeutic Targets…
DOI: http://dx.doi.org/10.5772/intechopen.90762
CSDA acts as a repressor of many cellular genes including the human granulocyte-
macrophage colony-stimulating factor (GM-CSF), an important hematopoietic 
growth factor [17]. More recently, it has been demonstrated that CSDA acts as a repres-
sor of fetal globin gene expression by binding a region −200 bp upstream of the HBG2 
gene [18] (Figure 2). This region consists of alternating homopurine and homopyrim-
idine tracts generating an H-DNA structure [19]. Mutations (HBG2 -200 C → G, −202 
C → T, −196 C → T e − 195 G → A) that destabilize the intramolecular triplex struc-
ture have been found associated with HPFH [20]. Previous studies had suggested that 
disruption of the intramolecular triplex could abolish CSDA binding sites conditions 
in this HBG2 promoter region [19, 21, 22], thus leading to persistent expression of fetal 
hemoglobin in adult life [19]. Based on RNA interference (RNAi) and overexpression 
studies in human erythroleukemia K562 cells and in primary erythroid cells, CSDA 
was demonstrated to directly play a repression role in HBG expression [18]. In fact, 
down- and up-modulation of CSDA levels consistently corresponded to variations of 
HBG expression levels: CSDA knockdown induced by RNAi resulted in significantly 
increased expression of HBG genes, whereas its overexpression was associated with 
reduced HBG mRNA levels. Also, chromatin immunoprecipitation (ChiP) analysis 
in K562 cells showed that CSDA interacts with this promoter region, thus confirming 
that CSDA modulates HBG expression at the transcriptional level [18]. Subsequently, 
it has been proposed that NF-kB and histone deacethylase 2 (HDAC2) interact with 
CSDA to form a multiprotein complex which take part to the regulation of HBG2 
expression by modulating local chromatin conformation [23], thus highlighting the 
relevance of the role played by CSDA in fetal globin gene expression and shedding 
novel light on the molecular mechanisms involved in globin gene switching (Figure 3).
2.3 B-cell lymphoma/leukemia 11A (BCL11A)
The B-cell lymphoma/leukemia 11A (BCL11A) is a multiple zinc-finger transcrip-
tion factor encoded on chromosome 2p15, previously reported as being implicated 
in B-lymphocyte production and neurodevelopment [28]. More recently, genome-
wide association studies (GWAS) identified single nucleotide polymorphisms 
(SNPs) in intron 2 of the BCL11A gene as strictly associated with HPFH conditions, 
thus revealing a hitherto unexplored but crucial role of BCL11A in HbF silencing 
[29]. Indeed, as was later demonstrated, such SNPs are able to disrupt erythroid-spe-
cific enhancer elements required for high-efficient expression of the BCL11A gene 
[30]. Similarly to CSDA, BCL11A knockdown experiments performed in K562 cells 
and in human erythroblasts led to increased expression of fetal globin genes, thus 
providing further evidence that this factor acts as a repressor of HbF expression.
In the last years, many efforts have been aimed at clarifying the repression 
mechanism exerted by BCL11A at the HBB locus. At this regard, an important 
contribution has been provided by the identification of the multiprotein complex 
Figure 3. 
Transcriptional repressor mechanisms of fetal globin genes in adult erythropoiesis involving BCL11A and 
CSDA multiprotein complexes [23–27].
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in K562 cells showed that CSDA interacts with this promoter region, thus confirming 
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interacting with BCL11A that includes GATA-1, FOG-1, RUNX1, KLF1, and SOX6 
[24, 31, 32]. In addition, further insights have been provided regarding the BCL11A 
repression mechanisms by demonstrating how these protein complexes drive the 
recruitment of a variety of epigenetic factors such as the nucleosome remodel-
ing and deacetylase (NuRD) repressor complex, histone deacetylase (HDAC1 
and HDAC2), lysine-specific demethylase (LSD1), and DNA methyl-transferase 
(DNMT1) [25–27] (Figure 3). ChiP analysis also revealed binding sites for BCL11A 
at regulatory elements within the LCR, as well as at the promoter regions of both 
embryonic and fetal globin genes and in an intergenic region between the fetal and 
adult genes, thus indicating that these protein complexes are directly involved in 
fetal globin gene silencing as well as in long-range interactions that contribute to 
reshape chromatin loop domains in order to spatially separate the fetal and adult 
globin genes from the transcriptional machinery and, in the meantime, to promote 
long-range LCR interactions with the adult globin genes [33–35].
2.4 Krüppel-like factor 1 (KLF1)
The transcription factor KLF1 (Krüppel-like factor 1), formerly known as 
erythroid Krüppel-like factor (EKLF) for its restricted expression in erythroid cells 
and its similarity to the protein encoded by the Drosophila segmentation Krüppel 
gene), plays a multifunctional role in the regulation of a variety of cellular events 
leading to erythroid differentiation, including erythroid lineage commitment, 
heme synthesis, and globin gene switching [36–39].
The KLF1 gene (~3kb) is located on chromosome region 19p13.2 and consists 
of three exons encoding a 362 amino acid protein with an N-terminal region rich 
in proline residues and containing two short transactivation domains (TAD1 
and TAD2) and a C-terminus with three highly conserved Cys2/His2 zinc-
finger domains (ZF1, ZF2, and ZF3) that interact with the DNA sequence motif 
5′CCMCRCCCN3′ located in CACCC boxes and GC-rich elements in the regulatory 
regions of its target genes [38].
In the HBB cluster, KLF1 exerts a dual role in fetal-to-adult globin gene switch-
ing by different mechanisms. On one hand, as also evidenced by studies on (+/−) 
KLF1 transgenic mice [12], KLF1 contributes to directly activate the HBB gene in 
adult life by inducing the formation of chromatin loops that relieve the HBB gene 
from competition with the HBG genes and favor interactions of the HS2 and HS3 
sites in the LCR with the HBB promoter region [40]. On the other hand, KLF1 
indirectly contributes to silencing fetal globin gene expression through the activa-
tion of BCL11A, a repressor of HBG globin genes transcription, as described above. 
To date, more than 65 loss-of-function mutations have been reported for the KLF1 
gene, most of which are missense mutations found largely within the three zinc-
finger domains [41]. Mutations in the KLF1 gene have been reported to interfere 
with its functions in the erythropoiesis process, thus leading to a wide range of 
hematological phenotypes, including high borderline HbA2 levels, mild microcyto-
sis, and/or hypochromia but also, importantly, with persistence of fetal hemoglobin 
expression in adult life. It is thus not surprising that, although identification of 
carriers of KLF1 mutations may be quite challenging because their phenotypic 
traits do not present relevant clinical implications, the majority of KLF1 muta-
tions have been detected in populations at risk for hemoglobinopathies according 
to the evidence that defective KLF1 activity can lead to impaired HbF silencing 
with ameliorating effects in SCD and in β-thalassemia. Therefore, KLF1 mutations 
have been considered as a natural model of impaired hemoglobin switching, and, 
accordingly, KLF1 has been proposed as a new potential therapeutic target in these 
diseases [39, 42].
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2.5 Myb
Myb is a DNA-binding transcriptional regulator of approximately 75 kDa that 
plays a crucial role in hematopoiesis and erythropoiesis. The MYB gene is located 
on chromosome 6q23 and codifies for a protein with three functional domains: a 
highly conserved DNA-binding domain (DBD) near its N-terminus that recognizes 
and binds the consensus sequence PyAACG/TG, a central transactivation domain 
(TAD), and a C-terminal negative regulatory domain (NRD) containing a leucine 
zipper motif important for homodimeration and for protein interactions [43].
A large variety of proteins have been identified so far as Myb interactors: DNA-
binding transcription factors that directly bind Myb, transcriptional coactivators 
that mediate interactions with the transcriptional machinery, and protein factors 
that are able to modify Myb activity. Each of these of protein factors can act either 
as activator or repressor of Myb function, depending both on cell type and protein 
microenvironment [43].
In the last decade, a GWAS approach led to the identification of a set of single 
nucleotide polymorphisms at the HBS1L-MYB intergenic region, subsequently iden-
tified as HMIP-2, displaying a strong association with persistence of fetal hemoglo-
bin in adult life [44–46]. By demonstrating that these SNPs disrupt binding sites at 
key erythroid enhancers and cause reduced Myb expression levels, it was possible 
to provide an explanation for the association of the HMIP-2 region with HbF levels 
and, in the meantime, to identify Myb as a negative regulator of fetal globin genes.
Notably, further evidence of the repressive role of Myb on fetal globin gene 
expression has also been provided by clinical observations of higher HbF levels in 
patients with trisomy 13. It has been demonstrated that in this condition, the high 
HbF levels are related to the dysregulation of two microRNAs, miR-15a and miR-
16-1, both localized on chromosome 13q14, which mediate Myb downregulation 
through the binding to its 3′-UTR region [47].
Nevertheless, in spite of all these evidences, the mechanism of repression of 
fetal globin genes exerted by Myb is not fully understood. It has been proposed that 
Myb could regulate HbF expression by two not mutually exclusive mechanisms: by 
activating the expression levels of fetal globin gene repressors as BCL11A and KLF1 
or by controlling the kinetics of erythroid differentiation. In fact, low Myb levels 
have been found associated with reduced levels of these HBG repressors and also 
with accelerated erythroid differentiation leading to the release of early erythroid 
progenitor cells that are still synthesizing predominantly HbF [48]. Furthermore, 
it has also been found that Myb and BCL11A cooperate with DNMT1 to achieve 
developmental repression of embryonic and fetal globin genes in adult erythropoi-
esis [25], thus supporting the evidence that the network of factors involved in fetal 
globin gene silencing converges on common mechanisms and cooperates at different 
levels to sustain globin gene switching and to reinforce the process of HbF repression.
3. Novel therapeutic approaches for β-thalassemia
Currently, clinical management of β-thalassemia and SCD patients is largely 
dependent on regular blood transfusions associated with chelating agents for the 
treatment of systemic iron overload. Indeed, except for allogeneic transplantation 
strategies, whose favorable outcome is anyway restricted to the availability of a well-
matched donor, or for the more recent haploidentical transplantation option that 
however carries substantial risks, no other curative option is currently available for 
hemoglobinopathies. Therefore, due to the relevant global health burden of these 
diseases, there is still a great need for effective and definitive large-scale treatments.
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In the last decades, given the ameliorative effects of elevated HbF levels that 
can lead to decreased hemoglobin polymerization in SCD as well as to reduced 
α-chain imbalance in β-thalassemia, a great deal of effort has been devoted to the 
development of new therapies aimed at reactivating fetal globin gene expression. 
Therefore, according to the evidences that hypo-methylated DNA and hyper-acety-
lated histones are well-known epigenetic marks of transcriptionally active regions, 
inhibitors of DNA methyltransferase (DNMT) and histone deacetylase (HDAC) 
have been developed as novel pharmacologic approaches to support transfusion 
therapy. Among the first drugs to be identified, 5-azacytidine and decitabine were 
found to induce increased HbF levels through DNA hypo-methylation process. 
Subsequently, the use of hydroxyurea (HU) was also investigated as a promising 
HbF inducer agent in adults with severe SCD. Although the mechanism through 
which HU induces HbF reactivation is still not completely understood, HU treat-
ment was found to increase HbF levels and reduce HbS polymerization, thus 
improving clinical symptoms and quality of life of these patients. Another epigen-
etic approach was also exploited through the use of HDAC inhibitors, including 
butyrate and its derivatives that have been demonstrated to stimulate HbF produc-
tion in β-thalassemia patients [49].
More recently, many hopes were directed toward the development of gene 
therapy procedures designed to introduce a normal copy of the β-globin gene by viral 
vectors that offer the advantages of long-term benefits and, even more importantly, 
being based on autologous transplant, do not require a matched donor. However, in 
spite of great expectations for a rapid development of this approach, for many years 
it proved a difficult goal, and only recently it has been successfully introduced in clin-
ical practice. Notably, during the last years, additional promising therapeutic options 
have been provided by progress in gene-editing technologies, including the clustered, 
regularly interspaced, short palindromic repeat (CRISPR)-CRISPR-associated 9 
(Cas9) (CRISPR-Cas9) tool, designed to introduce highly specific genome modifica-
tions for either gene disruption or correction [48, 50, 51]. At the same time, progress 
in understanding the molecular mechanisms underlying fetal globin gene silencing 
has contributed to identify several potential molecular targets, thus paving the way 
to novel therapeutic approaches for hemoglobinopathies that, besides correcting the 
defective β-globin gene, are now aimed at editing genomic segments that regulate 
fetal hemoglobin synthesis in hematopoietic stem cells (HSCs).
Interestingly, some of the most promising editing strategies for hemoglobin-
opathies that are being pursued include the reactivation of fetal globin genes that 
could be achieved either by silencing fetal globin gene repressors or, alternatively, 
by introducing known HPFH mutations in the HBB cluster. Since the beginning, 
targeting Myb or KLF1 appeared to be rather problematic given the pleiotropic roles 
played by these two factors in hematopoiesis and in erythropoiesis, respectively, 
whereas BCL11A emerged as one of the most appropriate candidate to be silenced, 
given its well-recognized role in HbF repression [48, 50, 51]. However, ubiquitous 
BCL11A knockdown rapidly turned out to be an unsuccessful strategy, given its role 
in other biological pathways including neuronal and B-lymphocyte development 
[28]. Consequently, alternative strategies are being underway focused on reducing 
its expression selectively in erythroid cells that could be achieved by disruption 
of its intronic erythroid-specific enhancer without affecting non-erythroid cells 
[51]. A similar approach could also be used to tune down Myb expression levels by 
editing SNPs at the HBS1L-MYB intergenic region that are known to disrupt the 
structure and the functionality of erythroid-specific enhancers causing reduced 
Myb expression levels. Anyway, other repressors such as CSDA or erythroid-
specific cofactors could represent potential suitable candidates to be considered for 
novel genome-editing strategies. Furthermore, genome-editing procedures leading 
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to the introduction of KLF1 mutations that emerged as a natural model of impaired 
hemoglobin switching or HPFH mutations in the regulatory regions of fetal globin 
genes have been proposed either as alternative or supportive therapeutic strategies 
to induce clinically significant increases in HbF levels [48, 50, 51].
4. Conclusions
The research in this field should be immediately focused on the development of 
safe, effective drug therapies that can be accomplished through fetal globin gene 
induction and at the same time on the prospect of cures through bone marrow 
transplantation using the promise of genome-editing strategies that will bring 
a vastly improved quality and quantity of life to patients who suffer from these 
devastating disorders.
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Nutraceutical Benefits of Green 
Tea in Beta-Thalassemia with Iron 
Overload
Pimpisid Koonyosying, Suthat Fucharoen  
and Somdet Srichairatanakool
Abstract
Secondary iron overload in patients with β-thalassemia is caused by multiple 
blood transfusions and increased iron absorption. Most of them die from cardiac 
arrest and infections while others from oxidative tissue damage and organ dysfunc-
tion. Under high saturation of transferrin with iron, redox-active iron such as non-
transferrin-bound iron, labile plasma iron, and cellular labile iron pool is prone to 
the production of reactive oxygen species, oxidized biomolecules, oxidative tissue 
damages, and complications. Iron chelation therapy and antioxidant supplementa-
tion are a supportive treatment for patients’ better quality of life and life expec-
tancy. Green tea (Camellia sinensis) extract (GTE) is abundant with polyphenols, 
mainly epigallocatechin-3-gallate and nutraceuticals, which are beneficial for cell 
functions and health. Importantly, GTE possesses antioxidant, free radical scav-
enging, metal-chelating, anti-hemolysis properties in cell cultures, animals, and 
humans. This article has reported modes of actions and challenged such wonderful 
properties of green tea used to remove excessive iron, scavenge harmful radicals, 
restore malfunctions of vital organs, and treat patients with β-thalassemia with iron 
overload. Infeasibility and sustainability, the benefits of green tea can be applied for 
use in other diseases with iron toxicity and oxidative stress.
Keywords: Camellia sinensis, catechins, green tea, iron, oxidative stress, thalassemia
1. Introduction
Erythrocytes or red blood cells (RBC) play a crucial role in oxygen carrying and 
transportation. The main component of RBC is hemoglobin (Hb) which consists of 
four subunits of globin chain with heme group at the center of each subunit. The types 
of Hb can be defined by different globin chain compositions. For instances, hemoglo-
bin A (HbA) consists of two α-globin chains and two β-globin chains (α2β2), which is 
found in high levels of normal human blood. Hemoglobin A2 (HbA2) consists of two 
α-globin chains and two δ-globin chains (α2δ2), which is found in low levels of normal 
human blood and may be increased in the blood of patients with β-thalassemia. Fetal 
hemoglobin (HbF) consists of two α-globin chains and two γ-globin chains (α2γ2), 
which is present in high levels in fetal and newborn human blood. Likewise, embry-
onic hemoglobin such as hemoglobin Gower I (ζ2ε2) and Gower II (α2ε2) are produced 
in early life and switched to other Hb types during development.
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Abstract
Secondary iron overload in patients with β-thalassemia is caused by multiple 
blood transfusions and increased iron absorption. Most of them die from cardiac 
arrest and infections while others from oxidative tissue damage and organ dysfunc-
tion. Under high saturation of transferrin with iron, redox-active iron such as non-
transferrin-bound iron, labile plasma iron, and cellular labile iron pool is prone to 
the production of reactive oxygen species, oxidized biomolecules, oxidative tissue 
damages, and complications. Iron chelation therapy and antioxidant supplementa-
tion are a supportive treatment for patients’ better quality of life and life expec-
tancy. Green tea (Camellia sinensis) extract (GTE) is abundant with polyphenols, 
mainly epigallocatechin-3-gallate and nutraceuticals, which are beneficial for cell 
functions and health. Importantly, GTE possesses antioxidant, free radical scav-
enging, metal-chelating, anti-hemolysis properties in cell cultures, animals, and 
humans. This article has reported modes of actions and challenged such wonderful 
properties of green tea used to remove excessive iron, scavenge harmful radicals, 
restore malfunctions of vital organs, and treat patients with β-thalassemia with iron 
overload. Infeasibility and sustainability, the benefits of green tea can be applied for 
use in other diseases with iron toxicity and oxidative stress.
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Human β-thalassemia is characterized by mutations of β-globin gene, resulting 
in deficient production of the β-globin chains of Hb molecule (ineffective erythro-
poiesis) and chronic anemia. Over 200 mutations have been identified in this gene, 
and the type of mutations can influence the severity of the disease. Blood transfu-
sions aim to maintain normal Hb levels to prevent tissue hypoxia, whereas repeated 
blood transfusions lead to the inevitable consequence of iron accumulation in the 
body. Iron deposition occurs considerably in almost all tissues but is primarily 
located in the spleen, liver, heart, and endocrine glands. Besides ferritin iron and 
hemosiderin, the uncommon forms of iron including labile or transient iron pools 
(LIP) in the tissues, nonheme iron in RBC membrane, and non-transferrin-bound 
iron (NTBI) and labile iron pool (LPI) in plasma appear to be redox-active and 
subsequently generate reactive oxygen species (ROS) via Haber-Weiss and Fenton 
reactions. The ROS can oxidize biomolecules, causing oxidative tissue damage, 
organ dysfunctions, complications, and death. Effective iron chelation needs giving 
to counteract the resulting iron overload and prevent oxidative tissue damage. So 
far, monotherapy or combined therapy with iron chelators such as desferrioxamine 
(DFO), deferiprone (DFP), and deferasirox (DFX) has been used for the treat-
ment of patients with β-thalassemia with iron overload, but they present some side 
effects. Modified medical regimens such as adjunctive iron chelator and antioxidant 
and drug cocktail are purported to increase the chelation efficacy, minimize the side 
effects, and achieve additive chelation efficacy. Moreover, commercially available 
antioxidants such as vitamin C, vitamin E, and N-acetylcysteine (NAC) are usu-
ally given together with the chelators to relieve the oxidative stress in patients with 
thalassemia. Herein, an interesting natural product such as green tea extract from 
tea leaves (Camellia sinensis) has been documented in terms of bifunctional antioxi-
dant and iron-chelating properties in iron-overloaded cells and mouse and human 
thalassemia, rather than its general biological and pharmacological properties.
2. β-Thalassemia
2.1 Etiology and pathophysiology
β-Thalassemia is a quantitative hemoglobinopathy which impairs the produc-
tion of β-globin chains in Hb due to mutations of the gene located on the short arm 
of chromosome 11. Accordingly, a reduction of β+ or an absence of β0 in β-globin 
synthesis causes the precipitation of excessive unbound α-globin chains in ery-
throid precursors due to chain imbalances. The abnormal erythroid precursors 
are driven into apoptosis pathway during their differentiation and maturation in 
the bone marrow, consequently leading to erythroid expansion, accelerated extra-
medullary erythropoiesis, increased dietary iron absorption, and high turnover of 
RBC. Moreover, impaired β-globin synthesis and ineffective erythropoiesis result 
in microcytic anemia and progressive splenomegaly. There are three main types of 
β-thalassemia, in order of decreasing severity, homozygous β-thalassemia major 
(TM), β-thalassemia intermedia (TI), and heterozygous β-thalassemia minor. 
Hemoglobin E (HbE)/β-thalassemia is the most prevalent in Southeast Asia where 
the carrier frequency is around 50%. The interaction of HbE and β-thalassemia 
results in a clinical spectrum ranging from a severe condition that is indistinguish-
able from TM to a mild form of TI [1].
Nowadays, β-thalassemia is divided into transfusion-dependent β-thalassemia 
(TDT) and non-transfusion-dependent β-thalassemia (NTDT). In other mammals, 
mouse homozygous beta-globin knockout (BKO) thalassemia shows many clinical 
features of abnormal RBC indices including a decrease in blood Hb concentration, 
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hematocrit (Hct), RBC numbers, and osmotic fragility and an increase of reticulo-
cyte count. Likely, increased degradation of abnormal RBC is an important conse-
quence of unstable Hb and excessive membrane iron in patients with β-thalassemia. 
Invasive and noninvasive laboratory investigations reveal systemic and cellular iron 
overload in TDT and NTDT patients. Large amounts of the irons from enterocytes 
and reticuloendothelial (RE) macrophages in the spleen can get into plasma com-
partment and subsequently bind to transferrin (Tf). Accordingly, this can lead to 
a high saturation of Tf with iron, an appearance of NTBI and LPI, and high levels 
of ferritin in plasma compartment, together with high iron deposition ferritin (Ft) 
in several tissues in the body. Consequently, iron accumulation in the vital organs 
is the cause of susceptibility to infections and immunological abnormalities, liver 
diseases (e.g., hepatitis, hepatic fibrosis, and hepatocellular carcinoma), cardiomy-
opathies (e.g., cardiac arrhythmia and heart failure), and endocrine gland dysfunc-
tion (e.g., diabetes, growth retardation, hypogonadism, and hypoparathyroidism) 
[2–4]. Evidentially, most of patients with β-thalassemia with iron overload die of 
heart failure, while some patients frequently die from infections and suffer from 
liver diseases and endocrinopathies.
2.2 Iron overload and oxidative stress
2.2.1 Iron transport into cells
In fact, abnormal iron absorption in patients with thalassemia produces an 
increase in the body iron burden evaluated at 2–5 g per year, and regular blood 
transfusion (420 mL/U, equivalent to 200 mg of iron) leads to double iron accumu-
lation [5]. Normally, iron is bound to iron-transporting protein in plasma (called 
transferrin) and in milk (called lactoferrin), forms transferrin-bound iron (TBI), 
and is transported in blood circulation to target cells. The circulating TBI, which is 
low saturation in iron-deficiency persons, one-third saturation in normal people, 
and high saturation in iron overload patients, is taken up into iron-requiring 
target cells by using ATP-dependent transferrin receptor 1 (TfR1)-mediated 
endocytosis and delivered in cells for functions and storage in ferritin molecules 
(H- and L-subunits). When the capacity of transferrin to incorporate iron derived 
from gastrointestinal (GI) tract and RE cells becomes limited, the transferrin 
iron-binding capacity (TIBC) has been surpassed [6]. Afterward, two forms of 
redox-active iron such as NTBI and LPI appear primarily in plasma of patients with 
β-thalassemia. Pathologically, the NTBI fraction seems to translocate across plasma 
membrane via specific transporters on specific cell types. NTBI transporter which 
is originally called divalent metal ion transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2) is proposed to locate on intestinal epi-
thelial cells, erythroid cells and astrocytes, L-type calcium channel (LTCC), T-type 
calcium channel (TTCC) on cardiomyocytes, T-type calcium channel (TTCC) 
on hepatocytes, pancreatic islets β cells and kidney tubular cells, anion-exchange 
protein 2 (AE2) on bronchial epithelial cells, ferrireductases on kidney proximal 
tubule, and zinc ion protein 18 (ZIP18) on kidney tubular cells and hippocampal 
neuronal cells [7–14]. Importantly, NTBI and LPI are redox-active and susceptible 
to chelation [15].
2.2.2 Iron overload
The iron that cells do not require immediately for metabolic processes is stored 
in ferritin in the liver, enterocytes, and RE macrophages, representing the stor-
age iron pool. The iron that mobilizes transiently inside the cells is called LIP that 
Beta Thalassemia
40
Human β-thalassemia is characterized by mutations of β-globin gene, resulting 
in deficient production of the β-globin chains of Hb molecule (ineffective erythro-
poiesis) and chronic anemia. Over 200 mutations have been identified in this gene, 
and the type of mutations can influence the severity of the disease. Blood transfu-
sions aim to maintain normal Hb levels to prevent tissue hypoxia, whereas repeated 
blood transfusions lead to the inevitable consequence of iron accumulation in the 
body. Iron deposition occurs considerably in almost all tissues but is primarily 
located in the spleen, liver, heart, and endocrine glands. Besides ferritin iron and 
hemosiderin, the uncommon forms of iron including labile or transient iron pools 
(LIP) in the tissues, nonheme iron in RBC membrane, and non-transferrin-bound 
iron (NTBI) and labile iron pool (LPI) in plasma appear to be redox-active and 
subsequently generate reactive oxygen species (ROS) via Haber-Weiss and Fenton 
reactions. The ROS can oxidize biomolecules, causing oxidative tissue damage, 
organ dysfunctions, complications, and death. Effective iron chelation needs giving 
to counteract the resulting iron overload and prevent oxidative tissue damage. So 
far, monotherapy or combined therapy with iron chelators such as desferrioxamine 
(DFO), deferiprone (DFP), and deferasirox (DFX) has been used for the treat-
ment of patients with β-thalassemia with iron overload, but they present some side 
effects. Modified medical regimens such as adjunctive iron chelator and antioxidant 
and drug cocktail are purported to increase the chelation efficacy, minimize the side 
effects, and achieve additive chelation efficacy. Moreover, commercially available 
antioxidants such as vitamin C, vitamin E, and N-acetylcysteine (NAC) are usu-
ally given together with the chelators to relieve the oxidative stress in patients with 
thalassemia. Herein, an interesting natural product such as green tea extract from 
tea leaves (Camellia sinensis) has been documented in terms of bifunctional antioxi-
dant and iron-chelating properties in iron-overloaded cells and mouse and human 
thalassemia, rather than its general biological and pharmacological properties.
2. β-Thalassemia
2.1 Etiology and pathophysiology
β-Thalassemia is a quantitative hemoglobinopathy which impairs the produc-
tion of β-globin chains in Hb due to mutations of the gene located on the short arm 
of chromosome 11. Accordingly, a reduction of β+ or an absence of β0 in β-globin 
synthesis causes the precipitation of excessive unbound α-globin chains in ery-
throid precursors due to chain imbalances. The abnormal erythroid precursors 
are driven into apoptosis pathway during their differentiation and maturation in 
the bone marrow, consequently leading to erythroid expansion, accelerated extra-
medullary erythropoiesis, increased dietary iron absorption, and high turnover of 
RBC. Moreover, impaired β-globin synthesis and ineffective erythropoiesis result 
in microcytic anemia and progressive splenomegaly. There are three main types of 
β-thalassemia, in order of decreasing severity, homozygous β-thalassemia major 
(TM), β-thalassemia intermedia (TI), and heterozygous β-thalassemia minor. 
Hemoglobin E (HbE)/β-thalassemia is the most prevalent in Southeast Asia where 
the carrier frequency is around 50%. The interaction of HbE and β-thalassemia 
results in a clinical spectrum ranging from a severe condition that is indistinguish-
able from TM to a mild form of TI [1].
Nowadays, β-thalassemia is divided into transfusion-dependent β-thalassemia 
(TDT) and non-transfusion-dependent β-thalassemia (NTDT). In other mammals, 
mouse homozygous beta-globin knockout (BKO) thalassemia shows many clinical 
features of abnormal RBC indices including a decrease in blood Hb concentration, 
41
Nutraceutical Benefits of Green Tea in Beta-Thalassemia with Iron Overload
DOI: http://dx.doi.org/10.5772/intechopen.92970
hematocrit (Hct), RBC numbers, and osmotic fragility and an increase of reticulo-
cyte count. Likely, increased degradation of abnormal RBC is an important conse-
quence of unstable Hb and excessive membrane iron in patients with β-thalassemia. 
Invasive and noninvasive laboratory investigations reveal systemic and cellular iron 
overload in TDT and NTDT patients. Large amounts of the irons from enterocytes 
and reticuloendothelial (RE) macrophages in the spleen can get into plasma com-
partment and subsequently bind to transferrin (Tf). Accordingly, this can lead to 
a high saturation of Tf with iron, an appearance of NTBI and LPI, and high levels 
of ferritin in plasma compartment, together with high iron deposition ferritin (Ft) 
in several tissues in the body. Consequently, iron accumulation in the vital organs 
is the cause of susceptibility to infections and immunological abnormalities, liver 
diseases (e.g., hepatitis, hepatic fibrosis, and hepatocellular carcinoma), cardiomy-
opathies (e.g., cardiac arrhythmia and heart failure), and endocrine gland dysfunc-
tion (e.g., diabetes, growth retardation, hypogonadism, and hypoparathyroidism) 
[2–4]. Evidentially, most of patients with β-thalassemia with iron overload die of 
heart failure, while some patients frequently die from infections and suffer from 
liver diseases and endocrinopathies.
2.2 Iron overload and oxidative stress
2.2.1 Iron transport into cells
In fact, abnormal iron absorption in patients with thalassemia produces an 
increase in the body iron burden evaluated at 2–5 g per year, and regular blood 
transfusion (420 mL/U, equivalent to 200 mg of iron) leads to double iron accumu-
lation [5]. Normally, iron is bound to iron-transporting protein in plasma (called 
transferrin) and in milk (called lactoferrin), forms transferrin-bound iron (TBI), 
and is transported in blood circulation to target cells. The circulating TBI, which is 
low saturation in iron-deficiency persons, one-third saturation in normal people, 
and high saturation in iron overload patients, is taken up into iron-requiring 
target cells by using ATP-dependent transferrin receptor 1 (TfR1)-mediated 
endocytosis and delivered in cells for functions and storage in ferritin molecules 
(H- and L-subunits). When the capacity of transferrin to incorporate iron derived 
from gastrointestinal (GI) tract and RE cells becomes limited, the transferrin 
iron-binding capacity (TIBC) has been surpassed [6]. Afterward, two forms of 
redox-active iron such as NTBI and LPI appear primarily in plasma of patients with 
β-thalassemia. Pathologically, the NTBI fraction seems to translocate across plasma 
membrane via specific transporters on specific cell types. NTBI transporter which 
is originally called divalent metal ion transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2) is proposed to locate on intestinal epi-
thelial cells, erythroid cells and astrocytes, L-type calcium channel (LTCC), T-type 
calcium channel (TTCC) on cardiomyocytes, T-type calcium channel (TTCC) 
on hepatocytes, pancreatic islets β cells and kidney tubular cells, anion-exchange 
protein 2 (AE2) on bronchial epithelial cells, ferrireductases on kidney proximal 
tubule, and zinc ion protein 18 (ZIP18) on kidney tubular cells and hippocampal 
neuronal cells [7–14]. Importantly, NTBI and LPI are redox-active and susceptible 
to chelation [15].
2.2.2 Iron overload
The iron that cells do not require immediately for metabolic processes is stored 
in ferritin in the liver, enterocytes, and RE macrophages, representing the stor-
age iron pool. The iron that mobilizes transiently inside the cells is called LIP that 
Beta Thalassemia
42
is potentially redox-active and increased when the cells are heavily loaded with 
a large number of extracellular irons, TBI, and NTBI. Iron distribution in the 
body is strictly regulated by two regulatory systems, systemic and cellular iron 
homeostasis. Systemic iron homeostasis strictly responds to ensure a balance of 
iron absorption and iron utilization, which relies on the hepatic hepcidin hormone 
and the ferroportin actions and occurs in enterocytes, hepatocytes, and splenic 
macrophages. Hepcidin levels found to decrease in primary hemochromatosis and 
secondary hemochromatosis such as TI patients due to an acceleration of eryth-
ropoietic activity driven by increases of erythropoietin (EPO) production and 
TfR1 expression. Inversely, hepcidin levels increased in TM patients due to blood 
transfusion that they do not need to increase erythropoiesis to compensate inef-
fective erythropoiesis [16]. The regulation will reduce iron efflux from ferroportin 
at the basolateral part of duodenal epithelial cells and from RE macrophage into 
the plasma, resulting in iron retention within the cells. Drugs or natural products 
that increase hepcidin expression and production would be beneficial for the 
supportive treatment of TI patients with iron overload. Cellular iron homeostasis 
is dependent on the expression and function of TfR1 and ferritin mediated by iron 
regulatory element (IRE)/iron regulatory protein (IRP) system. Once TBI is inter-
nalized into cells via TfR-mediated endocytosis, iron is mainly stored by ferritin 
inside the cells [17]. In patients with thalassemia, large amounts of iron from diet 
and degradation of effete RBC by RE macrophage drain into plasma transferrin 
and subsequently taken into cells. Consequently, this will result in iron overload, 
oxidative stress, and depletion of antioxidant defense systems in plasma compart-
ment and many vital organs in the body.
2.2.2.1 Blood
Thalassemia RBC containing large amounts of iron and low protective antioxi-
dant system is prone to be damaged by ROS, leading to chronic hemolytic anemia. 
In young patients with β-thalassemia, plasma and RBC levels of thiobarbituric 
acid-reactive substances (TBARS), superoxide dismutase (SOD), and ferritin 
were increased, but the level of catalase (CAT) was decreased when compared 
with normal children [18]. Interestingly, Aphinives and colleagues have found 
decreased levels of antioxidants such as reduced glutathione (GSH) and vascular 
endothelial dysfunction in young Thai patients with β-thalassemia with HbE 
patients [19]. Additionally, blood levels of CAT, glutathione-S-transferase (GST), 
GSH, and vitamin C were found to decrease in β-thalassemia major patients while 
blood SOD level was increased [20]. Importantly, the levels of blood antioxidant 
system including GST, glutathione peroxidase (GPx), glutathione reductase (GR), 
peroxiredoxin 2 (Prx2), thioredoxin 1, and thioredoxin reductase were decreased 
in β-thalassemia major patients with regular blood transfusion and iron chela-
tion therapy, whereas the blood levels of CAT and SOD were increased when 
compared to healthy subjects [21]. Consistently, the levels of red cell SOD, GPx, 
and CAT activities increased in hemoglobin H (HbH) disease (a moderately severe 
α-thalassemia) patients when compared to healthy control. However, the Chinese 
medicine “Yisui Shengxue” granules which have been officially prescribed and 
clinically used for the treatment of thalassemia for a long time effectively decreased 
the GPx and CAT activities but increased the SOD activity [22]. Prolonged bleeding 
times and abnormal platelet aggregation can be found in transfusion-dependent 
β-thalassemia major patients, possibly due to artifacts caused by in vitro manipula-
tions, oxidative platelets, and circulating procoagulants such as microparticles 
(MP) tissue factors and platelet-derived MP [23, 24]. Platelet numbers were 
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approximately 1.5- and 4-fold increase in Thai non-splenectomized and splenecto-
mized patients with HbE/β-thalassemia when compared with normal subjects [25]. 
In comparison, thrombocytosis, platelet hyperaggregation, and decreased levels 
of protein S, protein C, and antithrombin III were detected in NTDT (such as TI) 
patients (9.4% with splenectomy and 90.6% without splenectomy) [26]. Increased 
oxidative stress of thalassemia platelets was restored by the treatment of iron chela-
tors such as DFO and antioxidants such as NAC and vitamin C [24].
2.2.2.2 Spleen
The spleen is an organ containing some of the RE cells that function to 
destroy RBC hemoglobin by macrophages and store the released iron in 
the form of ferritin and hemosiderin. The number of blood transfusions in 
β-thalassemia major patients seems to correlate with their splenic hemosiderosis 
and splenic weight [27]. Hemosiderin deposition was found to be greater in 
the iron-overloaded livers than in the iron-overloaded spleens. Ferritin and 
hemosiderin increased in hepatocytes and splenic RE cells [28]. Splenectomy is 
one of the therapeutic options in hyper-transfused β-thalassemia major patients 
to reduce hyperactivity of RE macrophages; nevertheless, it may increase the 
iron overload. As a consequence, complications in patients with splenectomized 
thalassemia have included hypercoagulability, an increased incidence of vascular 
thrombosis, and an increased risk of infection. Iron overload in the spleen can 
activate latent nuclear factor-kappa B (NFκB) in alveolar macrophage, reduce 
immunity, and increase susceptibility to infection [29]. Notably, Prx2, which is 
a typical-2 cysteine peroxiredoxin and a key antioxidant system, is upregulated 
during erythropoiesis in patients with β-thalassemia and contributes to the stress 
erythropoiesis in the patients. Nuclear factor erythroid 2 (Nrf2) is a redox-
response transcriptional nuclear factor and cellular adaptive process in response 
to and protection of oxidative stress [30]. Therefore, the regulation of Prx2 and 
Nrf2 genes results in the upregulation of antioxidant (antioxidant responsive 
element, ARE) genes required to ensure the survival of iron-overloaded cells.
2.2.2.3 Liver
The liver is one of the main storage organs for iron. Iron overload is considered 
to be when the ferritin level consistently exceeds 1000 ng/mL (normal range 
20–200 ng/mL). Excess free radicals can cause progressive tissue injury and eventu-
ally cirrhosis or hepatocellular carcinoma in iron overload patients whose iron is 
sequestrated predominantly in ferritin or hemosiderin [31]. When plasma transfer-
rin becomes highly saturated, NTBI is detectable and is rapidly transported across 
the hepatocyte membrane via a specific pathway. Likely, ferroportin 1 is the only 
protein that mediates the transport of iron out of hepatocytes and is then oxidized 
by ceruloplasmin and bound to transferrin. Iron deposition affects hepatic paren-
chymal cells (hepatocytes and bile duct cells) and mesenchymal cells (endothelial 
cells, macrophage, and Kupffer cells) and often distributes differently from one 
area to another [32]. As mentioned above, iron overload can induce ROS which 
can oxidize biomolecules. Lipid peroxidation activates tumor growth factor-beta1 
(TGF-β1) expression which is the most potent pro-fibrogenic cytokine, and its 
expression is increased in almost all of fibrotic diseases. Type I collagen is induced 
by TGFβ resulting in uncontrolled collagen production and leads to tissue scarring 
and organ failure. The scar tissue replaces normal parenchyma, increases fibrosis, 
and blocks the liver portal blood flow consequently generating liver cirrhosis.
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Iron overload cardiomyopathy is a common cause of death in patients with 
β-thalassemia. Biochemically, irons in iron-sulfur clusters and cytochromes are key 
players for oxidative phosphorylation and superoxide production in the mitochon-
dria. Iron deposition in the heart cells seems to lead oxidative stress and cellular 
damage. The heart is the most mitochondrial-rich tissue in the body, making iron of 
particular importance to cardiac function. In cardiac cells, excess iron may result in 
oxidative stress and alteration of myocardial function because of the DNA damage 
caused by hydrogen peroxide through the Fenton reaction. Heart failure is the lead-
ing cause of death among patients with β-thalassemia with hemosiderosis, of whom 
around 60% die from cardiac failure. Harmful effects of iron overload on the heart 
of β-thalassemia major patients can be monitored using noninvasive and invasive 
techniques. Treatment with iron chelators can protect these patients from cardiac 
disease induced by iron overload [33–36].
2.2.2.5 Bone marrow
Bone marrow iron deposition (186 μg/g wet weight) increases in proportion 
to the total body iron stored in a dietary iron overload of African Bantu people 
and Caucasian patients with idiopathic hemochromatosis [37]. Myelodysplastic 
syndrome patients who are a heterogeneous group of clonal hematopoietic stem 
cell malignancies show bone marrow hemosiderosis and also develop systemic iron 
overload.
2.2.2.6 Endocrine glands
Though hematologic care has improved in patients with homozygous trans-
fusion-dependent β-thalassemia, multi-endocrine dysfunction is still a common 
complication. Thyroid dysfunction defined as overt hypothyroidism, subclinical 
hypothyroidism, and exaggerated thyroid-stimulating hormone response was 
reported in patients with β-thalassemia [38]. In addition, lower serum thyroxine 
and higher thyrotrophic hormone levels were found in young patients with thalas-
semia than in normal children. Pituitary siderosis of β-thalassemia major patients 
causes oxidative tissue damage [39], consequently hypogonadotropic hypogonadism 
and growth hormone deficiency. Approximately half of the patients’ pituitary gland 
dysfunction associated with iron overload is irreversible. Toxic irons in patients with 
β-thalassemia major (TDT) and patients with HbE/β-thalassemia are catalytically 
harmful to adrenal glands and can cause adrenal function insufficiency [40]. A 
previous study demonstrated that all β-thalassemia major patients were nondiabetic 
and some of them have decreased oral glucose tolerance test. They showed a normal 
response of cortisol to insulin and adrenocorticotropic hormone stimulation [41]. 
Moreover, the β cell pancreatic function and adrenal cortical function are depressed 
in severe iron loaded. The pancreas is another vital organ for iron accumulation 
especially pancreatic β cell in the islet of Langerhans. Importantly, TDT patients 
present iron deposition in the pancreatic beta cells beginning in the early age of life, 
resulting in decreased insulin secretion [42]. Normal iron level mediates insulin 
secretion via electron transport chain and endoplasmic reticulum calcium release 
by ROS triggering. Inversely, highly accumulated iron produces a high level of ROS 
which damages cell organelles and consequently affects iron-mediated insulin 
secretion mechanism (Figure 1).
As mentioned above, iron overload in thalassemia was assessed with a highly 
elevated level of plasma iron, and highly accumulated tissue iron concentrations 
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lead to many complications. Importantly, effective iron chelators are regularly 
administrated to patients with β-thalassemia for removing the redox iron, amelio-
rating the complications, and prolonging their life expectancy.
2.2.3 Oxidative stress
Iron can participate in the redox process known as the Haber-Weiss/Fenton 
reactions to generate ROS including hydrogen peroxide (H2O2) and hydroxyl radical 
(OH•) (Figure 2) [43]. Subsequently, ROS can oxidize biomolecules such as pro-
teins, carbohydrates, lipids, and nucleic acids in the body causing oxidative tissue 
damage, organ dysfunctions, complications, and pathogenesis [44, 45]. In addition, 
ROS can induce cell apoptosis through initiating serial chemical reactions including 
DNA strand breakage and fragmentation, protein oxidation, and lipids peroxida-
tion [43, 46, 47]. Excessive redox iron can also react with unsaturated lipids to 
produce alkoxyl and peroxyl radicals [48]. These oxidative reactions result in the 
impairment of cellular functions and lead to damage of cells, tissues, and organs, 
which is evident in the iron-loading diseases, β-thalassemia, and Friedreich’s ataxia.
2.3 Assessment methods
For blood samples, the levels of serum iron, TIBC, transferrin saturation, 
ferritin, soluble transferrin receptors, protoporphyrin IX, and routinely measured 
iron parameters indicate whether the body iron status is normal iron balance, iron 
deficiency, or iron overloaded. In addition, the levels of redox irons (e.g., NTBI 
and LPI) and iron-responsive proteins such as EPO, hepcidin, and erythroferrone 
(ERFE) are determined to distinguish the iron imbalance.
Biopsied liver tissue is a clinical sample that is collected for stoichiometric 
determination of nonheme iron. However, this invasive technique requires an 
Figure 1. 
Iron-mediated insulin secretion in pancreatic β cells (modified from [42]). Abbreviations/symbols: 
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Figure 1. 
Iron-mediated insulin secretion in pancreatic β cells (modified from [42]). Abbreviations/symbols: 
ATP = adenosine-5′-triphosphate, DMT1 = divalent metal ion transporter 1, Fe2+ = ferrous ion.
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expert hepatologist to operate. The liver tissue will be investigated for its iron 
content using histochemical Pearl’s staining, physical atomic absorption spec-
trometry (AAS), and colorimetric ferrozine methods. Liver iron concentration 
(LIC) is correlated closely with serum ferritin concentration and is a valuable 
alternative to assess visceral iron overload in heavily iron-loaded β-thalassemia 
major patients. In contrast, the collection of other tissues such as the myocar-
dium, liver, pancreas, adrenal glands, anterior pituitary gland, and skin would be 
too harmful to be collected [49]. Sophisticated noninvasive techniques includ-
ing magnetic resonance imaging [50], magnetic iron detector susceptometry, 
superconducting quantum interference device, and nuclear resonance scattering 
are used to assess iron content in tissues. These methods are valuable for evaluat-
ing iron load in the tissues and monitoring the response of different organs to 
chelation therapy.
2.4 Iron chelation therapy
Iron chelation therapy aims to prevent the accumulation of toxic iron and elimi-
nate the excess iron in patients with transfusion-dependent β-thalassemia. Effective 
chelation and good management of the patients have correlated with a decline in 
early deaths and complications. The reduction of plasma and cellular chelatable 
irons (e.g., NTBI, LPI, and LIP) is a slow process and requires aggressive chelation 
therapy. The chelation will maintain the iron balance at safe levels to prevent high 
iron accumulation and oxidative tissue injury. Such non-iron and iron-overloaded 
models as RBC, cell cultures (e.g., hepatocytes, HepG2 cells, and cardiomyocytes), 
animals (e.g. mice, gerbils, rats, and transgenic BKO mice), and even human 
patients with thalassemia are experimentally investigated and clinically tested to 
assess the safety and efficacy of various iron chelators. Individually, DFO, DFP, and 
DFX are promising iron chelators widely used for the treatment of patients with 
β-thalassemia with iron overload. Combined DFO/DFP and DFP/DFX treatments 
can reverse endocrine complications by improving glucose intolerance and gonadal 
dysfunction in TD-TM patients [51].
A combination therapy is when two chelators were combined and presented 
some degree of overlap which pharmacologically lead to improve efficacy and 
rate of iron removal [52–54]. The most extensively studied combination therapy 
is a combination between DFO and the oral chelator DFP which has been shown 
to rapidly reduce liver iron, serum ferritin, and myocardial siderosis compared 
with DFO monotherapy. Clinical trial data for the combination of DFX and DFO 
chelation has reinforced the benefits of combination therapy [55]. In addition, the 
clinical combination of DFX and DFP would be more appealing to patients than 
other combination therapy regimens involving the parenterally administered DFO. 
However, concrete data regarding the safety, efficacy, and dosing of each regimen 
are limited.
Figure 2. 
Iron-catalyzed generation of reactive oxygen species. Abbreviations/symbols: Fe2+ = ferrous ion, Fe3+ = ferric 
ion, SOD = superoxide dismutase.
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In principle, when two chelators are used together, they can act either additively 
or synergistically. Additivity refers to the predicted level of effect achieved by a 
drug combination based on individual drug potencies, whereas synergy refers to 
the exaggerated effect noted upon concurrent use of drugs. Synergism may occur in 
conditions allowing “iron shuttling.” The rate of the chelators’ access to cells, both in 
vitro and in vivo, is determined by size, charge, and lipid solubility of the chelators 
[55–58]. In plasma, the previous demonstration showed that low concentrations of 
DFP can act as a “shuttle” by gaining more rapid access to some non-transferrin-
bound iron (NTBI) pools than DFO and subsequently donating iron to a DFO as a 
“sink” [54]. The isobologram analysis was reported to distinguish between syner-
gistic, additive, or a sub-additive response to iron chelator combinations in human 
hepatic cells (HuH7) [59]. The synergy can imply that the primary chelator can act 
as a “shuttle” for iron chelated and delivered to the secondary “sink” chelator at low 
concentrations (Figure 3).
2.5 Supplementation of antioxidants
All patients with β-thalassemia have higher oxidative stress levels than normal 
people. Hitherto, supplementation of antioxidants has been recommended for them 
to ameliorate oxidative stress, give a better quality of life, and sustain long lives. 
Many antioxidants such as water-soluble vitamins C (L-ascorbic acid), fat-soluble 
vitamin E (α-tocopherol), and vitamin A, β-carotenoids, glutathione, curcumi-
noids, and quercetin are the compounds of interest.
2.5.1 Vitamin C
The levels of AA in leukocytes, platelets, and urine of patients with iron over-
load such as patients with idiopathic hemochromatosis, TDT patient, and Bantu 
people were decreased [60, 61]. After treatment of TM patients with AA, the serum 
levels of iron, transferrin saturation, and ferritin were increased [62]. Possibly, AA 
would involve mobilization of storage iron from tissue ferritin by reducing ferric 
oxyhydroxide to ferrous ion, which will subsequently catalyze ROS production 
via Haber-Weiss reaction and increase oxidative damage in the patients. However, 
Figure 3. 
Iron shuttling mechanism described combination therapy. Abbreviations/symbol: CH = chelator, Fe = iron.
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vitamin C plus vitamin E supplementation seemed to be more effective than vita-
min E alone for promoting antioxidant activity in patients with β-thalassemia [63].
2.5.2 Vitamin E
Evidently, the serum levels of vitamins A, vitamin E, zinc, selenium, and cop-
per were decreased in young patients with thalassemia, while the serum levels of 
retinol and selenium inversely correlated with those of iron and ferritin. Moreover, 
low serum level of vitamin E was found in homozygous β-thalassemia and 
β-thalassemia/Hb E. Administration of vitamin E and polyphenols together with 
iron chelators abolished the increase of oxidative stress in patients with thalassemia, 
suggesting a substantial improvement of their anemia and complications [64]. 
The results from clinical studies using curcuminoids and vitamin E supported the 
free radical scavenging activity in the improvement of oxidative stress and platelet 
functions in patients with thalassemia [65, 66]. Surprisingly, oral administration of 
high doses of vitamin E effectively decreased plasma lipid peroxidation in patients 
with β-thalassemia and prolonged RBC survival in some patients. Furthermore, the 
treatment of TM and TI patients with vitamin E (750 to 1000 IU/day) for 16 months 
showed a fourfold increase in serum and RBC vitamin E levels and a reduction of 
serum malondialdehyde (MDA) level when compared with the untreated group 
[41]. Unchern and colleagues have reported that daily vitamin E supplementation 
for 3 months significantly increased plasma β-tocopherol levels and decreased 
plasma oxidant levels in splenectomized β-thalassemia/Hb E patients [66].
2.5.3 N-Acetylcysteine
NAC is a potent antioxidant and free radical scavenger, which involves glutathi-
one biosynthesis and promotes detoxification. It is utilized for the treatment option 
for sickle cell anemia and diseases involved in the generation of ROS. Under iron 
overload condition, NAC provides a protective effect on brain dysfunction in iron-
overloaded rats; therefore, the compound can diminish ROS production and DNA 
damage in patients with β-thalassemia [67–69].
2.5.4 Natural products
Quercetin is one of the predominant flavonoids of polyphenolics found in many 
fruits, vegetables, leaves, grains, red onions, kale, apples, and tea. Flavonoids are 
commonly present in their glycosylated form in the diet and presence of aglycone, 
glycoside, as well as methyl, glucuronide, and sulfate conjugates, which have been 
reported in human plasma. Quercetin has been reported to exert antioxidant and 
free radical scavenging properties in vitro, while quercetin supplementation has 
been promoted for the treatment of cancer and other diseases. Surprisingly, dietary 
quercetin supplementation was found to attenuate liver injury in iron-overloaded 
mice [70]. As a novel idea, we wish to investigate their role as adjuncts in iron 
mobilization [71].
Curcuminoids are the phytochemicals from turmeric Curcuma longa Linn (family 
Zingiberaceae), which are composed of three main constituents including cur-
cumin, demethoxycurcumin, and bis-demethoxycurcumin, in which the important 
bioactive molecular structure is diketone moiety. Curcumin was found to suppress 
the ROS generation and lipid peroxidation in erythrocytes. Surprisingly, curcumin 
metabolites including di-, tetra-, and hexa-hydrocurcumin exhibit strong antioxi-
dant, free radical scavenging, anti-lipid peroxidative and iron-chelating properties. 
The other effects are antithrombotic and anti-inflammatory activities. Oxidative 
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stress condition in red blood cells of β-thalassemia/HbE patients is reduced after 
treatment with curcuminoids [65], leading to an improvement of their quality 
of life.
Green tea exhibits many interesting biological, biochemical, and pharmacologi-
cal properties in health benefits. Normally, tea leaves (Camellia sinensis) are pro-
cessed without fermentation for the preparation of green tea extract (GTE), which 
is abundant with epigallocatechin-3-gallate (EGCG) and exhibits antioxidative 
iron-chelating activity. In a recent study, the effect of GTE products on the status 
of iron overload, oxidative stress, and endocrine hormones was studied in iron 
overload pancreatic and liver cell lines, β-thalassemic mice, and β-thalassemia/HbE 
patients.
3. Green tea for thalassemia’s health
Green tea is prepared without fermentation from tea leaves and one of the 
most popular beverages in the world. It is composed of proteins, amino acids 
(e.g., 5-methylglutamine, glutamic acid, tryptophan, glycine, serine, aspartic 
acid, tyrosine, valine, leucine, threonine, arginine, and lysine), carbohydrates 
(e.g., cellulose, pectin, glucose, fructose, and sucrose), lipids (e.g., linoleic acid 
and α-linolenic acids), sterols (e.g., stigmasterol), vitamin B, vitamin C, vitamin 
E, caffeine, theophylline, chlorophyll, carotenoids, volatile compounds (e.g., 
aldehydes, alcohols, esters, lactones, and short-chain hydrocarbons), minerals, 
and essential elements. Importantly, green tea is rich in polyphenols, particularly 
flavonoids (0.5–1.5%) in forms of catechins (flavan-3-ols). Five main green tea 
catechins (GTC) are included, EGCG which is the main proportion (59% of total 
catechins), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and 
(−)-epicatechin (EC) (Figure 4). In addition, green tea contains gallic acid, 
chlorogenic acid, caffeic acid, kaempferol, myricetin, and quercetin. During the 
fermentation process, flavonoids in green tea are oxidized into theaflavins and 
thearubigins, which are the main ingredients in black tea.
In health benefits, green tea plays many important roles in cells and systems 
in the body. Green tea has been considered a medicine and a healthful beverage 
since ancient times. Traditional Chinese medicine has recommended this plant 
for headaches, body aches and pains, digestion, depression, detoxification, as an 
energizer, and, in general, to prolong life. Caffeine acts mainly upon the central 
nervous system, stimulating wakefulness, facilitating ideas association, and 
decreasing the sensation of fatigue [73]. Green tea polyphenols present antioxi-
dant, ROS and reactive nitrogen species (RNS) scavenging, and metal-chelating 
activities [72, 74, 75]. They may also function indirectly through (1) inhibition 
of redox-sensitive transcription factors; (2) inhibition of “prooxidant” enzymes 
including inducible nitric oxide synthase (iNOS), lipoxygenase (LOX), cyclo-
oxygenase (COX), and xanthine oxidase (XO); and (3) induction of antioxidant 
enzymes including GST and SOD [76].
3.1 Neuronal cells
We have presented that GTE treatment at 0–100 μg/mL was not toxic to the 
neuroblastoma (SH SY5Y) cells (viability >90%). Nevertheless, the cell viability 
significantly decreased in iron-loaded condition, and the treatment of the cells 
with GTE (10–40 μg/mL) was found to improve the viability. GTE monotherapy 
(10–20 μM) was not effective to reduce LIP levels in SH SY5S cells, whereas com-
bined treatment with GTE and CM1 iron chelator significantly reduced the LIP. 
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low serum level of vitamin E was found in homozygous β-thalassemia and 
β-thalassemia/Hb E. Administration of vitamin E and polyphenols together with 
iron chelators abolished the increase of oxidative stress in patients with thalassemia, 
suggesting a substantial improvement of their anemia and complications [64]. 
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free radical scavenging activity in the improvement of oxidative stress and platelet 
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treatment of TM and TI patients with vitamin E (750 to 1000 IU/day) for 16 months 
showed a fourfold increase in serum and RBC vitamin E levels and a reduction of 
serum malondialdehyde (MDA) level when compared with the untreated group 
[41]. Unchern and colleagues have reported that daily vitamin E supplementation 
for 3 months significantly increased plasma β-tocopherol levels and decreased 
plasma oxidant levels in splenectomized β-thalassemia/Hb E patients [66].
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NAC is a potent antioxidant and free radical scavenger, which involves glutathi-
one biosynthesis and promotes detoxification. It is utilized for the treatment option 
for sickle cell anemia and diseases involved in the generation of ROS. Under iron 
overload condition, NAC provides a protective effect on brain dysfunction in iron-
overloaded rats; therefore, the compound can diminish ROS production and DNA 
damage in patients with β-thalassemia [67–69].
2.5.4 Natural products
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fruits, vegetables, leaves, grains, red onions, kale, apples, and tea. Flavonoids are 
commonly present in their glycosylated form in the diet and presence of aglycone, 
glycoside, as well as methyl, glucuronide, and sulfate conjugates, which have been 
reported in human plasma. Quercetin has been reported to exert antioxidant and 
free radical scavenging properties in vitro, while quercetin supplementation has 
been promoted for the treatment of cancer and other diseases. Surprisingly, dietary 
quercetin supplementation was found to attenuate liver injury in iron-overloaded 
mice [70]. As a novel idea, we wish to investigate their role as adjuncts in iron 
mobilization [71].
Curcuminoids are the phytochemicals from turmeric Curcuma longa Linn (family 
Zingiberaceae), which are composed of three main constituents including cur-
cumin, demethoxycurcumin, and bis-demethoxycurcumin, in which the important 
bioactive molecular structure is diketone moiety. Curcumin was found to suppress 
the ROS generation and lipid peroxidation in erythrocytes. Surprisingly, curcumin 
metabolites including di-, tetra-, and hexa-hydrocurcumin exhibit strong antioxi-
dant, free radical scavenging, anti-lipid peroxidative and iron-chelating properties. 
The other effects are antithrombotic and anti-inflammatory activities. Oxidative 
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stress condition in red blood cells of β-thalassemia/HbE patients is reduced after 
treatment with curcuminoids [65], leading to an improvement of their quality 
of life.
Green tea exhibits many interesting biological, biochemical, and pharmacologi-
cal properties in health benefits. Normally, tea leaves (Camellia sinensis) are pro-
cessed without fermentation for the preparation of green tea extract (GTE), which 
is abundant with epigallocatechin-3-gallate (EGCG) and exhibits antioxidative 
iron-chelating activity. In a recent study, the effect of GTE products on the status 
of iron overload, oxidative stress, and endocrine hormones was studied in iron 
overload pancreatic and liver cell lines, β-thalassemic mice, and β-thalassemia/HbE 
patients.
3. Green tea for thalassemia’s health
Green tea is prepared without fermentation from tea leaves and one of the 
most popular beverages in the world. It is composed of proteins, amino acids 
(e.g., 5-methylglutamine, glutamic acid, tryptophan, glycine, serine, aspartic 
acid, tyrosine, valine, leucine, threonine, arginine, and lysine), carbohydrates 
(e.g., cellulose, pectin, glucose, fructose, and sucrose), lipids (e.g., linoleic acid 
and α-linolenic acids), sterols (e.g., stigmasterol), vitamin B, vitamin C, vitamin 
E, caffeine, theophylline, chlorophyll, carotenoids, volatile compounds (e.g., 
aldehydes, alcohols, esters, lactones, and short-chain hydrocarbons), minerals, 
and essential elements. Importantly, green tea is rich in polyphenols, particularly 
flavonoids (0.5–1.5%) in forms of catechins (flavan-3-ols). Five main green tea 
catechins (GTC) are included, EGCG which is the main proportion (59% of total 
catechins), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and 
(−)-epicatechin (EC) (Figure 4). In addition, green tea contains gallic acid, 
chlorogenic acid, caffeic acid, kaempferol, myricetin, and quercetin. During the 
fermentation process, flavonoids in green tea are oxidized into theaflavins and 
thearubigins, which are the main ingredients in black tea.
In health benefits, green tea plays many important roles in cells and systems 
in the body. Green tea has been considered a medicine and a healthful beverage 
since ancient times. Traditional Chinese medicine has recommended this plant 
for headaches, body aches and pains, digestion, depression, detoxification, as an 
energizer, and, in general, to prolong life. Caffeine acts mainly upon the central 
nervous system, stimulating wakefulness, facilitating ideas association, and 
decreasing the sensation of fatigue [73]. Green tea polyphenols present antioxi-
dant, ROS and reactive nitrogen species (RNS) scavenging, and metal-chelating 
activities [72, 74, 75]. They may also function indirectly through (1) inhibition 
of redox-sensitive transcription factors; (2) inhibition of “prooxidant” enzymes 
including inducible nitric oxide synthase (iNOS), lipoxygenase (LOX), cyclo-
oxygenase (COX), and xanthine oxidase (XO); and (3) induction of antioxidant 
enzymes including GST and SOD [76].
3.1 Neuronal cells
We have presented that GTE treatment at 0–100 μg/mL was not toxic to the 
neuroblastoma (SH SY5Y) cells (viability >90%). Nevertheless, the cell viability 
significantly decreased in iron-loaded condition, and the treatment of the cells 
with GTE (10–40 μg/mL) was found to improve the viability. GTE monotherapy 
(10–20 μM) was not effective to reduce LIP levels in SH SY5S cells, whereas com-
bined treatment with GTE and CM1 iron chelator significantly reduced the LIP. 
Beta Thalassemia
50
Moreover, GTE monotherapy (40 μM), as well as the combination of GTE and CM1 
chelator, exhibited significant free radical scavenging activity in a concentration-
dependent manner [77]. Consistently, Xu and colleagues have reported that the oral 
administration of EGCG (25 mg/kg/day, 7 days) regulated the iron-export protein 
ferroportin in the substantia nigra and reduced oxidative stress in Parkinson’s 
disease mice [78].
3.2 Blood cells
Phenolic acids (e.g., chlorogenic acid, caffeic acid, and gallic acid) and flavonols 
(e.g., kaempferol, myricetin, and quercetin) are present in green tea. GTE and 
EGCG, which show iron-chelating and antioxidant properties, decrease labile 
iron (e.g., NTBI and LPI) levels and consequently deplete lipid peroxidation as 
well as oxidative stress in both iron-loaded rats and thalassemic mice [73, 74]. The 
compounds were effective in the inhibition of RBC hemolysis, resulting in pro-
longed RBC lifespan and decreased iron deposition and oxidative damage in liver 
[75]. Logically, antioxidative GTE interferes duodenal absorption of dietary iron 
and iron-chelating properties in vitro and in vivo. The preparation also shows the 
inhibitory effect on catecholamine secretion from isolated rabbit adrenal glands, 
possibly by blocking LTCC in the adrenomedullary glands. Active compounds in 
GTE are effective in the inhibition of red blood cell hemolysis; therefore, red blood 
cell lifespan can be expanded, and iron deposition in the liver can be decreased [79]. 
Green tea extract improves the abnormality of sickle red cells [80]. Using fluoro-
chrome labeling and flow cytometry, we found feeding ferrocene diet-induced 
iron overload and oxidative stress, leading to a significant decrease of RBC survival 
half-time (T1/2) in WT (T1/2 = 23 days) and BKO thalassemic mice (T1/2 = 13 days) 
when compared with feeding normal diet (T1/2 = 30 days). Surprisingly, the RBC 
survival rate was approximately 15% increase in GTE-treated WT mice and 27% 
increase in GTE-treated BKO mice when compared with placebo-treated WT mice 
(Ounjaijean, S. unpublished data). Antioxidative GTE, particularly EGCG, would 
possibly scavenge ROS and recycle oxidized glutathione (GSSG) to GSH in RBC 
cytoplasm, leading to the inhibition of RBC hemolysis and prolonged RBC survival. 
Tea extracts can be used as a therapeutic agent in case of anemia resulting from 
red blood cell destruction and alleviate infection-induced inflammation or other 
Figure 4. 
Chemical structures of five catechins in green tea (modified from [72]). Abbreviations: C = catechin, 
EC = epicatechin, ECG = epicatechin-3-gallate, EGC = epigallocatechin, EGCG = epigallocatechin-3-gallate.
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inflammatory diseases [81, 82]. EGCG is presented to ameliorate inflammation via 
the nuclear factor erythroid-derived 2-like-2 (Nrf2 signaling pathway), leading to 
prevent osteoblasts [83]. On the other hand, excessive green tea consumption may 
cause iron-deficiency anemia [67].
3.3 Liver and pancreas cells
By using lactate dehydrogenase assay, Koonyosying and colleagues have found 
that GTE at 1–10 μM EGCG equivalent was not toxic to rat insulinoma (RINm-5F) 
cells, whereas GTE doses of 1–30 μM EGCG equivalent were not toxic to human 
hepatocellular carcinoma (Huh7) cells either, showing 20% inhibitory concentra-
tions (IC20) of 10.6 and 17.4 μM EGCG equivalent, respectively [84]. Interestingly, 
GTE monotherapy (10 μM EGCG equivalent) revealed an almost twofold reduction 
of LIP in iron-loaded RINm-5F and Huh7 cells when compared to treatment without 
GTE, while GTE treatment (1 and 10 μM EGCG equivalent) together with 10 μM 
DFO showed a synergistic effect of the LIP mobilization. Similarly, the GTE treat-
ments efficiently lowered ROS levels in these two cells in the same manner. Most 
importantly, the GTE treatments effectively restored the production of insulin from 
iron-loaded RINm-5F cells and hepcidin production from iron-loaded Huh7 cells, 
indicating relief of endocrine gland dysfunction from iron-induced oxidative tissue 
damage [84].
3.4 Hypercoagulability and thrombosis in thalassemia
Oral green tea catechins significantly inhibited arachidonic acid (AA)-induced 
platelet aggregation in rats [85]. Likewise, EGCG suppressed adenosine diphosphate 
(ADP)-induced platelet aggregation in a dose-dependent manner and reduced the 
ADP-induced phosphorylation of p38 mitogen-activated protein kinase and heat 
shock protein [86]. In addition, EGCG inhibited the ADP-stimulated release of 
platelet-derived growth factor-AB and soluble CD40 ligand [87]. Moreover, green 
tea catechins inhibited ATP release from dense granules in washed platelets and AA 
liberation stimulated by collagen in platelets [85]. Interestingly, GTC and EGCG 
prevented death due to pulmonary thrombosis, prolonged bleeding time in mice in 
vivo, and inhibited human platelet aggregation [88]. Nowadays, the life expectancy 
of TM patients has been improved because of regular blood transfusions and iron 
chelation therapy. However, patients with thalassemia still suffer from many compli-
cations from their chronic disease. Regular transfusion therapy leads to iron overload-
related complications including growth retardation, hypoparathyroidism, diabetes 
and impaired glucose intolerance, osteoporosis, cardiomyopathy, liver fibrosis, and 
cirrhosis [89]. Heart failure and arrhythmia have been reported as the main cause of 
death in TM patients, whereas pulmonary hypertension and thrombosis are also the 
major cardiovascular complications in TI patients possibly due to pro-atherogenic 
biochemical factors (e.g., iron status and lipid profile) [90–94]. Hypercoagulable pul-
monary microthromboembolism in Thai pediatric TE patients was previously inves-
tigated [95]. TI patients had thrombosis (9.4%), thrombocytosis (15%), mostly after 
splenectomy, and lower levels of anticoagulation inhibitors (e.g., protein S, protein C, 
and antithrombin III) (15%) [26]. Splenectomy also promotes portal vein thrombosis 
in TM patients [96]. Ineffective erythropoiesis, chronic anemia, iron overload, and 
polycythemia by erythrocytosis and thrombosis are coincidently occurring in patients 
with 𝛽𝛽-thalassemia. Signs of cerebrovascular accident (brain ischemia, hemorrhage, 
and infarct) and heart disease (congestive heart failure and atrial fibrillation) were 
described in patients with chronically hypercoagulable thromboembolic thalassemia, 
so anticoagulant and/or anti-platelet therapy is recommended [97].
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inflammatory diseases [81, 82]. EGCG is presented to ameliorate inflammation via 
the nuclear factor erythroid-derived 2-like-2 (Nrf2 signaling pathway), leading to 
prevent osteoblasts [83]. On the other hand, excessive green tea consumption may 
cause iron-deficiency anemia [67].
3.3 Liver and pancreas cells
By using lactate dehydrogenase assay, Koonyosying and colleagues have found 
that GTE at 1–10 μM EGCG equivalent was not toxic to rat insulinoma (RINm-5F) 
cells, whereas GTE doses of 1–30 μM EGCG equivalent were not toxic to human 
hepatocellular carcinoma (Huh7) cells either, showing 20% inhibitory concentra-
tions (IC20) of 10.6 and 17.4 μM EGCG equivalent, respectively [84]. Interestingly, 
GTE monotherapy (10 μM EGCG equivalent) revealed an almost twofold reduction 
of LIP in iron-loaded RINm-5F and Huh7 cells when compared to treatment without 
GTE, while GTE treatment (1 and 10 μM EGCG equivalent) together with 10 μM 
DFO showed a synergistic effect of the LIP mobilization. Similarly, the GTE treat-
ments efficiently lowered ROS levels in these two cells in the same manner. Most 
importantly, the GTE treatments effectively restored the production of insulin from 
iron-loaded RINm-5F cells and hepcidin production from iron-loaded Huh7 cells, 
indicating relief of endocrine gland dysfunction from iron-induced oxidative tissue 
damage [84].
3.4 Hypercoagulability and thrombosis in thalassemia
Oral green tea catechins significantly inhibited arachidonic acid (AA)-induced 
platelet aggregation in rats [85]. Likewise, EGCG suppressed adenosine diphosphate 
(ADP)-induced platelet aggregation in a dose-dependent manner and reduced the 
ADP-induced phosphorylation of p38 mitogen-activated protein kinase and heat 
shock protein [86]. In addition, EGCG inhibited the ADP-stimulated release of 
platelet-derived growth factor-AB and soluble CD40 ligand [87]. Moreover, green 
tea catechins inhibited ATP release from dense granules in washed platelets and AA 
liberation stimulated by collagen in platelets [85]. Interestingly, GTC and EGCG 
prevented death due to pulmonary thrombosis, prolonged bleeding time in mice in 
vivo, and inhibited human platelet aggregation [88]. Nowadays, the life expectancy 
of TM patients has been improved because of regular blood transfusions and iron 
chelation therapy. However, patients with thalassemia still suffer from many compli-
cations from their chronic disease. Regular transfusion therapy leads to iron overload-
related complications including growth retardation, hypoparathyroidism, diabetes 
and impaired glucose intolerance, osteoporosis, cardiomyopathy, liver fibrosis, and 
cirrhosis [89]. Heart failure and arrhythmia have been reported as the main cause of 
death in TM patients, whereas pulmonary hypertension and thrombosis are also the 
major cardiovascular complications in TI patients possibly due to pro-atherogenic 
biochemical factors (e.g., iron status and lipid profile) [90–94]. Hypercoagulable pul-
monary microthromboembolism in Thai pediatric TE patients was previously inves-
tigated [95]. TI patients had thrombosis (9.4%), thrombocytosis (15%), mostly after 
splenectomy, and lower levels of anticoagulation inhibitors (e.g., protein S, protein C, 
and antithrombin III) (15%) [26]. Splenectomy also promotes portal vein thrombosis 
in TM patients [96]. Ineffective erythropoiesis, chronic anemia, iron overload, and 
polycythemia by erythrocytosis and thrombosis are coincidently occurring in patients 
with 𝛽𝛽-thalassemia. Signs of cerebrovascular accident (brain ischemia, hemorrhage, 
and infarct) and heart disease (congestive heart failure and atrial fibrillation) were 
described in patients with chronically hypercoagulable thromboembolic thalassemia, 
so anticoagulant and/or anti-platelet therapy is recommended [97].
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According to a high incidence of coagulopathy affecting life expectancy, patients 
with thalassemia have been reported recently to understand contributing factors. 
Thrombosis related to the hypercoagulable state in thalassemia has been mostly 
reported. Factors contributing to the hypercoagulable state in patients have been 
identified [98]. Hypoxia and iron overload are the two major mechanisms of ROS 
overproduction that can cause oxidative tissue damage and complications [99]. The 
levels of plasma hemostatic and thrombotic markers including thrombin-antithrom-
bin III complex, β2 thromboglobulin, C-reactive protein, tissue plasminogen activator 
antigen, protein C, protein S, antithrombin, prothrombin fragments, fibrinogen, 
and lipoprotein (a) were significantly higher in patients with splenectomized 
HbE/β-thalassemia than non-splenectomized ones, implying that splenectomy 
increases platelet hyperactivity, blood hypercoagulability, and risk of thrombosis 
[100, 101]. ROS-induced activation of vascular endothelial cells can cause vasculitis 
and thrombosis, showing increased levels of soluble adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1), E-selectin (ELAM-1), vascular cell 
adhesion molecule-1 (VCAM-1), and von Willebrand factor (vWF) in thalassemia 
blood [102]. Procoagulant activity of circulating damaged RBC or RBC microvesicles 
may also contribute to thrombotic events in thalassemia hypercoagulability [103]. 
Carotid artery thrombus is usually associated with severe cardiovascular diseases 
(CVD), iron-deficiency anemia, and thrombocytosis. Thromboembolic complica-
tions are documented in patients with thalassemia, possibly due to the aggregability 
of abnormal RBC and high amounts of RBC membrane-derived microparticles [104]. 
The treatment of β-thalassemia/HbE patients with antioxidants can improve oxidative 
stress and hypercoagulable state [105]. Particularly, NTBI presenting in thalassemia 
plasma would be one of the risk factors in pulmonary thrombosis and hypertension in 
splenectomized NTDT patients [106]. DFO and DFP were effective in the ameliora-
tion of iron overload and oxidative stress in thalassemic mice, possibly in the preven-
tion of pulmonary thrombosis [107].
Excessive iron and carbon monoxide liberated from heme oxygenase-1 catalyzed 
heme degradation also contribute to hypercoagulability [108]. Moreover, low argi-
nine bioavailability and elevated arginase I activity in patients with β-thalassemia 
are possible causes of pulmonary hypertension leading to cardiopulmonary 
dysfunctions [109]. However, there are no difference in serum arginine between 
young patients with β-thalassemia and young control children [110]. Anemia (e.g., 
iron-deficiency anemia) can be linked to cerebral venous thrombosis as well [111]. 
Ex vivo Hb released from old RBC and in vivo Hb released from thalassemia RBC 
per se directly bind nitric oxide, whereas arginase will degrade available arginine 
during hemolysis [112]. Splenectomy, thrombocytosis, and only platelet MP are 
proposed to be residual hypercoagulable/thrombotic risks in TDT patients [23, 113]. 
Liver diseases such as liver inflammation and cirrhosis can involve in hypercoagula-
bility, thrombosis, and reduced fibrinolysis [114, 115].
3.5 β-Thalassemic mice
Upanan and colleagues have demonstrated that hepatic hepcidin gene (Hamp1) 
mRNA levels in heterozygous β-globin knockout thalassemic mice (BKO, muβth-
3/+) were significantly lower than that in wild-type mice (WT, muβ+/+) and 
significantly upregulated with iron loading. However, combined treatment of DFP 
(50 mg/kg) and GTE (50 mg EGCG equivalent) for 90 days was more effective in 
the upregulation of the Hamp1 mRNA levels in BKO thalassemic mice significantly. 
Similarly, monotherapy with the GTE effectively decreased serum levels of alanine 
aminotransferase in BKO thalassemic mice (∆11 + 9 U/L), while the combined 
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GTE/DFP chelation showed greater effect (∆1 + 9 U/L) (P < 0.05) when compared 
without GTE (∆17 + 12 U/L), suggesting protection of oxidative liver damage. 
Likewise, GTE monotherapy and GTE plus DFP therapy was found to lower the 
levels of serum NTBI, spleen, and liver iron from iron-loaded BKO mice significantly 
when compared without GTE treatment [84, 116]. Currently, Al-Basher has shown 
that oral administration of GTE (100 mg/kg) for two more months lowered iron 
Figure 5. 
Challenging with green tea for treatments of iron overload and oxidative: from cells to bedsides. Abbreviations/
symbols: BKO = β-globin knockout, BUN = blood urea nitrogen, EGCG = epigallocatechin-3-gallate, 
GTE = green tea extract, HepG2 cells = human hepatocellular carcinoma cells, HPLC = high-performance 
liquid chromatography, Huh7 cells = human hepatocellular carcinoma cells, RBC = red blood cells, RINm5F 
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accumulation, improved antioxidant capacity, and restored the increase of hepcidin 
in the livers of iron-overloaded rats [117]. Recently, Koonyosying and colleagues have 
demonstrated that GTE decreased the amounts of iron in the livers (P < 0.05) and 
pancreas insignificantly from iron-loaded BKO mice; however, combination therapy 
of DFP and GTE was not efficient superior to the GTE monotherapy in the two cells 
[84]. Similarly, GTE treatment efficiently lowered the levels of lipid peroxidation 
products such as plasma TBARS and tissue MDA in liver and pancreatic tissues from 
BKO mice fed with ferrocene diet, and the combined treatment was not superior to 
the GTE monotherapy either [84]. Consistent with studies of the cells, GTE restored 
the production of hepatic hepcidin and pancreatic insulin in iron-loaded BKO mice, 
and the combined treatment was not more efficient over the GTE monotherapy [84]. 
The findings suggest protective effects of iron-induced oxidative hepatic and pan-
creatic damages by GTE, which the action would be mainly free radical scavenging 
property.
3.6 Patients with β-thalassemia
A recent study of controlled trial in British healthy volunteers has demon-
strated that the interval between meal consumption and tea consumption did not 
affect plasma levels of hepcidin-25 [118]. Surprisingly, the consumption of GTE-
curcumin drinks for 60 days tentatively decreased the levels of Hb, Hct, and RBC 
numbers in TDT patients [84]. Moreover, the drink with the GTE dose of 50 mg 
EGCG equivalent was found to lower the levels of NTBI and LPI. Taken together, 
green tea polyphenols and curcuminoids present in the drink could possibly 
interfere absorption of dietary iron and mobilize delivery of iron to the erythrons 
[65, 79, 119]. Taken all our studies, we summarize the applications of nutraceuti-
cal green tea extract for the amelioration of iron-overloaded cells, β-thalassemic 
mice, and patients with β-thalassemia (Figure 5) [79, 84, 106, 116, 119–128]. In our 
expectations, we hope the patients will have safer chelation therapy, a better quality 
of lives, and good health.
4. Conclusions
Patients with β-thalassemia suffer from ineffective erythropoiesis and chronic 
anemia and from secondary iron overload caused by multiple blood transfusions 
and increased iron absorption. Iron chelation therapy and antioxidant administra-
tion are supportive treatments to ameliorate iron overload and oxidative tissue 
damage. Green tea (Camellia sinensis) abundant with EGCG possesses diuretic, free 
radical scavenging, and iron-chelating properties. Accordingly, green tea products 
can decrease the levels of redox-active iron, ROS, and lipid peroxidation products 
in iron-overloaded cells, β-thalassemic mice, and patients. In addition, green tea 
can restore pancreatic insulin secretion and hepatic hepcidin production from 
hepatocytes with iron overload. Furthermore, the nutraceutical properties of green 
tea products have to be investigated intensively in patients with oxidative stress and 
neurodegenerative disorders.
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HepG2 human hepatocellular carcinoma cells
H2O2 hydrogen peroxide
HPLC high-performance liquid chromatography
Huh7 human hepatocellular carcinoma cells
IC20 20% inhibitory concentrations
iNOS inducible nitric oxide synthase
IRE iron regulatory element
IRP iron regulatory protein
LIC liver iron concentration
LIP labile iron pools
LOX lipoxygenase
LPI labile iron pool




NFκB nuclear factor-kappa B
Nrf2 nuclear factor erythroid 2
NTBI non-transferrin-bound iron




RBC red blood cells
RE reticuloendothelial
RINm5F rat insulinoma cells
RNS reactive nitrogen species
ROS reactive oxygen species
SH SY5Y neuroblastoma cells
SOD superoxide dismutase
T1/2 half-time




TfR1 transferrin receptor 1
TGF-β1 tumor growth factor-beta1
TI β-thalassemia intermedia
TIBC transferrin iron-binding capacity
TM β-thalassemia major
TTCC T-type calcium channel
TTCC T-type calcium channel
XO xanthine oxidase
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Model Human β Thalassemic 
Erythrocytes: Effect of Unpaired 




β thalassemias arise from genetic defects that interfere with the synthesis of 
the β hemoglobin chain and the subsequent production of the normal α2β2 hemo-
globin tetramer. As a consequence of this decreased β-chain synthesis, unpaired 
α-hemoglobin chains are found within the red blood cell (RBC). The unstable 
α-chains are associated with a number of cellular defects, including: membrane-
bound globin; membrane thiol oxidation; altered cytoskeletal proteins; decreased 
cellular and membrane deformability; and increased susceptibility to both endog-
enous and exogenous oxidants. Surprisingly, while significant injury to human 
thalassemic RBC arise from the unpaired α-chains, the underlying intra-RBC 
mechanisms are not easily studied in patient samples or in mouse models. To better 
study the fate of excess α-chains in human RBC, the model β Thalassemic cell was 
developed. Model human β thalassemic RBC is made by entrapping purified human 
α-chains within normal RBC via osmotic lysis and resealing. This human model 
allows for the systematic examination of the mechanisms underlying the α-chain 
mediated damage in the β thalassemic RBC. Studies utilizing the model β thalas-
semic RBC have demonstrated that the α-chains give rise to an iron and glutathione-
dependent, self-amplifying and self-propagating oxidative reaction.
Keywords: β thalassemia, α-hemoglobin chains, iron, red blood cell, erythrocyte, 
oxidation, free radicals, glutathione, deformability
1. Introduction
The thalassemias are a major cause of morbidity and mortality throughout much 
of the world [1–9]. Thalassemias are characterized by the disruption of the synthesis 
of normal adult hemoglobin (HbA; an α2β2 tetramer; Figure 1) consequent to a diverse 
array of genetic mutations/deletions to either the β or α-hemoglobin chain genes 
(Chromosomes 11 and 16, respectively). As a consequence of reduced/absent produc-
tion of β-chains, β thalassemia is characterized by the presence of highly unstable 
monomeric α-chains as these chains cannot self-associate and indeed require a chap-
erone protein to prevent precipitation [10]. In contrast, α thalassemia is characterized 
by the presence of relatively stable tetrameric β chains. Interestingly, as schematically 
shown in Figure 1, unlike most genes, there are four copies of the α-globin genes; 
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this is in contrast to the expected two copies of the β-globin genes. The evolutionary 
duplication of the human α-chain genes may have been favored consequent to the 
inherent instability of monomeric α-chains. Indeed, the instability of the α-chains 
is the key factor underlying the pathophysiology of the β thalassemic red blood cell 
(RBC). Moreover, the pathophysiology of β thalassemia can be further complicated by 
the geographical prevalence, and high frequency, of a number of mutated β hemo-
globin genes (e.g., sickle hemoglobin, hemoglobin E and hemoglobin C). If a mutated 
β-chain is the only functional β-chain present, the resultant disease will be more severe 
than that observed in β thalassemia Intermedia (a single normal β-globin gene). Loss 
of both β-chain genes gives rise to severe β Thalassemia Major which is fatal in the 
absence of transfusion therapy. The α thalassemias are characterized by a broader 
range of disease states due to the presence of 4 α genes. The loss of expression from a 
single gene (α Thalassemia1 Trait) is often asymptomatic and undiagnosed; though 
the individual is a carrier for α Thalassemia and, in high frequency geographic areas 
may be at elevated risk for symptomatic disease transmission to an offspring. Deletion 
of two or three α-genes results in severe disease as a single active α-gene cannot, due 
to the instability of the chain, produce sufficient mature α-chains to form sufficient 
HbA. Loss of all four α-genes is fatal (resulting in Hydrops fetalis) due to the crucial 
role that α-chains play in embryonic and fetal hemoglobin. In contrast to β thalas-
semia, stable mutated α-chains are rare so typically these do not pose a significant 
complication in the pathophysiology of α thalassemia.
In this chapter we will further explore the pathophysiology of the β thalassemic 
RBC. Surprisingly, while significant injury to the thalassemic erythrocyte arises 
from the excess α-chains, the underlying mechanisms by which these chains damage 
and subsequently destroy the thalassemic RBC in the bone marrow and peripheral 
blood have not been clearly delineated. Our lack of understanding of the mecha-
nisms of α-chain mediated damage is due, in part, to three major factors: (1) studies 
of RBC from β thalassemic individuals are difficult to do since these cells, upon 
collection, already exhibit significant injury and represent a survivorship bias since 
up to 80% of erythroid precursors are destroyed within the bone; (2) β thalassemic 
patients are typically transfused to both correct the severe anemia accompanying 
the disease and to prevent endogenous erythropoiesis of defective RBC; and (3) the 
lack of a good experimental model by which the pathophysiology of excess globin 
chains on human RBC can be examined.
While little can be done to change the first two problems, researchers have 
attempted to tackle the third issue using murine models of thalassemia [11–17]. 
Original murine studies examining the knockout of the murine β-chains were not 
Figure 1. 
Molecular basis and clinical diagnosis of the α and β thalassemias [1–9]. β* denotes abnormal β hemoglobin 
gene such as HbS or HbE.
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productive as the murine α-chains behave significantly different from their human 
counterpart. To overcome this problem, human α-chain genes were inserted into the 
mouse genome in place of the murine genes. Again, these studies failed to give rise 
to as severe a phenotype as is seen in the human disease. Subsequent studies utilized 
additional mutations to produce symptomatic disease in the murine context—albeit 
with still substantial differences from the pathophysiology seen in the human β 
thalassemic RBC. Hence, an alternative approach for studying the pathophysiology 
of unpaired α-chains on the human RBC was needed.
2. Model human β thalassemic RBC
To this end, our laboratory developed an in vitro model of the HUMAN β 
thalassemic erythrocyte [18–27]. In this model, purified human α-chains are 
entrapped within normal human RBC (or, if desired, mouse RBC) by osmotic 
lysis and resealing (Figure 2) [18–34]. As previously shown, osmotic lysis and 
resealing results in RBC exhibiting normal hemoglobin concentration and volume 
(Table 1) as well as normal ATP concentration, oxidant sensitivity, morphology and 
Figure 2. 
Generation of model β thalassemic RBC from normal human donor cells via osmotic lysis and resealing 
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deformability while allowing for the efficient entrapment of exogenous compounds 
[18–34]. Indeed, studies with resealed human RBC demonstrate that this meth-
odology can be used to correct enzyme deficiencies, enhance antioxidant levels, 
and be used in vitro to study malarial growth and maturation. Moreover, murine 
studies demonstrated that osmotically resealed murine RBC exhibited normal in 
vivo survival. To manufacture the model β thalassemic RBC from normal human 
donor cells, purified, heme-containing, α-hemoglobin chains were prepared by 
dissociation of CO-treated HbA in the presence of parahydroxymercuribenzoate, 
followed by ion exchange chromatography, to isolate the purified CO-α-chains as 
previously described [1, 18, 20–22, 35, 36]. Analysis of the purified α-chains by 
mass spectroscopy demonstrated the expected mass values for the α-globin chain. 
The purified α-chains can be stored at −80°C as carbon monoxide stabilized chains 
(CO-α-chains) and then thawed immediately prior to use.




K+ Loss + +
Unpaired α-chains 1–3% of total hemoglobin in 
peripheral blood reticulocytes
3–4% of total hemoglobin
Membrane Bound 
Globin
Increased Increased; correlated with α-chain 
autoxidation & heme release.
Membrane proteins/
thiols
Loss of spectrin and ankyrin. 
Oxidation of membrane thiol 
(-SH) groups.
Loss of spectrin and ankyrin correlated with 
membrane thiol (-SH) oxidation, α-chain 
autoxidation, and heme release.
Cellular 
deformability
Decreased cellular and 
membrane deformability




Evidence supporting increased 
oxidative damage
Increased H2O2; correlated with α-chain 
autoxidation & heme release.
Oxidant 
susceptibility




Increased membrane associated 
hemoglobin & Heinz body 
formation
Increased membrane heme; correlated with 
α-chain autoxidation.
Short in vivo survival + + (murine model β Thal RBC)
Table 2. 
Comparison of the pathologic characteristics of β thalassemic and model β thalassemic erythrocytes [18–27].
Parameter N Normal Resealed* Model β 
thal*
Model α thal*,**
Mean cell volume (μm3) 7 88.9 ± 1.5 85.8 ± 4.5 78.6 ± 0.8 76.0 ± 4.0
Mean cell hemoglobin (pg) 7 30.5 ± 0.8 28.5 ± 2.7 23.4 ± 0.6 26.9 ± 2.1
Mean cell Hb conc. (g/dl) 7 34.2 ± 0.7 33.2 ± 1.7 29.6 ± 0.6 35.5 ± 1.3
Red cell distribution width 
(RDW)
7 12.9 ± 0.2 17.5 ± 4.5 29.2 ± 0.5 21.3 ± 3.8
*Immediately post resealing and washing 3×.
**Made via the entrapment of purified human β hemoglobin chains.
Table 1. 
Cellular characteristics of model β and α thalassemic RBC [18–27].
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Entrapment of the purified α-chains within normal erythrocytes is done by 
osmotic lysis and resealing as previously described [18–34]. Briefly, washed, packed 
erythrocytes (80–85% hematocrit) are mixed with the purified CO-α-chains 
(10 mg/ml packed red cells) and then placed as a thin film within 11.5 mm diameter 
dialysis tubing (MW cutoff of 3500). The samples are dialyzed against a hypotonic 
lysis buffer (5 mM potassium phosphate buffer and 2 mM EDTA; pH 7.4) at 4°C 
for 60 min. The dialysis tubing is then transferred to an isotonic resealing buffer 
(5 mM potassium phosphate, 160 mM NaCl, and 5 mM glucose; pH 7.4) with gentle 
agitation for 30 min at 37°C. Following resealing, cells are washed with saline until 
the supernatant is clear. Using this procedure, approximately 70–80% of the initial 
packed erythrocyte volume is recovered. Radiolabeled α-chains can be utilized to 
quantitate the intracellular entrapment [18, 20].
To determine whether the model β thalassemic erythrocytes exhibit the cellular 
abnormalities characteristic of true β thalassemic cells, a number of cellular param-
eters have been examined. The results of these studies demonstrate that the α-chain 
loaded erythrocytes exhibit structural and functional changes very similar to those 
seen in β thalassemic erythrocytes (Table 2). Consequently, this model allowed for 
the systematic examination of the mechanisms underlying the α-chain mediated 
damage within the β thalassemic RBC and to directly determine the ontogeny of the 
pathologic events underlying the RBC injury and to experimentally test potential 
therapeutic approaches.
3. Iron-glutathione driven progeria of the thalassemic RBC
Containing approximately 20 mM iron, the RBC is the most ferruginous somatic 
cell in mammals. Under normal conditions, most of this iron is complexed within 
hemoglobin (as heme) with virtually none present as free metal (i.e., non-heme). 
This near perfect compartmentalization of iron may, however, break down in 
certain pathologic states such as β thalassemia and sickle cell disease resulting in the 
autoxidation of hemoglobin (i.e., formation of methemoglobin and hemichromes). 
Of physiologic importance, the monomeric α-chains spontaneously autoxidize to 
Figure 3. 
Free radical basis of α-hemoglobin autoxidation and free radical injury. Consequent to the formation of 
methemoglobin, the non-covalently bound heme is 8-times more likely to escape the globin chain. Release of the 
heme initiates iron-dependent free radical reactions. References: [18–27].
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seen in β thalassemic erythrocytes (Table 2). Consequently, this model allowed for 
the systematic examination of the mechanisms underlying the α-chain mediated 
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therapeutic approaches.
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Containing approximately 20 mM iron, the RBC is the most ferruginous somatic 
cell in mammals. Under normal conditions, most of this iron is complexed within 
hemoglobin (as heme) with virtually none present as free metal (i.e., non-heme). 
This near perfect compartmentalization of iron may, however, break down in 
certain pathologic states such as β thalassemia and sickle cell disease resulting in the 
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methemoglobin, simultaneously generating superoxide (O2−), at a rate 8-times that 
of normal hemoglobin (Figure 3) [18, 20, 22–27, 37–39]. Moreover, consequent to 
the formation of methemoglobin, the non-covalently bound heme is more likely 
to escape the heme pocket of the globin chain giving rise to elevated levels of 
free, redox-active, intraerythrocytic iron. The O2− produced via the autoxidation 
of hemoglobin can reduce ferric (Fe+3) to ferrous (Fe+2) iron or form hydrogen 
peroxide (H2O2; either spontaneously or enzymatically via superoxide dismutase). 
Importantly, the iron, O2−, and H2O2 can, via the Haber-Weiss Reaction, give rise 
to the formation of the ‘dreaded’ hydroxyl radical (•OH) which rapidly reacts with 
virtually all biological constituents converting pristine materials into biological 
garbage (Figure 3). However, despite the general concept that free iron and the 
formation of free radicals are bad, the actual iron-dependent pathophysiology of 
the β thalassemic RBC has been poorly understood.
Mechanistically, studies using the model β thalassemic RBC have demonstrated 
that the initial autoxidation of the unpaired α-chains initiates an iron and reduced 
glutathione (GSH) dependent, self-amplifying and self-propagating reaction with 
the subsequent release of even more heme and, eventually, free iron. Schematically, 
this self-amplifying, self-propagating injury pathway is shown in Figure 4. As noted, 
the reaction process is initiated by the autoxidation of the unpaired α-chains which 
gives rise to the release of free heme and the generation of O2−. Interestingly, at this 
Figure 4. 
Damage to multiple components of the β thalassemic RBC is mediated by an Fe-GSH dependent mechanism. 
As thalassemic RBC circulate, α-hemoglobin chains autoxidize (A) giving rise to superoxide (O2−) and 
methemoglobin [MetHb]. The heme moiety of the α metHb chains are released yielding free heme and globin 
(B). Free heme reacts with reduced glutathione [GSH; reaction (C)] resulting in cleavage of the heme group 
and the formation of a glutathione radical (GS•) and the release of free Fe+2 (D). The free iron (E) reacts with 
hemoglobin derived reactive oxygen species (ROS: O2− and H2O2) to generate •OH – A highly reactive radical 
capable of damaging all cellular components including cellular metabolism and cation/anion balance. The 
ferric iron (Fe+3), in the presence of additional GSH or O2− regenerates Fe+2 which then oxidizes additional 
hemoglobin (F). Reactions (G) and (H) represent subsequent oxidative and non-oxidative injury to the cell. 
Oxidative pathway generated from references: [18–27, 40].
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point, a key component of this pathway is GSH; an ‘anti-oxidant’ present at high 
intracellular (~2.3 mM) concentrations within the RBC [41, 42]. GSH readily reacts 
with free heme resulting in the cleavage of the heme ring, the release of free iron, 
and the formation of a thiol radical (GS•). This reaction leads to the rapid amplifica-
tion of the oxidative damage to the RBC [18, 20, 22–27]. .The importance of the 
released iron and GSH was documented experimentally. As shown in Figure 5A, 
addition of Fe+3 to hemolysates from normal RBC results in the rapid oxidation of 
oxyhemoglobin in an iron-dose dependent manner. The oxidation of hemoglobin 
can be inhibited by the inclusion of an iron chelator (shown is deferoxamine; DFO) 
or by chemical depletion of GSH (not shown) [23, 27]. Moreover, in the intact model 
β thalassemic RBC, chemical depletion of GSH inhibited iron-driven hemoglobin 
oxidation (Figure 5B) [23, 27]. In contrast, as shown in Figure 5C, increasing the 
amount of intracellular GSH (via osmotic lysis and resealing; see Figure 2) in the 
model β thalassemic RBC significantly exacerbated injury to the cell. This enhanced 
injury is readily seen by the significantly reduced deformability (i.e., increased mean 
cell transit time) of the GSH-loaded model β thalassemic cells relative to the control 
model β thalassemic RBC. Importantly, as shown, GSH supplementation of normal 
RBC in the absence of iron had no detrimental effects on cellular deformability.
The enhanced oxidative stress, and consumption of GSH, was further noted by 
the time dependent decrease in GSH noted in the model β thalassemic RBC (Table 3) 
[27]. Moreover, a decrease in the NADPH/NADPtotal ratio was noted. NADPH is 
utilized to regenerate reduced GSH from oxidized (GSSG) glutathione via gluta-
thione reductase. This decrease in the NADPH/NADPtotal ratio is likely reflective of 
both the high GSH-GSSG-GSH cycling but also of metabolic abnormalities arising 
consequent to iron and free radical mediated inhibition of normal glucose metabo-
lism (Figure 4). Also of physiological importance, was the finding that the model 
β thalassemic RBC exhibited significantly (p < 0.001) decreased catalase activity 
Figure 5. 
Role of iron and GSH in the destruction of the β thalassemic RBC. (A) Fe+3 is a potent accelerator of 
hemoglobin oxidation. Shown is the oxyhemoglobin concentration following the addition of 100, 175 and 
250 μM Fe+3 to a fresh RBC hemolysate. In contrast to the Fe+3-treated samples, no oxidation was observed 
in the absence of added Fe+3 or in the presence of an iron chelator [DFO (deferoxamine) or, not shown, the 
tripeptide Gly-His-Lys]. Also shown are sequential, hemoglobin scans of the hemolysates treated with Fe+3. The 
time, in minutes, of the individual scan line following addition of Fe+3 are indicated [23, 27]. (B) Depletion 
of GSH in model β thalassemic RBC inhibits hemoglobin oxidation. Shown is the percent oxyhemoglobin in 
control-resealed and model β thalassemic cells RBC over 27 h at 37°C. GSH was depleted by treatment with 
1-chloro-2.4-dinitrobenzene (CDNB) as previously described [18, 20, 31, 32]. (C) Elevated intracellular GSH 
levels in model β thalassemic RBC adversely affects cellular deformability as demonstrated by the cell transit 
analyzer. Less deformable cells take much longer to transit through a pore of known diameter and length. The 
results shown are the mean ± S.D. of a minimum of four experiments with >2000 RBC measured at each time 
point. From references: [23, 27].
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thione reductase. This decrease in the NADPH/NADPtotal ratio is likely reflective of 
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lism (Figure 4). Also of physiological importance, was the finding that the model 
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Figure 5. 
Role of iron and GSH in the destruction of the β thalassemic RBC. (A) Fe+3 is a potent accelerator of 
hemoglobin oxidation. Shown is the oxyhemoglobin concentration following the addition of 100, 175 and 
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(Table 3). Catalase is the pre-eminent defense against H2O2 within the RBC, mak-
ing β thalassemic cell particularly increasingly sensitive to H2O2 generated via the 
pathway described in Figure 4 [31–34, 43]. Following 20 h incubation at 37°C, only 
61.5 ± 2.9% of the initial catalase activity remained in the α-hemoglobin chain loaded 
cells versus 104.6 ± 4.5% in the control RBC. The loss of catalase arose due to the 
decrease in the NADPH/NADPtotal ratio as studies have demonstrated that NADPH 
is essential for maintaining catalase in an enzymatically active state [31–34, 43–47]. 
Indeed, as noted in Table 3, the model β thalassemic erythrocytes exhibit a signifi-
cant decrease in the NADPH/NADPtotal ratio similar to that seen in severe G6PD 
deficiency. Hence, consequent to the oxidation of hemoglobin and the formation of 
free radicals in the thalassemic RBC, significant metabolic and functional changes 
are noted in the model β thalassemic RBC that mirror those seen in patient derived 
samples (Figure 4 and Table 2). It is also important to note that non-oxidative driven 
damage also occurs. As shown in Figure 4, precipitated globin proteins, as well as 
iron and heme, can alter the intracellular viscosity of the cytoplasm and interact with 
the cytoskeleton and membrane lipids resulting in mechanical dysfunction. These 
oxidative and non-oxidative injuries can dramatically affect the function of the RBC.
4. Loss of RBC deformability and vascular survival
From a functional standpoint, perhaps the most important consequence of the 
oxidative changes to the β thalassemic RBC, as well as other RBC abnormalities, 
is the loss of cellular deformability [18–27, 29–33, 48–52]. The physiology, fluidics 
and vascular bed of the circulatory system impart unique rheological stresses on cir-
culating RBC (Figure 6A) [53]. These include extreme variations in shear stress and 
viscosity as well as biomechanical obstacles (e.g., capillaries and splenic filtration). 
With an average resting cardiac output of approximately 5 L/min, blood flow varies 
from approximately 40 cm/s in the aorta to 0.03 cm/s in the smallest capillaries 
[53, 54]. Moreover, blood viscosity (affecting shear stress) is also variable. At high 
RBC counts and high flow rates, blood is highly viscous while at low RBC counts 
and low flow rates (capillaries), blood viscosity is greatly reduced. Rheological 
stress is further exacerbated by the biomechanical stresses induced by the extreme 
disparity in the size of RBC (~8 μm) to the minimum diameter of the vascular capil-
lary beds (4–5 μm) and splenic interendothelial clefts (0.5–1.0 μm) [55, 56]. Hence, 
consequent to the shear forces, viscosity and biomechanical stresses placed on 
blood cells, a key biologic/physiologic requirement of the RBC within the vascular 
space is rheological deformability. Biomechanically, the intracellular viscosity 
and membrane rigidity of the RBC are the key factors in imparting their vascular 
Population Hours 
(37°C)
GSH (μmol/g Hb) NADPH/NADPtotal 
(1.0 = Normal)
Cat. activity (IU/g Hb)
Control 
RBC
0 5.6 ± 0.4 0.870 147,300 ± 17,000
20 6.0 ± 0.6 1.063 154,100 ± 14,800
Model β 
Thal
0 5.2 ± 0.3 0.898 145,600 ± 12,300
20 2.1 ± 0.0* 0.478* 89,540 ± 8200*
Modified from [27].*p < 0.001 from time-matched Control RBC.
Table 3. 
Association between NADPH, GSH and catalase.
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rheological deformability; both of which can be dramatically altered consequent to 
hemoglobin oxidation, heme release and/or redox-damage to cytoplasmic, cytoskel-
etal, or membrane components (Figure 4) [57–68]. Indeed, as shown in Figure 6B, 
Figure 6. 
Vascular deformability of model β thalassemic RBC. (A) The vascular bed is composed of blood vessels of 
various sizes which create significant disparity in blood (fluid and cellular) velocity consequent to vessel 
diameter. The fluid flow induces rheological sheer stress while the vessel size creates biomechanical deformation 
of cellular elements. Shown is an RBC undergoing deformation in a microfluidic channel. (B) Ektacytometric 
analysis of α-chain loaded RBC demonstrate that these chains dramatically reduce the sheer-induced shape 
change of the cell [24]. Ektacytometry bests approximates high flow rates. (C) The mean cell transit time (in 
ms) of model β thalassemic cells was significantly increased, similarly to that observed in patient samples [20]. 
This microfluidic flow best approximates capillary flow.
Figure 7. 
Model β thalassemic RBC are immunologically recognized and cleared rapidly from the peripheral circulation 
in vivo. (A) Blood group A RBC that were loaded with purified α-chains were phagocytosed by human 
monocytes. Shown for comparison are control cells from the same donor that were either unopsonized or 
opsonized with an anti-A blood typing antibody. (B) Model β thalassemic mouse RBC were made by the 
entrapment of purified human α-hemoglobin chains within Normal murine RBC. Oxidatively damaged RBC 
were made by treating mouse RBC with 50 μM phenazine methosulfate (PMS) for 2.5 h then washing. Both 
PMS-treatment and the entrapment of α-hemoglobin chains lead to membrane iron deposition and extensive 
RBC oxidation. The model β thalassemic and PMS-treated RBC have half-lives of 4 and 7 days, respectively 
in the peripheral circulation versus 26 days for normal murine RBC. Shown is the percent total RBC mass that 
is PKH-26 labeled. Inset: The peripheral blood lifespan of the human β thalassemic RBC are approximately 
6–10 days in a patient with a functioning spleen and 12–16 days in a splenectomized individual. Normal RBC 
circulates approximately 120 days, data modified from Blendis et al. [69].
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hemoglobin oxidation, heme release and/or redox-damage to cytoplasmic, cytoskel-
etal, or membrane components (Figure 4) [57–68]. Indeed, as shown in Figure 6B, 
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various sizes which create significant disparity in blood (fluid and cellular) velocity consequent to vessel 
diameter. The fluid flow induces rheological sheer stress while the vessel size creates biomechanical deformation 
of cellular elements. Shown is an RBC undergoing deformation in a microfluidic channel. (B) Ektacytometric 
analysis of α-chain loaded RBC demonstrate that these chains dramatically reduce the sheer-induced shape 
change of the cell [24]. Ektacytometry bests approximates high flow rates. (C) The mean cell transit time (in 
ms) of model β thalassemic cells was significantly increased, similarly to that observed in patient samples [20]. 
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Figure 7. 
Model β thalassemic RBC are immunologically recognized and cleared rapidly from the peripheral circulation 
in vivo. (A) Blood group A RBC that were loaded with purified α-chains were phagocytosed by human 
monocytes. Shown for comparison are control cells from the same donor that were either unopsonized or 
opsonized with an anti-A blood typing antibody. (B) Model β thalassemic mouse RBC were made by the 
entrapment of purified human α-hemoglobin chains within Normal murine RBC. Oxidatively damaged RBC 
were made by treating mouse RBC with 50 μM phenazine methosulfate (PMS) for 2.5 h then washing. Both 
PMS-treatment and the entrapment of α-hemoglobin chains lead to membrane iron deposition and extensive 
RBC oxidation. The model β thalassemic and PMS-treated RBC have half-lives of 4 and 7 days, respectively 
in the peripheral circulation versus 26 days for normal murine RBC. Shown is the percent total RBC mass that 
is PKH-26 labeled. Inset: The peripheral blood lifespan of the human β thalassemic RBC are approximately 
6–10 days in a patient with a functioning spleen and 12–16 days in a splenectomized individual. Normal RBC 
circulates approximately 120 days, data modified from Blendis et al. [69].
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ektacytometric analysis of the model β thalassemic RBC shows a significant loss of 
cellular deformability induced by shear stress (e.g., large vessels). Moreover, cell 
transit analysis of these cells (analogous to capillary deformation) showed a very 
significant loss of deformability in the model β thalassemic cells as reflected by the 
very large and significant increase in transit time (Figure 6C).
Consequent to the loss of deformability and immune recognition (e.g., Kupffer 
cells of the liver and, potentially, antibodies), the circulatory survival of β thalas-
semic RBC is impacted. As demonstrated in Figure 7A, model β thalassemic RBC 
(Blood group A) exhibited enhanced immune recognition and phagocytosis by 
autologous monocytes when compared to control cells from the same donor. 
Indeed, the level of phagocytosis was similar to that of the anti-A opsonized posi-
tive control RBC. The loss of deformability and enhanced immune recognition both 
contribute to decreased in vivo survival. This was demonstrated using mice trans-
fused with model β thalassemic murine cells (mouse RBC + human α-chains) in 
which the transfused RBC exhibited a dramatic reduction in the circulatory lifespan 
(Figure 7B). The role of α-chain mediated oxidation was supported by the find-
ing that lightly oxidized (phenazine methosulphate treated; 50 μM) murine cells 
showed similar circulatory dynamics. These results are comparable to that observed 
in humans where, consequent to the α-chain driven oxidation, β thalassemic RBC 
have a very short circulatory lifespan (7–14 days depending on spleen status) 
compared to the 120 days of a normal RBC.
5. Immunological dysfunction: Effect on antigen presentation
Interestingly, thalassemias have been clinically associated with an increased risk 
of recurrent bacterial infections [70–87]. This is most evident in under-developed 
nations where sanitary and medical facilities are most lacking. Despite the clinical evi-
dence of recurrent bacterial infections in thalassemic patients, the biological events 
underlying this finding are unclear. This confusion arises as a natural consequence of 
the heterogeneity of the microbial disease itself, the patients age, the state of splenic 
function, the frequency of transfusion, the degree of similarity between the patient 
and the blood donor pool, the nutritional status of the patient (e.g., United States 
versus Thailand) and whether one is looking at humoral or cell-mediated immunity 
[70–87].
In general, studies on the humoral (i.e., immunoglobulin-based) immunity 
of thalassemic patients suggest that this arm of the immune system is ‘relatively’ 
normal. These studies have indicated normal to elevated levels of IgG, IgA, and 
IgM but decreased levels of Factor B, C3, and C4 (perhaps due to consumption 
via oxidatively damaged β thalassemic cells). Reflective of this normality, and 
consequent to the extensive oxidant injury to the thalassemic cells, circulating 
immune complexes and an elevated risk of autoimmune hemolytic anemia have 
been described in β thalassemia intermedia and major patients. Serum fractions 
from these patients also exhibited increased amounts of C1q-precipitable immune 
complexes. In contrast, as suggested by the clinically described recurrent bacterial 
infections, cell-mediated immunity is highly suspect in the thalassemic patient (and 
sickle cell patients). The few direct studies on cell-mediated immunity in thalas-
semic patients were, typically, enumeration of the mononuclear cell populations 
(T cells, B cells, NK cells and monocytes). In general, these studies suggest normal 
cell numbers but a skewed distribution of the CD4+ to CD8+ T cell ratio. The altered 
ratio was characterized by a relative depression in CD4+ T cells (i.e., helper T cells) 
and NK (Natural Killer) cells and a relative rise in CD8+ (cytotoxic and suppressor) 
T cells that increased linearly with the number of units transfused. However, very 
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few functional studies have been done in thalassemic patients to answer the ques-
tion: Why are β thalassemic patients at risk of recurrent bacterial infections?
Previous studies have suggested that increased bioavailable iron in transfused 
patients might facilitate the growth of organisms in which iron is a limiting nutri-
ent (i.e., most bacteria). Other studies have implicated the loss of splenic function. 
While both of these factors may indeed play important roles in recurrent bacterial 
infections, they may not offer a complete explanation. In addition to thalassemia, 
a number of other diseases and trauma scenarios are characterized by recurrent 
bacterial infections (e.g., malaria and burn injury) suggestive of impaired cell-
mediated immunity. Interestingly, a common characteristic of all these conditions is 
erythrophagocytosis. Previous studies have demonstrated that phagocytic uptake of 
IgG-coated and oxidatively stressed RBC resulted in a transient depression of further 
macrophage phagocytosis, decreased respiratory burst (i.e., NADPH-oxidase activ-
ity; O2− production), and impaired killing of bacteria [88–93]. Interestingly, in the 
case of Plasmodium falciparum-infected RBC, only phagocytosis of mature (tropho-
zoite), but not immature (ring stage), stages had an inhibitory effect on monocyte 
function. Importantly, a major difference between the mature and immature malar-
ial infected RBC is the presence of malarial pigment (hemozoin), an iron/heme rich 
degradation product of parasite hemoglobin catabolism. Τhe heme- and iron-rich 
membranes of the β thalassemic RBC, which we have previously documented [22], 
may function in a manner analogous to malarial pigment or iron salts and impair 
cell-mediated immunity—primarily at the level of the APC but potentially extending 
to the T cell level. Some data from thalassemic patients support the hypothesis for 
impairment of the T cell response. For example, patients with thalassemia intermedia 
have been reported to have diminished T cell mitogen responses when their serum 
iron and ferritin were higher than 200 and 600 μg/dl, respectively [94].
Hence, injury arising from the iron-GSH pathway can result in (any combina-
tion of) RBC opsonization by endogenous antibodies, phosphatidylserine (PS) 
exposure, protein clustering, sublytic levels of complement binding, and/or loss 
of cellular deformability (Figure 7) that leads to the removal of the damaged β 
thalassemic cells from the circulatory system by components of the mononuclear 
phagocytic system (MPS). Erythrophagocytosis can occur within the spleen (if 
present and functioning), liver (Kupffer cells) or the microvasculature itself when 
Figure 8. 
Antigen processing and presentation is inhibited by oxidized RBC and hemin. (A) Antigen presentation of TT 
and SM was inhibited by the erythrophagocytosis of oxidized RBC. Normal RBC had no inhibitory effect. The 
efficacy of antigen processing and/or presentation was assessed by 3H-thymidine incorporation in proliferating 
T cells. PBMC were resuspended in Aim V media at a final concentration of 2.5 × 105 PBMC per 200 μl. 
Final RBC concentration was 8 × 106 per 200 μl. Antigens were diluted in Aim V and added at the indicated 
concentrations. Results shown are of a representative experiment with quadruplicate samples. (B, C) Heme 
pretreatment of PBMC (2 h at 37°C) dramatically inhibits the proliferative response to tetanus toxoid (B) and 
S. mutans (C). Interestingly, the ability of PBMC to respond to intact bacteria is more significantly blunted 
than is the response to tetanus toxoid at intermediate hemin concentrations (50 μM). Results shown are of a 
representative experiment with quadruplicate samples.
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non-deformable RBC are trapped and then cleared by circulating macrophages. 
Regardless of the location of removal, erythrophagocytosis results in impaired 
MPS function. As shown in Figure 8A, antigen presentation of purified tetanus 
toxoid (TT; a peptide) or fixed, intact, S. mutans (SM; an intact bacteria) by normal 
human antigen presenting cells (APC; blood monocytes) was dramatically, and 
differentially, affected by the presence of either control (unoxidized) or oxidized 
(50 μM PMS as per Figure 7) human RBC. As shown, oxidized RBC prevented 
successful antigen presentation to human T cells while normal RBC showed no 
detrimental effects. Further experimentation demonstrated that the inhibitory 
effect was due to heme/iron. As shown in Figure 8B, C, direct addition of hemin to 
the APC impaired successful antigen presentation of both tetanus toxoid and Strep. 
mutans in a dose dependent manner.
6. Conclusions
β thalassemias arise from a number of underlying genetic defects that interfere 
with the synthesis of the β hemoglobin chain and the subsequent production of 
the normal α2β2 hemoglobin tetramer. As a consequence of this decreased/absent 
β-chain synthesis, unpaired, monomeric, α-hemoglobin chains are produced. 
While the presence of the highly unstable α-chains mediate the pathophysiology 
of the RBC, it has been difficult to fully elucidate the mechanisms underlying their 
destructive processes in human cells. This lack of understanding of the mechanisms 
of α-chain mediated damage is due, in large part, to the fact that peripheral RBC 
isolated from β thalassemic individuals are already severely damaged cells (with 
most being destroyed within the bone marrow). Moreover, severe β thalassemia 
patients are typically transfused to both correct the severe anemia accompanying 
the disease and to prevent endogenous erythropoiesis of defective RBC. Hence, 
murine models of β thalassemia have been developed and extensively studied. 
However, problems exist with these models (e.g., mouse vs. human α-chains; 
interaction of human globins with mouse cytoskeletal proteins) and these mice, as 
in human patients, still suffer from the heterogeneity of RBC changes arising from 
the different ages of the peripheral blood RBC [11–17].
To better study the fate of unpaired α-chains in human RBC, the model β thal-
assemic cell was developed [18–34]. The entrapment of purified α-hemoglobin 
chains within normal erythrocytes via osmotic lysis and resealing provides an 
excellent and reproducible human model for studying the pathologic effects of 
the unpaired α-chains on the structural and functional characteristics of the 
RBC. Indeed, as noted in Table 2, the α-chain induced structural and functional 
RBC changes are very similar to those observed in human donor derived β thalas-
semic RBC. Schematically the pathophysiology of the β thalassemic RBC, and its 
downstream consequences, as elucidated by the model human β thalassemic RBC, 
are summarized in Figure 9. Importantly, these studies have demonstrated that 
the unpaired α-chains initiate an iron, GSH-dependent, self-amplifying and self-
propagating reaction with the subsequent release of even more heme and, eventually, 
free iron (Figure 4). Membrane proteins and reactive thiol groups (not shown) 
were rapidly decreased in a pattern similar to that observed in vivo in β thalassemia 
[18, 20–23, 25–27]. These oxidative events also result in membrane vesiculation of 
the thalassemic RBC. One consequence of membrane vesiculation is the prefer-
ential loss of phosphatidylinositol (PI) anchored proteins from the RBC. Among 
these PI-anchored proteins are decay accelerating factor (DAF; CD55) and the 
membrane inhibitor of reactive lysis (MIRL; CD59) both of which play important 
roles in preventing complement-mediated binding and lysis. The effects of the 
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vesiculation-mediated loss of CD55 and CD59 can range from sublytic levels of 
bound complement enhancing phagocytosis to overt hemolysis. Indeed, a common 
endpoint for all the α-chain mediated injury is enhanced erythrophagocytosis. As 
shown, oxidized RBC or the heme from these cells (Figure 8) significantly inhibits 
antigen processing, presentation and T cell proliferation. The systemic importance 
of this on cell-mediated immunity has not be fully appreciated and may potentially 
explain the predisposition of thalassemic patients to recurrent bacterial infections.
In sum, these findings show the utility of the model β thalassemic human RBC 
for investigating the pathophysiology of the unpaired α-chains. Moreover, these 
cells are easily ‘manufactured’ from normal donor RBC and may provide an effec-
tive means to evaluate therapeutic approaches to ameliorate the damage to the 
thalassemic cell in β thalassemia intermedia in order to prolong RBC survival and 
reduce transfusions [23, 25–27, 40].
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Abstract
In β-thalassemia, the erythropoietic process is markedly altered, and the lack 
or reduced synthesis of β-globin chains induces an excess of free α-globin chains 
within the erythroid cells. Aggregation, denaturation, and degradation of these 
chains lead to the formation of insoluble precipitates causing damage to the red 
blood cell membrane. One of the major consequences in this genetic disorder is 
iron overload due to ineffective erythropoiesis and premature hemolysis in the 
plasma and in major organs such as heart, liver, and endocrine glands. The chapter 
describes the etiology of iron accumulation, the role of hepcidin in regulating 
increased iron absorption, and the pathophysiology resulting from excess of “free 
iron” and discusses new ways to decrease the iron overload and to neutralize its 
deleterious effects in the tissues other than iron chelation.
Keywords: oxidative stress, iron overload, β-thalassemia
1. Introduction
β-thalassemias are a group of hereditary blood disorders characterized by the 
reduced or absent synthesis of β-globin chains representing one of the most com-
mon autosomal recessive disorders worldwide. It is prevalent in the Mediterranean 
countries, the Middle East, and Southeast Asia, as well as countries along the 
Americas, coincidental with the occurrence of malaria. Carriers of β-thalassemia 
genes are considered relatively protected against malaria parasite. At present, 
because of vast population migration and intermarriage between different ethnic 
groups, β-thalassemia is also common in North and South America, Northern 
Europa, Australia, and the Caribbean. As a consequence of the reduced or absent 
synthesis of β-globin chains, there is an excess on α-globin chains that are instable 
and precipitate in red blood cell precursors causing abnormal cell maturation 
and their premature destruction in the bone marrow (ineffective erythropoiesis). 
Red blood cells that survive to reach the peripheral circulation are prematurely 
destroyed in the spleen. The break down products of Hb, heme, and iron catalyze 
chemical reactions that generate free radicals, including reactive oxygen spe-
cies (ROS), which in excess are toxic, causing damage to vital organs such as 
the heart and liver and the endocrine system [1]. More than 300 different point 
mutations cause β-thalassemia. They are inherited in a multitude of genetic 
combinations responsible for clinical manifestations extremely diverse, spanning 
a broad spectrum from the transfusion-dependent state of thalassemia major 
(TM) to the asymptomatic state of heterozygous carriers for β0 or β+ (thalas-
semia trait). β-thalassemia intermedia requires only periodic blood transfusion, 
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while β-thalassemia minor does not require a specific treatment. One of the 
major consequences in this genetic disorder is iron overload due to multiple blood 
transfusions, ineffective erythropoiesis, and premature hemolysis in the plasma. 
Cardiomyopathy is the most common cause of death in transfusion-dependent 
thalassemia patients as a consequence of iron overloading. Thanks to the signifi-
cant improvement in therapy, patients with β-thalassemia may reach an advanced 
age. This is associated with clinical symptoms that are the consequence of the 
disease itself and the treatment modalities. The aim of this chapter is that to give a 
complete picture of current knowledge on the etiology of iron accumulation, the 
role of hepcidin in regulating increased iron absorption, and the pathophysiology 
resulting from excess of “free iron.” It will also be explored whether there are ways 
to decrease the iron overload and to neutralize its deleterious effects in the tissues 
other than iron chelation (for an extensive revision, see Refs. [1–5]).
2. Iron overload in β-thalassemia
In β-thalassemia, as well as in other acquired and hereditary hemolytic anemia, 
iron overload is a common and serious complication and represents a major cause 
of morbidity and premature mortality in these patients. Hemoglobin instability, 
frequent blood transfusion, and increased iron absorption from the gastrointestinal 
tract represent the main causes of iron overload in β-thalassemia. Iron deposition 
occurs in visceral organs (mainly in the heart, liver, and endocrine glands), caus-
ing tissue damage and ultimately organ dysfunction and failure. Iron homeostasis 
depends on a coordinated regulation of molecules involved in the import of this 
element and those exporting it out of the cells. In particular, the iron status reflects 
the balance among iron uptake from the diet, its storage and mobilization, and its 
utilization [1]. Normally, 1–2 mg of iron is absorbed from the diet per day, with 
an equivalent amount lost by the turnover of gastrointestinal tract epithelial cells. 
In β-thalassemia and other transfusion-dependent anemias, iron overload may 
accumulate in relatively short time because there are no physiologically regulated 
means of iron excretion. Iron is essential for several vital biological processes. It 
regulates enzymatic activity and oxidation-reduction reactions playing a pivotal 
role in proliferation and cell survival. Iron ensures the transport of oxygen and the 
catalysis of reactions involved in electron transfer, DNA synthesis, and nitrogen 
fixation. However, it is also highly toxic due to its ability to react with oxygen and 
catalyze the production of reactive oxygen species (ROS). In solution, iron can exit 
in two states of oxidation, Fe (II) and Fe (III), and is very poorly soluble at physi-
ological pH, especially when it is in the oxidized form Fe (III). Living organisms 
have thus developed many proteins to carry iron in biological fluids and transport 
it through cellular membranes and to store it in a non-toxic and easily mobilizable 
form [2, 6–8]. Iron is bound to transferrin in the plasma, but the iron overload 
in β-thalassemia patients saturates the ability of the transferrin iron transport 
system, leading to nontransferrin bound iron (NTBI) and labile plasma iron (LPI) 
starting to circulate in plasma and subsequently becoming deposited inside the 
susceptible cells [9, 10]. Rather than using the transferrin receptor, NTBI enters 
cells by nontransferrin pathways [1, 11]. Long-term uptake and accumulation of 
NTBI and LIP, its redox active component, lead to increate levels of storage iron and 
labile cellular iron [12]. Tissues susceptible to iron accumulation by this mechanism 
include the liver, endocrine system, and myocardium [13]. When the magnitude of 
the cellular LIP exceeds the capacity of the cell to synthesize new ferritin molecule, 
a critical concentration is reached that can generate reactive oxygen species (ROS). 
ROS produced by the metabolism of NTBI play a central role in inducing cellular 
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dysfunction, apoptosis, and necrosis [14]. A variety of ROS, most notably hydroxyl 
radicals, increase lipid peroxidation and organelle damage, leading to cell death 
and fibrogenesis mediated by transforming growth factor β-1 (TGF-beta-1) [15]. 
An underappreciated effect of iron overload is increased the infection risk that is a 
high cause of mortality in β-thalassemia patients [16]. The LIP has been suggested 
as a low-molecular-weight intermediate or transitory pool between extracellular 
iron and intracellular firmly bound iron [17]. The intracellular LIP is redox active, 
catalyzing the Fenton and Haber-Weiss reactions that generate ROS [18]. Excess 
ROS are cytotoxic through their interaction with cellular components, such as DNA, 
proteins, and lipids, causing damage to vital organs [19].
3. Strategies to remove iron in excess
β-thalassemia is a significant health problem in various areas of the world due 
to its frequency and severity. The standard treatment of β-thalassemia is currently 
based on transfusion therapy, iron chelation, and, in rare cases, splenectomy. This 
has led to an increased survival and amelioration of the quality of life, although 
many patients continue to be affected by cardiac disease and other clinical com-
plications, e.g., developed endocrine failure and delayed pubertal maturation. The 
only approach that may lead to a definitive cure for β-thalassemia is represented by 
allogenic hemopoietic stem cell transplantation, but the need to control transplant-
related complications and the requirement for matched donors make this option 
not available to most patients. Thus, the main therapeutic option for the majority of 
patients remains to be supportive care in the form of blood transfusion combined 
with chelation therapy [2]. The function of iron chelators is that to remove excess 
iron from the plasma and the cells by binding the labile and chelatable iron, thus 
facilitating its excretion through the urine and feces. Deferoxamine was the first 
iron chelator to be used clinically and is given by a slow, continuous, subcutaneous, 
overnight infusion through a portable pump. Its side effects are minimal, but its 
mode of administration results in low compliance [1]. Deferasirox presents several 
side effects [1, 2]. Neutropenia is the main potential complication of deferiprone, 
the first effective oral iron chelator in removing excess iron from the organs and 
from the heart. The use of a combination of chelators leads to an improvement 
in the efficacy of chelation therapy: deferiprone may mobilize iron from tissues into 
the circulation, while deferoxamine binds and facilitates its excretion in the urine 
(the “shuttle mechanism”) [1]. An additional potential approach to reduce iron 
overload is the downregulation of transferrin receptor 1 (TfR1) by administration of 
exogenous iron-free (apo) transferrin. In addition to free iron, some iron-containing 
compounds, due to hemolysis, are elevated in the plasma of β-thalassemia patients. 
They are free hemin and hemoglobin and are of considerable toxicity [1, 2]. These 
compounds are neutralized by their scavengers: hemopexin for free hemin and 
haptoglobin for free hemoglobin. These proteins are reduced in β-thalassemia 
patients, leaving free, un-neutralized hemin, and hemoglobin. The administration 
of hemopexin and haptoglobin may be suggested to reduce iron toxicity.
4. Strategies to modulate iron absorption
The discovery of hepcidin has led to an important advancement in the under-
standing of iron metabolism. Hepcidin is a key regulator of whole body iron homeo-
stasis originally identified from urine as an antimicrobial peptide produced in the 
hepatocytes [20]. Mutations in the human HAMP gene or targeted deletion of the 
Beta Thalassemia
92
while β-thalassemia minor does not require a specific treatment. One of the 
major consequences in this genetic disorder is iron overload due to multiple blood 
transfusions, ineffective erythropoiesis, and premature hemolysis in the plasma. 
Cardiomyopathy is the most common cause of death in transfusion-dependent 
thalassemia patients as a consequence of iron overloading. Thanks to the signifi-
cant improvement in therapy, patients with β-thalassemia may reach an advanced 
age. This is associated with clinical symptoms that are the consequence of the 
disease itself and the treatment modalities. The aim of this chapter is that to give a 
complete picture of current knowledge on the etiology of iron accumulation, the 
role of hepcidin in regulating increased iron absorption, and the pathophysiology 
resulting from excess of “free iron.” It will also be explored whether there are ways 
to decrease the iron overload and to neutralize its deleterious effects in the tissues 
other than iron chelation (for an extensive revision, see Refs. [1–5]).
2. Iron overload in β-thalassemia
In β-thalassemia, as well as in other acquired and hereditary hemolytic anemia, 
iron overload is a common and serious complication and represents a major cause 
of morbidity and premature mortality in these patients. Hemoglobin instability, 
frequent blood transfusion, and increased iron absorption from the gastrointestinal 
tract represent the main causes of iron overload in β-thalassemia. Iron deposition 
occurs in visceral organs (mainly in the heart, liver, and endocrine glands), caus-
ing tissue damage and ultimately organ dysfunction and failure. Iron homeostasis 
depends on a coordinated regulation of molecules involved in the import of this 
element and those exporting it out of the cells. In particular, the iron status reflects 
the balance among iron uptake from the diet, its storage and mobilization, and its 
utilization [1]. Normally, 1–2 mg of iron is absorbed from the diet per day, with 
an equivalent amount lost by the turnover of gastrointestinal tract epithelial cells. 
In β-thalassemia and other transfusion-dependent anemias, iron overload may 
accumulate in relatively short time because there are no physiologically regulated 
means of iron excretion. Iron is essential for several vital biological processes. It 
regulates enzymatic activity and oxidation-reduction reactions playing a pivotal 
role in proliferation and cell survival. Iron ensures the transport of oxygen and the 
catalysis of reactions involved in electron transfer, DNA synthesis, and nitrogen 
fixation. However, it is also highly toxic due to its ability to react with oxygen and 
catalyze the production of reactive oxygen species (ROS). In solution, iron can exit 
in two states of oxidation, Fe (II) and Fe (III), and is very poorly soluble at physi-
ological pH, especially when it is in the oxidized form Fe (III). Living organisms 
have thus developed many proteins to carry iron in biological fluids and transport 
it through cellular membranes and to store it in a non-toxic and easily mobilizable 
form [2, 6–8]. Iron is bound to transferrin in the plasma, but the iron overload 
in β-thalassemia patients saturates the ability of the transferrin iron transport 
system, leading to nontransferrin bound iron (NTBI) and labile plasma iron (LPI) 
starting to circulate in plasma and subsequently becoming deposited inside the 
susceptible cells [9, 10]. Rather than using the transferrin receptor, NTBI enters 
cells by nontransferrin pathways [1, 11]. Long-term uptake and accumulation of 
NTBI and LIP, its redox active component, lead to increate levels of storage iron and 
labile cellular iron [12]. Tissues susceptible to iron accumulation by this mechanism 
include the liver, endocrine system, and myocardium [13]. When the magnitude of 
the cellular LIP exceeds the capacity of the cell to synthesize new ferritin molecule, 
a critical concentration is reached that can generate reactive oxygen species (ROS). 
ROS produced by the metabolism of NTBI play a central role in inducing cellular 
93
Oxidative Stress and Iron Overload in β-Thalassemia: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.90492
dysfunction, apoptosis, and necrosis [14]. A variety of ROS, most notably hydroxyl 
radicals, increase lipid peroxidation and organelle damage, leading to cell death 
and fibrogenesis mediated by transforming growth factor β-1 (TGF-beta-1) [15]. 
An underappreciated effect of iron overload is increased the infection risk that is a 
high cause of mortality in β-thalassemia patients [16]. The LIP has been suggested 
as a low-molecular-weight intermediate or transitory pool between extracellular 
iron and intracellular firmly bound iron [17]. The intracellular LIP is redox active, 
catalyzing the Fenton and Haber-Weiss reactions that generate ROS [18]. Excess 
ROS are cytotoxic through their interaction with cellular components, such as DNA, 
proteins, and lipids, causing damage to vital organs [19].
3. Strategies to remove iron in excess
β-thalassemia is a significant health problem in various areas of the world due 
to its frequency and severity. The standard treatment of β-thalassemia is currently 
based on transfusion therapy, iron chelation, and, in rare cases, splenectomy. This 
has led to an increased survival and amelioration of the quality of life, although 
many patients continue to be affected by cardiac disease and other clinical com-
plications, e.g., developed endocrine failure and delayed pubertal maturation. The 
only approach that may lead to a definitive cure for β-thalassemia is represented by 
allogenic hemopoietic stem cell transplantation, but the need to control transplant-
related complications and the requirement for matched donors make this option 
not available to most patients. Thus, the main therapeutic option for the majority of 
patients remains to be supportive care in the form of blood transfusion combined 
with chelation therapy [2]. The function of iron chelators is that to remove excess 
iron from the plasma and the cells by binding the labile and chelatable iron, thus 
facilitating its excretion through the urine and feces. Deferoxamine was the first 
iron chelator to be used clinically and is given by a slow, continuous, subcutaneous, 
overnight infusion through a portable pump. Its side effects are minimal, but its 
mode of administration results in low compliance [1]. Deferasirox presents several 
side effects [1, 2]. Neutropenia is the main potential complication of deferiprone, 
the first effective oral iron chelator in removing excess iron from the organs and 
from the heart. The use of a combination of chelators leads to an improvement 
in the efficacy of chelation therapy: deferiprone may mobilize iron from tissues into 
the circulation, while deferoxamine binds and facilitates its excretion in the urine 
(the “shuttle mechanism”) [1]. An additional potential approach to reduce iron 
overload is the downregulation of transferrin receptor 1 (TfR1) by administration of 
exogenous iron-free (apo) transferrin. In addition to free iron, some iron-containing 
compounds, due to hemolysis, are elevated in the plasma of β-thalassemia patients. 
They are free hemin and hemoglobin and are of considerable toxicity [1, 2]. These 
compounds are neutralized by their scavengers: hemopexin for free hemin and 
haptoglobin for free hemoglobin. These proteins are reduced in β-thalassemia 
patients, leaving free, un-neutralized hemin, and hemoglobin. The administration 
of hemopexin and haptoglobin may be suggested to reduce iron toxicity.
4. Strategies to modulate iron absorption
The discovery of hepcidin has led to an important advancement in the under-
standing of iron metabolism. Hepcidin is a key regulator of whole body iron homeo-
stasis originally identified from urine as an antimicrobial peptide produced in the 
hepatocytes [20]. Mutations in the human HAMP gene or targeted deletion of the 
Beta Thalassemia
94
HAMP gene in mice result in massive iron overload [21]. Conversely, high levels of 
hepcidin lead to decreased iron absorption and iron-restricted anemias indicating 
that hepcidin is a negative regulator of iron transport into plasma. Many experi-
mental data suggested that the hepcidin could be the regulator of iron absorption 
and recycling acting principally or solely by binding to ferroportin, the only known 
cellular iron exporter. The systemic iron homeostasis is controlled by hepcidin-
ferroportin interaction: hepcidin binds to ferroportin and induces its internaliza-
tion and degradation, thus regulating the distribution of iron in the body. When 
hepcidin concentration increases, hepcidin binds to ferroportin, causing its phos-
phorylation, internalization, ubiquitylation, sorting through the multivesicular 
body pathway, and degradation in lysosomes, and iron is retained within the cells 
in cytoplasmic ferritin [22–25]. The expression of hepcidin is regulated by different 
stimuli at the transcriptional level: hypoxia, iron deficiency, erythroid expansion, 
and anemia are all negative regulators of hepcidin expression, while transferrin 
receptor 2 (TfR2), the membrane isoform of hemojuvelin (HJV), IL-6, iron, and the 
hemochromatosis protein HFE are all positive regulators of hepcidin transcription 
[2]. In β-thalassemia, in spite of iron overload, hepcidin production is generally 
low, and consequently, iron absorption is high. The process of differentiation and 
maturation of erythroid precursors is markedly altered in β-thalassemia (ineffec-
tive erythropoiesis). An excess of free α-globin chains within the red blood cells is 
the consequence of the reduced or lack synthesis of β-globin chains. Aggregation, 
denaturation, and degradation of these chains lead to the formation of insoluble 
precipitates that cause oxidative membrane damage within the red blood cell and 
developing erythroblasts (Figure 1A) [26]. Ineffective erythropoiesis is accompa-
nied by a massive iron overload, due to an increase in iron absorption by the gas-
trointestinal tract and to frequent blood transfusions. Nevertheless, iron overload 
occurs also in patients who have not received transfusions such as patients suffering 
from thalassemia intermedia [27, 28]. If iron was a dominant regulator, patients 
with β-thalassemia should express very high levels of hepcidin in serum in order 
to decrease intestinal iron absorption. By contrast, the levels of hepcidin are very 
low in these patients, suggesting that the ineffective erythropoiesis alone is able to 
suppress the synthesis of hepcidin in spite of the presence of a severe iron overload  
[25, 29–31]. Transfusions of erythrocyte partially rerelieved suppression of 
hepcidin, but transfusions add large amounts of exogenous iron and lead to 
iron overload. Hepcidin mRNA expression in the HepG2 cell line by serum from 
β-thalassemia patients suggested the existence of a negative erythropoietic 
regulator of hepcidin expression [32]. The nature of this humoral factor is still 
uncharacterized but may include growth differentiation factor (GDF-15), twisted 
gastrulation protein homolog 1 (TWSG1), soluble transferrin receptor, and eryth-
roferrone, which are all overproduced by the proliferating erythroid precursors 
(Figure 2). Controlling absorption of iron may be beneficial to the administration 
of synthetic hepcidin or of agents that increase its expression. Hepcidin agonists or 
stimulators of hepcidin production are being developed for the treatment or pre-
vention of iron overload in hepcidin deficiency states, including hereditary hemo-
chromatosis and β-thalassemia [33]. The rationale for the use of hepcidin agonists 
is justified by two principal observations: first, the phlebotomy is an expensive and 
effective treatment for iron overload that is acceptable to must but not all patients 
affected by hereditary hemochromatosis; second, iron-loading anemias cannot be 
treated in this way and require iron chelation therapy, which is not well tolerate 
by many patients. Hepcidin agonists are agents that replace hepcidin activity or 
stimulate its endogenous production and, in both hereditary hemochromatosis and 
iron loading anemia, could prevent iron accumulation by redistributing iron from 
parenchymal tissues to macrophages where iron is less toxic [34, 35].
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TMPRSS6 suppression could be an alternative approach to increase hepatic 
synthesis of hepcidin. It is a transmembrane serine protease (matriptase-2) that 
normally suppresses the synthesis of hepcidin by deactivating hemojuvelin (HJV) 
[36]. Data showed that the deletion of TMPRSS6 gene in mouse model increased 
hepcidin expression resulting in anemia improvement, ineffective erythropoiesis, 
and splenomegaly reducing and decreased iron loading [37]. An improvement 
in anemia and iron overload has been showed in mice and in preclinical studies 
using antisense oligonucleotides or small interfering RNAs (siRNA9 decreasing 
TMPRSS6) [38, 39]. The somministration of exogenous transferrin, through the 
downregulation of TfR1, increased erythroid precursor enucleation and improved 
terminal erythroid differentiation and maturation in β-thalassemic mice [40, 41]. 
Recently, a new iron metabolism regulating factor produced in erythroblasts in 
response to erythropoietin, ERFE (erythroferrone), was identified. In murine mod-
els with β-thalassemia intermedia, ERFE is highly expressed and mediates hepcidin 
suppression and contributes to iron overload. On the contrary, a deficiency of ERFE 
leads to an increase in hepcidin expression, a significant reduction in iron overload, 
and a slight improvement of erythropoietic indices [42]. All these data indicate that 
the inhibition of ERFE may be a future target with therapeutic potential in diseases 
Figure 1. 
(A) Erythroid expansion and ineffective erythropoiesis represent oxidative events in the bone marrow.  
(B). Oxidative events in the circulation: (1) hemolysis leads to hemoglobin release in the plasma. Autoxidation 
of free hemoglobin produces ROS, free heme, and iron; (2) eryptosis and senescence: two different mechanisms 
of endocytosis of red blood cells (RBCs) by macrophages; and (3) membrane oxidative damage by ROS, 
free heme, and iron: activation of NF-κB and AP-1 by ROS and heme increases the production of pro-
inflammatory cytokines (IL-1, IL-6, and TNFα) and adhesion molecules on the endothelium. Activated 
leucocytes generate more ROS by their NAPDH oxidase, creating a loop of oxidative stress and inflammation.
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TMPRSS6 suppression could be an alternative approach to increase hepatic 
synthesis of hepcidin. It is a transmembrane serine protease (matriptase-2) that 
normally suppresses the synthesis of hepcidin by deactivating hemojuvelin (HJV) 
[36]. Data showed that the deletion of TMPRSS6 gene in mouse model increased 
hepcidin expression resulting in anemia improvement, ineffective erythropoiesis, 
and splenomegaly reducing and decreased iron loading [37]. An improvement 
in anemia and iron overload has been showed in mice and in preclinical studies 
using antisense oligonucleotides or small interfering RNAs (siRNA9 decreasing 
TMPRSS6) [38, 39]. The somministration of exogenous transferrin, through the 
downregulation of TfR1, increased erythroid precursor enucleation and improved 
terminal erythroid differentiation and maturation in β-thalassemic mice [40, 41]. 
Recently, a new iron metabolism regulating factor produced in erythroblasts in 
response to erythropoietin, ERFE (erythroferrone), was identified. In murine mod-
els with β-thalassemia intermedia, ERFE is highly expressed and mediates hepcidin 
suppression and contributes to iron overload. On the contrary, a deficiency of ERFE 
leads to an increase in hepcidin expression, a significant reduction in iron overload, 
and a slight improvement of erythropoietic indices [42]. All these data indicate that 
the inhibition of ERFE may be a future target with therapeutic potential in diseases 
Figure 1. 
(A) Erythroid expansion and ineffective erythropoiesis represent oxidative events in the bone marrow.  
(B). Oxidative events in the circulation: (1) hemolysis leads to hemoglobin release in the plasma. Autoxidation 
of free hemoglobin produces ROS, free heme, and iron; (2) eryptosis and senescence: two different mechanisms 
of endocytosis of red blood cells (RBCs) by macrophages; and (3) membrane oxidative damage by ROS, 
free heme, and iron: activation of NF-κB and AP-1 by ROS and heme increases the production of pro-
inflammatory cytokines (IL-1, IL-6, and TNFα) and adhesion molecules on the endothelium. Activated 
leucocytes generate more ROS by their NAPDH oxidase, creating a loop of oxidative stress and inflammation.
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with ineffective erythropoiesis and iron overload as β-thalassemia. Agents targeting 
hepcidin expression are more likely to be beneficial to patients with NTDT than 
those with TDT because transfusional iron overload is not mediated by low hepcidin 
levels. However, mini-hepcidins and TMRSS6 inhibitors can be evaluated for use in 
patients with TDT because improvement in erythropoiesis could potentially reduce 
transfusion requirements [43]. All discussed novel agents merit further evaluation 
of efficacy and safety in both preclinical and clinical development studies.
5. Oxidative stress in β-thalassemia
Oxidative stress plays a major role in pathophysiology of β-thalassemia, although 
it is not the primary etiology of disease. The cell oxidative status depends on the 
equilibrium between oxidants and anti-oxidants. The reactive oxygen species (ROS) 
are oxidants produced mainly as byproducts of cellular respiration, while reduced 
glutathione is an example of anti-oxidants. A balance between oxidants and anti-
oxidants is crucial for normal physiology. ROS are utilized from the cells as regula-
tors in many physiological processes, including proliferation and differentiation of 
the erythroid precursors. Oxidative stress ensues in many pathological processes 
when the balance between oxidants and anti-oxidants is broken, as it occurs in 
β-thalassemia. Excess ROS cause cytotoxicity by binding to cell components such as 
DNA, proteins, and membrane lipids [19]. In β-thalassemia, the main consequence 
of the unstable Hbs and iron overload is the oxidative stress. It mediates many of 
symptoms due to oxidative damage to red blood cells, leukocytes (recurrent infec-
tions), platelets (hypercoagulable state), as well as in heart, liver, and the endocrine 
glands (Figures 1A and B) [19, 44–46]. Endogenous and exogenous antioxidants 
may ameliorate the oxidative stress in β-thalassemia. They act scavenging and 
inactivating ROS and correcting their damage to cellular components. We introduce 
Figure 2. 
Dysregulation of iron homeostasis in β-thalassemia disease. Ineffective erythropoiesis and premature death of 
red blood cells are the main cause of anemia in β-thalassemia patients. Erythropoietin production induced by 
anemia causes an increase in erythropoiesis activating secretion of erythroid factors such as GDF15, TWSG1, 
and ERFE. The suppression of hepcidin expression caused by an excess of eryhtroid factors leads to an increase 
in intestinal iron absorption, release of iron from the liver, and reticuloendothelial system. All these lead to iron 
overload. GDF15: Growth differentiation factor 15; TWSG1: Twisted-gastrulation 1; ERFE: Erythroferrone.
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many antioxidants by nutrition. For example, a moderate wine consumption and 
a “Mediterranean diet” are thought to have a protective effect due to their high 
contents of antioxidants [47, 48]. Antioxidants can also be taken as food additives, 
or as crude extracts, such as preparation of papaya fermented and curcumin, either 
as pure compounds such as vitamins C and E and Q10 [49]. An improvement in 
many parameters of oxidative stress by using such additives in β-thalassemia was 
observed, but a clear clinical benefit, such as reducing transfusion dependence, was 
less successful. A combination of drugs affecting both the oxidative stress and the 
iron overload can give an effective outcome. Forkhead-box-O3 (Foxo3) is a critical 
transcription factor that protects the cell from oxidative stress by upregulating anti-
oxidant enzymes during early stages of erythropoiesis [50]. At early stages, Foxo3 is 
phosphorylated by proteins of the EPOR-P13K/AKT/mTOR signaling pathway and 
is translocated out of the nucleus, where it remains inactivated. At late stages, Foxo3 
is relocated into the nucleus, gets activated, and induces the production of antioxi-
dants that neutralize ROS to allow efficient erythropoiesis [1, 36, 51, 52]. In mice 
with β-thalassemia intermedia, downregulation of Foxo3, as a result of persistent 
activation of EPOR-p13K/AKT/mTOR pathway, was observed. Inactivation of Foxo3 
leads to oxidative damage in late erythroblasts and plays a significant role in the 
process of ineffective erythropoiesis [53]. β-thalassemia patients could be beneficial 
in improving anemia by activation of Foxo3 as a potential inducer of HbF. However, 
the function of Foxo3 in hemoglobinopathies has yet to be elucidated. A remark-
able improvement in erythroid cell maturation, production of β-globin chains, and 
anemia has been observed following the use of rapamycin, an mTOR inhibition, 
in mice with β-thalassemia intermedia [53]. In another study, rapamycin increased 
α-globin expression and HbF production in cultured erythroid precursors from 
patients with β-thalassemia intermedia [54, 55]. Similar findings were reported 
with the use of another Foxo3 activating agent, resveratrol (3,5,4′-trihydroxy-trans-
stilbene), a non-flavonoid polyphenol that upregulates antioxidant enzymes in mice 
with β-thalassemia intermedia [56]. Metformin, an approved drug for diabetes type 
2 and a Foxo3 inducer, has been investigated as an HbF inducer in an ongoing phase 
1 clinical trial in patients with sickle cell anemia and nontransfusion-dependent 
thalassemia (NTDT; NCT02981329) [57]. All these agents are in preclinical studies 
and need further evaluation. Then, further laboratory and clinical investigations 
are required in this field. A factor required for the initiation of translation through 
the binding of tRNA to the ribosomes is the eukaryotic initiation factor 2 (eIF2). It 
is regulated by a mechanism involving phosphorylation at its α-subunit by heme-
regulated eIF2a kinase (HRI) in the erythroid precursors. Stress, as heme deficiency 
and oxidative stress during the late stage of erythroid differentiation, activates 
HRI that coordinates the synthesis of heme and globin. It was demonstrated that 
the phosphorylated α-subunit of eIF2 turned on the activating transcription factor 
4 (ATF4) to diminish oxidative stress in erythroid precursors [58–60]. A selective 
inhibitor of eIF2aP dephosphorylation as salubrinal augmented the HRI signaling 
pathway and reduced the production of hemichromes in β-thalassemia erythroid 
precursors [59]. In another study, salubrinal increased HbF production with a 
concomitant decrease of HbA in differentiating human CD34 cells by a post-
transcriptional mechanism [61]. Thus, manipulation of the HRI-eIF2aP signaling 
pathway could represent a new approach for the treatment of β-thalassemia.
An antioxidant protein that scavenges and inactivates ROS is the peroxire-
doxin-2 (Prx2), essential during erythropoiesis. The expression of this protein is 
upregulated both murine and human β-thalassemia indicating that the oxidative 
stress induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic 
erythropoiesis [62, 63]. Heme oxygenase (HO-1) is an enzyme that catalyzes the 
degradation of heme in response to stress, such as oxidative stress or hypoxia, both 
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of which occur in β-thalassemia. In EPO-dependent fetal liver erythropoietic cells 
from β-thalassemic mice, the expression of HO-1 was augmented. The administra-
tion of tin protoporphyrin IX, an HO-1 inhibitor, improved ineffective erythropoi-
esis and Hb levels and decreased spleen size and liver iron [64, 65].
6. Potential role of antioxidants in β-thalassemia
Various antioxidant enzyme systems are activated by the oxidative stress to 
protect the body tissues from its damaging effects in β-thalassemia patients. These 
antioxidants include superoxide dismutase (SOD), catalase, glutathione (GSH), 
thioredoxin (Trx), and ferritin. Superoxide (O2−) is the first reactive radical pro-
duced, and this radical can be neutralized by SOD. There are three distinct SODs: 
SOD1 (cu/Zn-SOD) is present in cytoplasm, whereas SOD2 (Mn-SOD) is present 
in the mitochondria, and SOD3 is almost exclusively extracellular [66, 67]. Each of 
these distinct SODs performs a specific function in human cells. In β-thalassemia, 
major patients higher levels of erythrocyte superoxide dismutase and glutathione 
peroxidase (GPx) as well as higher plasma malondialdehyde (MDA) were observed 
as compared to healthy controls [68]. Iron overload through repeated blood transfu-
sions and subsequent oxidative stress produced by reactive oxygen species may be 
the cause of increased levels of MDA. The rise in SOD and glutathione peroxidase 
may occur as a result of compensatory mechanisms in response to oxidative stress 
[44]. Neutralization of O2− produces H2O2, which can be metabolized into nontoxic 
products by a catalase and glutathione peroxidase (GPx) in conjunction with 
glutathione. Location of GPx depends on the subtype, whereas catalase is present in 
peroxisomes [67]. The stability of the cellular and subcellular membranes depends 
mainly on glutathione peroxidase, and the protective antioxidant effect of glutathi-
one peroxidase depends on the presence of selenium. In patients with β-thalassemia, 
major was confirmed the peroxidative status generated by iron overload and the 
high increase in serum ferritin, iron, plasmatic thiobarbituric acid reactive sub-
stances (TBARS), SOD, and glutathione peroxidase activity, while the vitamin E 
and zinc concentration decreased in these patients [44, 69]. Glutathione (GSH) is 
present in nearly all cells in the body and is present in high levels in organs with high 
oxygen consumption and energy production, e.g., the brain [67, 70]. Glutathione, 
in conjunction with its oxidized form (GSSG), plays a major role in controlling 
cellular redox state. The ubiquitous thioredoxin system also plays an important role 
in maintaining the cell’s redox state [67, 71]. Finally, ferritin is considered an endog-
enous antioxidant as it performs the important function of sequestering potentially 
toxic labile iron. When endogenous antioxidants are unable to neutralize oxidative 
stress, as in β-thalassemia, exogenous antioxidants can be used to augment the 
antioxidant system of the body. Iron metabolism underlies the dynamic interplay 
between oxidative stress and antioxidants in many pathophysiological processes. 
Iron overload can affect redox state, and not only this condition can be restored to 
physiological conditions using iron chelation, but also the addition of antioxidants 
to these treatment regimens can be a viable therapeutic approach for attenuating 
tissue damage induced by oxidative stress (Table 1), (Figure 3, [72–74]). Vitamin A 
(β-carotene), vitamin C, vitamin E (α-tocopherol), polyphenols, and other bioac-
tive plant-derived compounds are effective exogenous antioxidants that also regu-
late iron metabolism. At the transcriptional level, antioxidant enzymes are regulated 
by the transcription factor Nrf2, which binds to the antioxidant response element 
(ARE) in the target gene’s promoter region. Nrf2 is believed to be phosphorylated 
by protein kinase C (PKC), which causes the transcription factor to translocate to 
the nucleus, where it activates ARE-containing genes [67, 75], ultimately leading 
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to the neutralization of free radicals and the attenuation of oxidative damage [76]. 
Table 1 summarizes the flavonoids and other antioxidants that regulate both iron 
homeostasis and redox state, in some cases via independent mechanisms. Flavonoids 
are present in a wide variety of plants and represent the most common class of 
polyphenols, organic chemicals that protect the plant from ultraviolet radiation, 
pathogens, and effects of oxidative stress, making them suitable for therapeutic pur-
poses [77, 78]. Examples of flavonoids include quercetin, cathechins, curcumin, and 
kaempferol, which are abundant in fruits, vegetables, legumes, red wine, and green 
tea. Curcumin is a potent flavonoid antioxidant that can chelate iron in addition to 
modulating redox state [79]. A flavonoid-rich extract of orange and bergamot juice 
has been shown to chelate iron in iron-overload A549 cells and to activate the anti-
oxidant enzyme catalase, leading to a decrease in ROS production and membrane 
lipid peroxidation [80]. It is a promising candidate for regulating both oxidative 
stress and iron homeostasis. Quercetin can reduce hepatic iron deposition in mice 
Antioxidant Mechanisms of iron regulation Sources of 
antioxidants
Curcumin • Potent flavonoid antioxidant
• Iron chelator
• Redox state modulator
• Decreased iron levels
• Attenuated lipopolysaccharide (LPS)-induced 
oxidative stress-related inflammation
• Activated hepatic IRPs and TfR1, repressed hepatic 
hepcidin and ferritin synthesis
Curcumin is a bright 
yellow chemical 
produced by Curcuma 
longa plants
Quercetin • Decreased hepatic iron levels
• Reduced iron-related damage
• Increased BMP6, intranuclear SMAD4, SMAD4 
binding to the HAMP promoter, and hepcidin 
expression
Vegetables, leaves, 
grains, red onions, 
kale, red wine, and tea
Flavonoid-rich 
extract of orange 
and bergamot juice
• Decreased ROS production and membrane lipid 
peroxidation by iron chelation in iron-overload 
A549 cells and activation of antioxidant catalase 
enzyme
Citrus fruits
Genistein • Reduced inflammation induced by ethanol and 
oxidative stress in mice
• Increased HAMP promoter activity in both 
zebrafish and human hepatocytes via Stat3- and 
Smad4-dependent process
Lupin, fava beans, soy 
beans, kudzu, psoralea, 
Maackia amurensis, 
and Flemingia vestita
Silymarine • Iron-chelating properties Silybum marianum 
extract
Ferulic acid • Decreased iron-induced oxidative stress, reduced 
liver injury, and ROS production
• Increased hepatic antioxidant and mitochondrial 
membrane potential
Vegetables, popcorn, 
bamboo shoots, cereals 
(bran, wheat, and 
barley grain)
Resveratrol • Reduced myocardial damage by modulating vas-
cular cell function, low density lipoprotein (LDL) 
oxidation, and platelet aggregation
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oxidative stress in mice
• Increased HAMP promoter activity in both 
zebrafish and human hepatocytes via Stat3- and 
Smad4-dependent process
Lupin, fava beans, soy 
beans, kudzu, psoralea, 
Maackia amurensis, 
and Flemingia vestita
Silymarine • Iron-chelating properties Silybum marianum 
extract
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liver injury, and ROS production
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that were exposed to either ethanol or excess iron and increase BMP6, intranuclear 
SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, lead-
ing to decreased hepatic iron levels and reduced iron-related damage [81]. Another 
potent antioxidant is genistein. It reduces inflammation induced by ethanol and 
oxidative stress in mice [82] and, similar to quercetin, increases HAMP promoter 
activity in both zebrafish and human hepatocytes via Stat3- and Smad4-dependent 
process [83]. Silymarin, another flavonoid, is present in milk thistle plant extract 
and may have iron-chelating properties [84]. It is safe, well tolerated, cost-effective 
alternative to currently available iron chelation therapies for treating patients 
with β-thalassemia [84]. Ferulic acid is present in a wide variety of plants, and the 
antioxidant effects are believed to be mediated via the neutralization of free radicals 
[85]. The antioxidant effects of resveratrol may prevent adverse changes that lead to 
cardiovascular disease by modulating vascular cell function, low density lipoprotein 
(LDL) oxidation, and platelet aggregation, thereby reducing myocardial damage 
[86, 87]. Both vitamin A and vitamin C have well-established antioxidant proper-
ties that are mediated via the attenuation of oxidative damage [88]. Vitamin A and 
β-carotene increase hepcidin and TfR expression and intestinal iron absorption, 
reduce inflammatory signaling and ferroportin expression, increase intracellular 
ferritin levels, and release intracellular trapped iron [89–91]. Vitamin C reduces 
Fe3+ to Fe2+ and inhibits hepcidin expression [92]. In recent years, research for new 
therapies based on plant-derived compounds has developed considerably. This is to 
maximize the benefits of plant phytochemicals and avoid the adverse effects often 
associated with synthetic pharmaceutical agents [93]. Several plant extracts, such 
as tucum-do-cerrado, astragalus, Angelica sinensis, Caulis Spatholobi, Scutellaria 
baicalensis, and others, have been studied for their putative effects on iron homeo-
stasis and oxidative stress. The results obtained are very promising (for esaustive 
review, see Ref. [76]).
Figure 3. 
Summary of the mechanisms regulating iron and oxidative stress by antioxidants. BMP6-SMAD-HAMP: 
Bone morphogenetic factor-mothers against decapentaplegic homolog-hepcidin antimicrobial peptide; GPx: 
Glutathione peroxidase;Nrf2-ARE: Nuclear factor erythroid 2-related factor 2-antioxidant response element; 
SOD: Superoxide dismutase.
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7. Conclusions
Alteration in iron homeostasis is associated with oxidative stress and inflamma-
tion. Many bioactive antioxidants and plant-derived phytochemicals can regulate 
iron homeostasis, inflammation, and oxidative stress. Nevertheless, the majority of 
data collected to date are derived from in vitro and animal experiments, and further 
studies are needed in order to evaluate the efficacy of these phytochemicals as a 
natural substitute for pharmaceutical agents. This is very important because many 
pharmaceutical agents are associated with adverse side effects.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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Thalassemia disease is a common inherited hemolytic anemia frequently found 
in several parts of the world, especially in the Mediterranean and some Asian 
countries. Besides the complications of secondary hemochromatosis from regular 
red blood cell (RBC) transfusion and increased gastrointestinal absorption of 
iron, thromboembolism (TE) is one of the common long-term complications of 
beta-thalassemia disease, particularly in patients with non-transfusion-dependent 
thalassemia (NTDT), which is commonly seen after the second decade of life. The 
risk factors of TE in beta-thalassemia disease including exposure of phosphatidyl-
serine of abnormal RBCs, increase of platelet activation and aggregation, elevation 
of endothelial microparticles and increased endothelial activation, decreased nitric 
oxide (NO) secondary to hemolysis, rise of platelet count and nucleated RBCs after 
splenectomy, organ dysfunction caused by hemochromatosis, and thrombophilia 
such as natural anticoagulant deficiencies leading to hypercoagulable state. The 
understanding of the pathophysiology would result in effective prevention of this 
complication of beta-thalassemia disease.
Keywords: thromboembolism, beta-thalassemia, NTDT
1. Introduction
Beta-thalassemia disease is one of the most common congenital hemolytic 
anemia commonly found in the malarial belt areas including the Mediterranean, 
the Middle East, Transcaucasus, Africa, South and Southeast Asian countries, and 
China [1]. It is inherited by autosomal recessive manner [1, 2]. Beta-thalassemia 
disease is the result from the mutation of beta-globin genes causing decrease of 
beta-globin leading to imbalance of alpha-globin and beta-globin and subsequently 
causing ineffective erythropoiesis. According to the Thalassemia International 
Federation (TIF), patients with thalassemia disease can be categorized into two 
groups, transfusion-dependent thalassemia (TDT) and non-transfusion-dependent 
thalassemia (NTDT), based on their phenotypes and genotypes [1–3]. The major 
long-term complication of TDT is hemochromatosis-induced organ failures second-
ary to red blood cell (RBC) transfusion [1, 2], while the complications of NTDT 
are hemochromatosis secondary to increased iron absorption from gastrointestinal 
tract, pulmonary hypertension, leg ulcer, and thromboembolism (TE) [3–5].
The incidence of thromboembolism is between 0.8 and 2.7 per 1000 population 
[6] which has been increasing over the decades in both adult and pediatric popula-
tion [6, 7] patients with thalassemia disease are at risk of hypercoagulable state and 
thromboembolism [8, 9]. The studies of thromboembolism in thalassemia disease 
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have been increasingly published recently. Understanding the pathophysiology of 
thromboembolism in thalassemia diseases is the key for the management to prevent 
this complication.
2. Incidence
The incidence of thromboembolism in patients with thalassemia diseases is 
between 1.7 and 9.2% [4, 10, 11]; therefore, the incidence of thromboembolism in 
patients with thalassemia diseases is approximately 10 times higher than normal 
population [6]. The incidence is 4.4 times more prevalent in patients with NTDT 
than ones with TDT [10]. However, this complication could be seen in both patients 
alpha- and beta-thalassemia diseases [4].
3. Pathophysiology
The pathophysiology of thromboembolism in beta-thalassemia disease is the 
combinations of abnormalities in several parts of hemostatic system including [9, 12]:
1. Exposure of phosphatidylserine (PS) to external membrane of abnormal RBCs 
called “flip-flop phenomenon” which is caused by the decrease of normal 
asymmetrical dissemination of RBC membrane phospholipids [9]. In addition, 
free iron secondary to hemochromatosis induces lipid oxidation and elevates 
the level of membrane-bounded hemichromes and immunoglobulin causing 
alteration of the structures of spectrin and band 3 protein of RBC membrane 
and consequently resulting in aggregation and adhesion of abnormal RBCs to 
endothelial cells [9].
2. Increased number of circulating activated and aggregated platelets which 
are especially found in splenectomized patients [13, 14]. The activated and 
aggregated platelets of splenectomized patients with thalassemia usually have 
shorter platelet lifespan [14], higher response to several agonists, i.e., adeno-
sine diphosphate (ADP), epinephrine, and collagen [15], and more elevated 
level of plasma beta-thromboglobulin [16] than the platelets of normal 
population. All findings reflect hyperaggregation of platelets which result in 
increased thrombin generation [15].
3. Increased endothelial activation caused by the activation of monocytes and 
granulocytes leads to endothelial injury and increased level of endothelial 
adhesion proteins and tissue factor contributing to hypercoaguable state. 
Moreover, the elevation of endothelial cell, platelet and white blood cell 
(WBC) and RBC microparticles, which are the shedded fragments containing 
high PS with the size of 0.1–2 μm from activated and apoptotic cells, leads to 
increased activation of hemostatic system [17–19].
4. Decreased nitric oxide (NO), secondary to hemolysis caused by the decreased 
level of arginine leads to pulmonary vasoconstriction and subsequently results 
in chronic pulmonary thromboembolism [12, 20].
5. Rise of platelet count and nucleated RBCs (NRBCs) after splenectomy which 
was firstly reported in 1966 [21]. This phenomenon is a strong associated 
factor of thromboembolism in patients with thalassemia disease particularly 
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when the platelet count is higher than 600,000/mm3 and the NRBCs count is 
more than 300/mm3 after splenectomy [22].
6. Organ dysfunction resulting from hemochromatosis particularly cardiac 
hemochromatosis causes cardiomyopathy and cardiac arrhythmia [12] which is 
found in beta-thalassemic patients who TDT for 42% [23].
7. Thrombophilia, i.e., natural anticoagulant deficiencies, leads to hyperco-
agulable state. Deficiencies of protein C and protein S, the natural antico-
agulant proteins, have been reported as a risk factor of thromboembolism 
in patients with beta-thalassemia disease [12, 24, 25]. In addition, increased 
incidence of antiphospholipid antibodies, i.e., lupus anticoagulant, anti-
cardiolipin, and anti-beta 2-glycoprotein 1, is commonly found in patients 
with beta-thalassemia disease. Those antibodies are considered as strong 
thrombophilic risk factors causing thromboembolism [12, 26].
4. Presentations of thromboembolism in beta-thalassemia
Thromboembolism in patients with beta-thalassemia diseases could be found in 
both arterial and venous sites. However, venous thromboembolism is more com-
monly found in patients with thalassemia intermedia or NTDT, while arterial throm-
boembolism is more frequently seen in patients with thalassemia major or TDT [10].
4.1 Venous thromboembolism
Although patients with beta-thalassemia disease are at risk of venous throm-
boembolism, deep vein thrombosis and pulmonary thromboembolism, the two 
common types of venous thromboembolism in normal population, are not generally 
observed. Pulmonary thromboembolism was found in lung biopsy to 41% of patients 
with beta-thalassemia/hemoglobin E. However, higher incidence was found in the 
older and splenectomized patients [27]. Simplified, revised Geneva score, based on 
several clinical variables, i.e., hemoptysis, old age of more than 65 years, history of 
venous thromboembolism, tachycardia, unilateral lower limb pain with or without 
deep palpation and edema, active malignancy, and surgery or fracture of lower limb 
within 1 month prior to the suspected symptoms and signs, has been published to 
use for diagnosing pulmonary thromboembolism. The more scores patients get, the 
higher chance of pulmonary embolism patients have [28]. Computed tomography 
pulmonary angiography, magnetic resonance pulmonary angiography, and ventila-
tion/perfusion scan could be used to diagnose pulmonary thromboembolism even 
though conventional pulmonary angiography is the gold standard [29].
Portal vein thrombosis, which is considered as venous thrombosis of an unusual 
site, is more commonly reported in patients with beta-thalassemia disease [30–34] 
with the odds ratio of 3.5 [31]. Patients with acute portal vein thrombosis usually 
present with symptoms and signs of portal hypertension of bowel ischemia, i.e., 
abdominal pain and distension, fever, nausea/vomiting, rectal hemorrhage, and 
splenomegaly. If patients were not diagnosed, they might turn to sepsis-like symp-
toms, e.g., shock, signs of peritonitis, and even death [35]. Unlike acute portal vein 
thrombosis, patients with chronic portal vein thrombosis are usually asymptomatic 
until the presence of first symptoms and signs, i.e., upper gastrointestinal hemor-
rhage, splenomegaly, and ascites [35]. Doppler ultrasound, computed tomogra-
phy, and magnetic resonance imaging could be used for diagnosis of portal vein 
thrombosis [35]. Apart from splenectomy, higher splenic weight and thalassemia 
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thrombosis [35]. Apart from splenectomy, higher splenic weight and thalassemia 
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intermedia are major risk factors of portal vein thrombosis in patients with beta-
thalassemia disease [30, 33]. Laparoscopic splenectomy was reported about the 
higher incidence of portal vein thrombosis even though this technique provided the 
better other surgical outcomes than the conventional technique [30].
4.2 Arterial ischemic stroke
Beta-thalassemia disease has been reported as a risk factor of arterial ischemic 
stroke since 1972 [36]. Compared to venous thromboembolism, arterial ischemic 
stroke is more common in patients with beta-thalassemia major [11]. Moyamoya 
syndrome, a cerebral vasculopathy caused by spontaneous occlusion of the arter-
ies at the circle of Willis [37], was also reported in pediatric patients with beta-
thalassemia disease and caused arterial ischemic stroke [38, 39]. Symptom and 
signs of acute ischemic stroke are based on the involved cerebral areas ranging from 
nonspecific symptoms, i.e., headache, nausea and vomiting, seizure, and impaired 
consciousness to specific neurological deficits, i.e., abnormal speech and spatial 
perception, hemiparesis, hemianesthesia, blurred vision, and poor coordination or 
walking, and cranial nerve palsies [40]. Though computed tomography of the head 
with or without angiography is the standard for diagnosing arterial ischemic stroke, 
magnetic resonance imaging of head with or without angiography could provide 
more details of the affected parts of the brain with higher sensitivity [40].
Moreover, the focal foci in the cerebral white matter on the magnetic resonance 
imaging of the brain called “silent cerebral infarction” could be found at 24–61% 
of patients with beta-thalassemia disease [41, 42]. However, a recent study in adult 
patients with beta-thalassemia disease who were asymptomatic showed that the 
abnormal findings on the magnetic resonance imaging of the brain were not differ-
ent from the adult controls [43].
4.3 Diagnosis
Making a diagnosis of thromboembolism in patients with beta-thalassemia does 
not differ from diagnosing this condition in normal population which is usually 
based on the imaging of the suspected area of thromboembolism, e.g., computed 
tomography with angiography of the brain in a patient who is suspicious for hav-
ing an arterial ischemic stroke. Several studies have demonstrated derangement 
of proteins hemostatic system in patients with beta-thalassemia diseases includ-
ing increased platelet aggregation and coagulation proteins (factor VIII and von 
Willebrand factor) and decreased natural anticoagulants (protein C, protein S, 
and antithrombin) [24, 25] which encourage hypercoagulable state [44]. Besides 
diagnosing a symptomatic patient, the novel investigations, i.e., thrombin genera-
tion assay and rotatory thromboelastometry (ROTEM®), are able to demonstrate 
patients with hypercoagulable state in patients with beta-thalassemia disease who 
are at risk of developing thromboembolism [45, 46]. In addition, yearly monitor-
ing of thrombin generation markers, e.g., D-dimer and thrombin-antithrombin 
(TAT) complex, is recommended by TIF in patients with thalassemia who are 
 splenectomized [47].
5. Treatment
1. Regular RBC transfusion is recommended to treat patients with beta- 
thalassemia disease, particularly NTDT, who are at risk of thromboembolism 
or have developed thromboembolic events by keeping hemoglobin level higher 
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than 9 g/dL [3] to correct hypercoagulable state as transfusion naïve patients 
are prone to have thromboembolism [12, 22, 48].
2. Hematopoietic stem cell transplantation (HSCT) has been reported as the 
management that could normalize the abnormal hemostatic derangement in 
patients with beta-thalassemia disease by increasing natural anticoagulant 
proteins and decreasing microparticles and RBC-expressing PS and activating 
platelets in the circulation [49, 50].
3. Antithrombotic agents in patients with beta-thalassemia disease who have 
thromboembolism are recommended as per the standard local or international 
guidelines to treat patients with thromboembolism [3, 12].
a. Anti-platelets: acetyl salicylic acid (ASA)
ASA 2–5 mg/kg/day is the mainstream management for the prevention and 
treatment of thromboembolism in patients in beta-thalassemia especially in 
splenectomized patients who have platelet count higher than 500,000/mm3 [3]. 
However, ASA resistance has been reported in patients with thalassemia who were 
splenectomized, and increase dose of ASA could overcome this resistance [51].
b. Anticoagulants consist of conventional anticoagulants, i.e., unfractionated 
heparin, low-molecular-weight heparin, vitamin K antagonist (VKA), and 
direct oral anticoagulants (DOAC) including direct oral anti-activated fac-
tor X (Xa), e.g., rivaroxaban, and direct oral antithrombin (IIa), i.e. dabi-
gratan. Those medications are used to treat thromboembolism in patients 
with beta-thalassemia disease. Unlike sickle cell disease, the evidences of 
using DOAC in patients with thalassemia disease who develop thrombo-
embolism are limited [52]. However, the recent study showed that using 
rivaroxaban in patients with hemoglobinopathies including thalassemia 
was effective and did not increase risk of bleeding or thrombosis [53].
4. Hydroxyurea, a hemoglobin F stimulating agent, was reported about the 
favorable effects not only increased hemoglobin F, hemoglobin level and 
improved the clinical symptoms of beta-thalassemia disease but also decreased 
hypercoagulable state due to the diminished exposure of PS on RBC membrane 
[54, 55]. Moreover, Iqbal et al. recently reported the change of metabolites, 
i.e., glycerol, triethanolamine, linoleic acid, palmitic acid, and stearic acid 
to the healthy pattern of metabolic pathway in pediatric patients with beta-
thalassemia disease after treating with hydroxyurea [56].
Since patients with beta-thalassemia disease are at risk of thromboembolism 
as the same as other medical inpatients, the current approach is to stratify patients 
with the optimal risk assessment model (RAM) by using the available approaches, 
e.g., Padua Prediction Score and the Caprini Risk Assessment Model, to guide 
thromboprophylaxis [57]. However, the systematic review showed that there 
was not any specific risk assessment model which was superior to the others [58]. 
Moreover, thalassemia-specific risk assessment model for thromboprophylaxis may 
need to be developed due to distinctive pathophysiology of thromboembolism in 
patients with beta-thalassemia disease.
In conclusion, the hypercoagulable state in beta-thalassemia disease is the 
result of several risk factors, a combination of which is often the drive behind a 
clinical thromboembolism. Splenectomy and transfusion naivety are increasingly 
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i.e., glycerol, triethanolamine, linoleic acid, palmitic acid, and stearic acid 
to the healthy pattern of metabolic pathway in pediatric patients with beta-
thalassemia disease after treating with hydroxyurea [56].
Since patients with beta-thalassemia disease are at risk of thromboembolism 
as the same as other medical inpatients, the current approach is to stratify patients 
with the optimal risk assessment model (RAM) by using the available approaches, 
e.g., Padua Prediction Score and the Caprini Risk Assessment Model, to guide 
thromboprophylaxis [57]. However, the systematic review showed that there 
was not any specific risk assessment model which was superior to the others [58]. 
Moreover, thalassemia-specific risk assessment model for thromboprophylaxis may 
need to be developed due to distinctive pathophysiology of thromboembolism in 
patients with beta-thalassemia disease.
In conclusion, the hypercoagulable state in beta-thalassemia disease is the 
result of several risk factors, a combination of which is often the drive behind a 
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highlighted as important risk factors for thromboembolism, especially in patients 
with NTDT. An individualized approach is recommended to establish an optimal 
strategy for preventing the occurrence of this complication in patients with beta-
thalassemia disease.
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β-Thalassemia and HbE, each, is a syndrome resulted from quantitative and qualita-
tive defects of β-globin chain, respectively. In addition to history retrieve and physical 
examination, diagnosis of these disorders requires laboratory information. Laboratory 
tests that are conventionally performed to diagnose the β-thalassemia and HbE are clas-
sified into two groups, based on the purposes, including the screening tests and confir-
matory tests. The screening tests are aimed to screen for carriers of the β-thalassemia 
and HbE, while confirmatory tests are the tests performed to definitely diagnose these 
disorders. This chapter will explain all of these tests, the information of which will be 
useful for those who are working and interested in the β-thalassemia and HbE.
Keywords: β-thalassemia, HbE, screening tests, confirmatory tests, 
thalassemia carrier, HbE carrier, β-thalassemia disease
1. Introduction
1.1 Thalassemia and hemoglobinopathies
Thalassemia is a type of anemia caused by reduction or absence of globin chain 
synthesis, which results in imbalanced-globin chain synthesis; the major pathogen-
esis of the disease. The unaffected globin chains continuing to be synthesized at the 
normal synthetic rate tend to form homotetramers and aggregation that can harm 
the red blood cells both at young and mature stages. The α-globin chain aggregation 
formed in β-thalassemia causes ineffective erythropoiesis due to oxidative stress. The 
γ- and β-globin chain homotetramer (γ4, β4) formed in α-thalassemia harm mature 
erythrocytes. The γ4 or Hb Bart’s has very high oxygen affinity and inhibits oxygen 
release from erythrocytes which, in turn, results in tissue anoxia. The β4 or HbH is an 
unstable hemoglobin and precipitates easily under the stress condition in the body. 
Once precipitates, the erythrocytes are removed by the RE system resulting in anemia.
Severe thalassemia cases suffer from chronic and marked anemia with life rely-
ing solely on blood transfusion. Anemia causes expansion of bone marrow, leading 
to osteoporosis and changes of bone structure. Blood transfusion and hemolysis 
cause iron overloading state in the body which causes several complications such as 
heart disease, growth retardation, diabetes mellitus, and infection.
Thalassemia is considered the most common autosomal single-gene disorder 
worldwide. It can be found in more than 150 countries with an estimated carrier 
frequency of about 7%. The Mediterranean region, certain parts of North and West 
Africa, Middle East, Indian subcontinent, Southern Far East, and South East Asia 
have the highest prevalence of the disease [1].
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In contrast to the thalassemia, hemoglobinopathy is an inherited disorder of 
hemoglobin productions characterized by production of abnormal hemoglobin or 
hemoglobin structural variants occurring from genetic alterations including point 
mutations, deletions or insertion of the normal globin genes. The well-known 
abnormal hemoglobins in the world are HbS, which is common in western countries 
as well as in the Middle East and HbE, which is common in Southeast Asia [2].
1.2 Types of thalassemia and hemoglobinopathies
Two major types of thalassemia are found across the world consisting of 
the α- and β-thalassemia. The α-thalassemia is further sub-divided into two 
types: α-thalassemia 1 or αO-thalassemia and α-thalassemia 2 or α+-thalassemia. 
Gene deletion is the leading cause of α-thalassemia. In α-thalassemia 1, two 
α-globin gene in-cis on chromosome 16 are deleted, while only one α-globin 
gene is absent in the α-thalassemia 2 [3]. In addition, there are two types of 
β-thalassemia; βO-thalassemia and β+-thalassemia. In contrast to α-thalassemia, 
mutations on the β-globin gene are found in the majority of the β-thalassemia 
patients [4].
Two broad types of hemoglobinopathies or structural variants are also found; 
α- and β-hemoglobinopathies. To date, approximately 1358 structural variants are 
described (http://globin.bx.psu.edu), around 90% of which are involved in the β, γ, 
and δ-globin chains and around 60% involves the α-globin chain. The most impor-
tant β-globin hemoglobinopathies are HbS (α2β26Glu−Val) and HbE (α2β226Glu−Lys). 
Hb E is found around the world and accounts for approximately 13–17% on the 
population of Thailand, especially in the Thai-Laos-Cambodian boundary or “Hb E 
triangle” where more than 32–60% of the people carry HbE gene [5].
1.2.1 β-Thalassemia
The β-thalassemia is a diverse group of disorders of hemoglobin synthesis which 
is characterized by reduced or absent β-globin chain synthesis. There are two main 
types of β-thalassemia: βO-thalassemia in which no β-globin chain is produced and 
β+-thalassemia in which some β-globin is produced but less than normal.
β0-Thalassemia is severe β-thalassemia with no production of β-globin chain. It is 
mainly caused by point mutations in coding region (exon) or exon-intron junction 
of β-globin gene which lead to premature stop codon or generation of abnormal 
β-globin mRNA. The end results of these abnormalities are absence of the β-globin 
chain production [6]. In Thailand, at least three common mutations in the β-globin 
gene are of this category. They comprise A-T substitution at codon 17 (CD17: A-T) 
which creates premature stop codon, the TTCT-deletion at codons 41/42 (CD41/42: 
−TTCT) which causes reading frameshift and premature stop codon at codon 59 
instead of codon 147, the G-T substitution at IVSI-nt1 which leads to abnormal 
splicing of immature β-mRNA and results in no production of normal β-mRNA. In 
general, thus, genotype of heterozygote is written as β0/βA and that for homozygote 
as β0/β0 [2, 7–9].
β+-Thalassemia is a milder form of β-thalassemia in which some β-globin chains 
are still produced. The majority of cases possess point mutations outside exons, 
especially in the promoter region. The mutations of β-globin gene leading to the 
β+-thalassemia include mutations at ATA box (nt-28, nt-29 or nt-30 from cap site), 
CACCC element (nt-86 to nt-90 from cap site), and mutations in introns or exons 
of gene to produce new splice site to race in RNA splicing process, as mutation in 
IVS2-nt654 (C-T) and mutation of IVS1-nt5 (G-C) [2, 6]. The genotypes were β+/βA 
and β+/β+ for heterozygote and homozygote consecutively.
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1.2.2 β-Hemoglobinopathies
β-Hemoglobinopathies are characterized by the production of abnormal 
β-globin chains due to changes or mutations (missense mutations) on the β-globin 
gene. Two abnormal β-globin chains then assemble with two normal α-globin 
chains to form abnormal hemoglobin or β-structural variants. These abnormal 
hemoglobins generally have different electrophysical properties from their normal 
counterparts; that is, due to the molecular conformational alteration. In theory, 
synthetic rate of the abnormal β-globin chain should be normal. However, some 
are produced in reduced rate, thus producing a phenotype resembling the β+-
thalassemia. To date, there are more than 737 β-globin structural variants reports 
across the world (http://globin.cse.psu.edu/).
1.3 Hemoglobin E
HbE is abnormal hemoglobin resulted from the G-A substitution at codon 26 of 
β-globin gene. This missense mutation partially activates a cryptic splice site toward 
the 3′ end of exon 1, resulting in a proportion of abnormally splice mRNA. Thus, 
less βE globin is synthesized, leading to a mild thalassemia phenotype. HbE is 
becoming the common β-globin structure variant across the world as a result of 
migration and inter racial marriage [2, 10]. It has been realized to be the hallmark of 
Southeast Asian region. In Thailand, HbE is very common accounting for approxi-
mately 8–70% of population [11].
1.4 Inheritance of genes for β-thalassemia and HbE
Gene for β-thalassemia and HbE is transmitted within the family from parents 
to descendants in an autosomal recessive fashion. Thus, those who are heterozygous 
for abnormal β-gene are clinically asymptomatic and called β-thalassemia carrier or 
β-thalassemia trait. Those who are heterozygote for HbE gene (βE) are also clini-
cally asymptomatic and called HbE carrier or HbE trait. However, homozygote or 
compound heterozygote of the β-thalassemia gene and/or HbE gene are clinically 
affected and suffer from chronic anemia with some life-threatening complication. 
Therefore, accurate diagnosis of carriers of the β-thalassemia and HbE as well as the 
disease is important.
1.5 Problem of β-thalassemia and HbE
The carriers of β-thalassemia and HbE do not have clinical burden as they are 
clinically normal and have normal quality of life. However, if the β-thalassemia 
carriers get married with the HbE carriers, they will have 25% chance of producing 
the HbE/β-thalassemia babies. The HbE/β-thalassemia or sometimes called the 
β-thalassemia/HbE disease is a thalassemia syndrome that presently is known to be 
clinically heterogeneous [10–12]. Some patients are very mild, while some are very 
severe. The severe cases always required regular blood transfusion which always 
ends up with iron overloading condition. Without proper management of this iron 
overloading, several fatal complications occur, leading to low quality of life and, 
finally, pre-death at young age.
1.6 Diagnosis of β-thalassemia and HbE
The diagnosis of β-thalassemia and HbE involves both clinical and laboratory 
investigations. Clinical data can only identify the affected patients, but cannot 
Beta Thalassemia
124
In contrast to the thalassemia, hemoglobinopathy is an inherited disorder of 
hemoglobin productions characterized by production of abnormal hemoglobin or 
hemoglobin structural variants occurring from genetic alterations including point 
mutations, deletions or insertion of the normal globin genes. The well-known 
abnormal hemoglobins in the world are HbS, which is common in western countries 
as well as in the Middle East and HbE, which is common in Southeast Asia [2].
1.2 Types of thalassemia and hemoglobinopathies
Two major types of thalassemia are found across the world consisting of 
the α- and β-thalassemia. The α-thalassemia is further sub-divided into two 
types: α-thalassemia 1 or αO-thalassemia and α-thalassemia 2 or α+-thalassemia. 
Gene deletion is the leading cause of α-thalassemia. In α-thalassemia 1, two 
α-globin gene in-cis on chromosome 16 are deleted, while only one α-globin 
gene is absent in the α-thalassemia 2 [3]. In addition, there are two types of 
β-thalassemia; βO-thalassemia and β+-thalassemia. In contrast to α-thalassemia, 
mutations on the β-globin gene are found in the majority of the β-thalassemia 
patients [4].
Two broad types of hemoglobinopathies or structural variants are also found; 
α- and β-hemoglobinopathies. To date, approximately 1358 structural variants are 
described (http://globin.bx.psu.edu), around 90% of which are involved in the β, γ, 
and δ-globin chains and around 60% involves the α-globin chain. The most impor-
tant β-globin hemoglobinopathies are HbS (α2β26Glu−Val) and HbE (α2β226Glu−Lys). 
Hb E is found around the world and accounts for approximately 13–17% on the 
population of Thailand, especially in the Thai-Laos-Cambodian boundary or “Hb E 
triangle” where more than 32–60% of the people carry HbE gene [5].
1.2.1 β-Thalassemia
The β-thalassemia is a diverse group of disorders of hemoglobin synthesis which 
is characterized by reduced or absent β-globin chain synthesis. There are two main 
types of β-thalassemia: βO-thalassemia in which no β-globin chain is produced and 
β+-thalassemia in which some β-globin is produced but less than normal.
β0-Thalassemia is severe β-thalassemia with no production of β-globin chain. It is 
mainly caused by point mutations in coding region (exon) or exon-intron junction 
of β-globin gene which lead to premature stop codon or generation of abnormal 
β-globin mRNA. The end results of these abnormalities are absence of the β-globin 
chain production [6]. In Thailand, at least three common mutations in the β-globin 
gene are of this category. They comprise A-T substitution at codon 17 (CD17: A-T) 
which creates premature stop codon, the TTCT-deletion at codons 41/42 (CD41/42: 
−TTCT) which causes reading frameshift and premature stop codon at codon 59 
instead of codon 147, the G-T substitution at IVSI-nt1 which leads to abnormal 
splicing of immature β-mRNA and results in no production of normal β-mRNA. In 
general, thus, genotype of heterozygote is written as β0/βA and that for homozygote 
as β0/β0 [2, 7–9].
β+-Thalassemia is a milder form of β-thalassemia in which some β-globin chains 
are still produced. The majority of cases possess point mutations outside exons, 
especially in the promoter region. The mutations of β-globin gene leading to the 
β+-thalassemia include mutations at ATA box (nt-28, nt-29 or nt-30 from cap site), 
CACCC element (nt-86 to nt-90 from cap site), and mutations in introns or exons 
of gene to produce new splice site to race in RNA splicing process, as mutation in 
IVS2-nt654 (C-T) and mutation of IVS1-nt5 (G-C) [2, 6]. The genotypes were β+/βA 
and β+/β+ for heterozygote and homozygote consecutively.
125
Laboratory Diagnosis of β-Thalassemia and HbE
DOI: http://dx.doi.org/10.5772/intechopen.90317
1.2.2 β-Hemoglobinopathies
β-Hemoglobinopathies are characterized by the production of abnormal 
β-globin chains due to changes or mutations (missense mutations) on the β-globin 
gene. Two abnormal β-globin chains then assemble with two normal α-globin 
chains to form abnormal hemoglobin or β-structural variants. These abnormal 
hemoglobins generally have different electrophysical properties from their normal 
counterparts; that is, due to the molecular conformational alteration. In theory, 
synthetic rate of the abnormal β-globin chain should be normal. However, some 
are produced in reduced rate, thus producing a phenotype resembling the β+-
thalassemia. To date, there are more than 737 β-globin structural variants reports 
across the world (http://globin.cse.psu.edu/).
1.3 Hemoglobin E
HbE is abnormal hemoglobin resulted from the G-A substitution at codon 26 of 
β-globin gene. This missense mutation partially activates a cryptic splice site toward 
the 3′ end of exon 1, resulting in a proportion of abnormally splice mRNA. Thus, 
less βE globin is synthesized, leading to a mild thalassemia phenotype. HbE is 
becoming the common β-globin structure variant across the world as a result of 
migration and inter racial marriage [2, 10]. It has been realized to be the hallmark of 
Southeast Asian region. In Thailand, HbE is very common accounting for approxi-
mately 8–70% of population [11].
1.4 Inheritance of genes for β-thalassemia and HbE
Gene for β-thalassemia and HbE is transmitted within the family from parents 
to descendants in an autosomal recessive fashion. Thus, those who are heterozygous 
for abnormal β-gene are clinically asymptomatic and called β-thalassemia carrier or 
β-thalassemia trait. Those who are heterozygote for HbE gene (βE) are also clini-
cally asymptomatic and called HbE carrier or HbE trait. However, homozygote or 
compound heterozygote of the β-thalassemia gene and/or HbE gene are clinically 
affected and suffer from chronic anemia with some life-threatening complication. 
Therefore, accurate diagnosis of carriers of the β-thalassemia and HbE as well as the 
disease is important.
1.5 Problem of β-thalassemia and HbE
The carriers of β-thalassemia and HbE do not have clinical burden as they are 
clinically normal and have normal quality of life. However, if the β-thalassemia 
carriers get married with the HbE carriers, they will have 25% chance of producing 
the HbE/β-thalassemia babies. The HbE/β-thalassemia or sometimes called the 
β-thalassemia/HbE disease is a thalassemia syndrome that presently is known to be 
clinically heterogeneous [10–12]. Some patients are very mild, while some are very 
severe. The severe cases always required regular blood transfusion which always 
ends up with iron overloading condition. Without proper management of this iron 
overloading, several fatal complications occur, leading to low quality of life and, 
finally, pre-death at young age.
1.6 Diagnosis of β-thalassemia and HbE
The diagnosis of β-thalassemia and HbE involves both clinical and laboratory 
investigations. Clinical data can only identify the affected patients, but cannot 
Beta Thalassemia
126
definitely identify types of thalassemia the patients are suffering. Laboratory data 
thus help define specific types of thalassemia disease of those affected individu-
als. For the carriers, as they are clinically normal, clinical data are of no use. Only 
laboratory data can define β-thalassemia and HbE carriers.
Conventionally, the laboratory tests for diagnosis of β-thalassemia and HbE 
include screening tests and confirmatory tests. Initial screening tests are defined 
as techniques that are simple and relatively low cost, which can indicate the possi-
bility of having thalassemia. These tests should involve the least sample pretreat-
ment and rapid sample preparation and may not need special instrumentation. 
This would lead to low cost and high sample throughput analysis. The screening 
tests, however, cannot provide the information on the exact type of thalassemia 
of the positive persons. Positive samples need further confirmatory test while 
negative samples can be eliminated from further complicated and expensive 
testing.
The screening tests for β-thalassemia carriers comprise one-tube osmotic fragil-
ity test (OFT) and automated red blood cell indices (mean corpuscular volume; 
MCV, mean corpuscular hemoglobin; MCH, and red cell distribution width; RDW). 
Screening tests for HbE carriers are composed of all tests performed to screen for 
the β-thalassemia carrier plus the specifically established for HbE screen such as 
dichlorophenolindophenol precipitation (DCIP) test or HbE tube test or HbE test 
[13–16]. These screening tests, however, cannot provide the information on the 
exact type of thalassemia of the positive persons.
The purpose and methodologies of confirmatory tests for β-thalassemia and 
HbE are identical. The confirmatory tests must be highly specific in order to obtain 
the correct diagnosis of carriers of β-thalassemia and HbE as well as the disease 
state of HbE/β-thalassemia and homozygote or compound heterozygote of the 
β-thalassemia gene. The confirmatory tests include;
• Hemoglobin studies: Tests for hemoglobin studies include cellulose acetate 
electrophoresis, microcolumn chromatography, alkaline denaturation test, 
cation-exchange high performance liquid chromatography (HPLC) [17–19], 
cation-exchange low pressure liquid chromatography (LPLC) [20–22], capil-
lary zone electrophoresis (CZE) [23–27], sandwich enzyme linked immu-
nosorbent assay (ELISA) for Hb F [28], Hb Bart’s [29] and Hb A2 [30], flow 
cytometric analysis of F cells [31], and immunochromatographic strip (IC 
strip) test for Hb Bart’s [32].
• DNA analysis: Tests for analysis of β-globin gene mutations include multiplex 
allele-specific polymerase chain reaction (MAS-PCR) [29], amplification 
refractory mutation system (ARMS)-PCR [33], mutagenically separated (MS)-
PCR [34–36], and high resolution melting curve (HRM) analysis [37–39].
2. Screening laboratory tests for β-thalassemia and HbE carriers
Two laboratory tests are usually performed for screening of the β-thalassemia 
carriers: automated red cell indices (mean corpuscular volume; MCV, mean cor-
puscular hemoglobin; MCH, and red cell distribution width; RDW) and one-tube 
osmotic fragility test (OFT). The screening tests for HbE carrier comprise those 
performed for the β-thalassemia screen plus the tests used for HbE screen. These 
tests include dichlorophenolindophenol precipitation (DCIP) test [40], HbE-tube 
test [15], and hemoglobin E test [16]. The results of these screening tests indicate 
chance that the blood samples are carriers of either β-thalassemia or HbE.
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2.1 Red blood cell indices
Red blood cells or erythrocyte indices used for screening for β-thalassemia carri-
ers and HbE carriers conventionally included mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH). These red cell indices must be obtained by 
automated blood cell analyzers. Normal ranges of MCV and MCH are 85.5 ± 6.8 fL 
and 27.1 ± 3.1 pg, respectively. Cut-off points of MCV and MCH are 80 fL and 27 pg, 
respectively.
MCV and MCH in β-thalassemia carriers are 68.7 ± 5.4 fL and 20.6 ± 2.1 pg. In 
HbE carriers, MCV and MCH values are 76.3 ± 4.6 fL and 24.2 ± 1.5 pg [41]. We 
found that the MCV and MCH in normal individuals, β-thalassemia carriers, and 
HbE carriers were significantly different [41]. With the cut-off points of 80 fL, 
MCV has been shown to be effective in screening for the β-thalassemia carriers 
with sensitivity and specificity of 92.9 and 83.9%, respectively [42, 43]. At 26.5 pg 
cut-off point of MCH, Pranpanus and co-workers found 92.5% sensitivity and 
83.2% specificity of MCH in screening for the β-thalassemia carriers. At the cut-off 
point of 80 fL for MCV and 27 pg for MCH, Karimi and co-workers found 98.5% 
sensitivity of MCH, which was more than that of MCV (97.6% sensitivity) in 
screening for β-thalassemia carriers. They concluded that the MCH was better than 
MCH [44].
MCV and MCH are not effective in screening for HbE carriers since mean 
levels in HbE carriers are just slightly lower than those in normal individu-
als, but the distribution overlaps substantially. Yeo et al. showed that the use 
of 80 fL cut-off point could miss cases of HbE carriers [45]. Ittarat et al. 
showed that 5% of HbE carriers would be missed in 80-fL cut-off points of 
MCV was used [46]. This group suggested the use of some discriminant func-
tions, F1 = 0.01 × MCH × (MCV) or F2 = RDW × MCH × 2(MCV)/Hb × 100 or 
F3 = MCV/RBC, to increase effectiveness of using red cell indices for screening 
for HbE carriers. Our unpublished data showed that using 80-fL and 27 pg cut-off 
points of MCV and MCH, respectively, did not miss cases HbE carriers regardless 
of hemoglobin levels (4.2–15.1 g/dL).
2.2 One-tube osmotic fragility test (OFT)
This simple test utilizes osmosis, the movement of water from lower to higher 
salt concentration region, to test for the osmotic resistance of the red blood cells. In 
a hypotonic condition, the fixed concentration of salt on the outside is lower than 
that on the inside of red blood cell, resulting in net water movement into the red 
blood cell. Normal red blood cells are then lysed and the mixture then turns red-
dish and clear. Red blood cells of the β-thalassemia and HbE carriers have higher 
osmotic resistance and thus have slower rupture rate, and the mixture remains 
turbid. Different laboratories may be using slightly different recipes for preparation 
of hypotonic salt solution such as 0.36% NaCl in distilled water (DW), 0.36% NaCl 
in phosphate buffer or buffered saline solution (BSS), and 0.45% NaCl in glycerine 
or glycerine saline solution (GSS). All of these solutions are normally based on the 
same concept of kinetic osmotic fragility.
2.2.1 0.36% NaCl-based and BSS-based one-tube osmotic fragility test
By mixing the 20 μL of red blood cells of normal and β-thalassemia carriers in 
2 mL of 0.36% NaCl in DW (0.36 g NaCl dissolved in 100 mL DW) or BSS (0.32 g 
NaCl, 0.05 g Na2HPO4, 0.01 g NaH2PO4 dissolved in 100 mL DW) and leave 
for 5 min, the normal red blood cells will completely lyse and the mixture turns 
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definitely identify types of thalassemia the patients are suffering. Laboratory data 
thus help define specific types of thalassemia disease of those affected individu-
als. For the carriers, as they are clinically normal, clinical data are of no use. Only 
laboratory data can define β-thalassemia and HbE carriers.
Conventionally, the laboratory tests for diagnosis of β-thalassemia and HbE 
include screening tests and confirmatory tests. Initial screening tests are defined 
as techniques that are simple and relatively low cost, which can indicate the possi-
bility of having thalassemia. These tests should involve the least sample pretreat-
ment and rapid sample preparation and may not need special instrumentation. 
This would lead to low cost and high sample throughput analysis. The screening 
tests, however, cannot provide the information on the exact type of thalassemia 
of the positive persons. Positive samples need further confirmatory test while 
negative samples can be eliminated from further complicated and expensive 
testing.
The screening tests for β-thalassemia carriers comprise one-tube osmotic fragil-
ity test (OFT) and automated red blood cell indices (mean corpuscular volume; 
MCV, mean corpuscular hemoglobin; MCH, and red cell distribution width; RDW). 
Screening tests for HbE carriers are composed of all tests performed to screen for 
the β-thalassemia carrier plus the specifically established for HbE screen such as 
dichlorophenolindophenol precipitation (DCIP) test or HbE tube test or HbE test 
[13–16]. These screening tests, however, cannot provide the information on the 
exact type of thalassemia of the positive persons.
The purpose and methodologies of confirmatory tests for β-thalassemia and 
HbE are identical. The confirmatory tests must be highly specific in order to obtain 
the correct diagnosis of carriers of β-thalassemia and HbE as well as the disease 
state of HbE/β-thalassemia and homozygote or compound heterozygote of the 
β-thalassemia gene. The confirmatory tests include;
• Hemoglobin studies: Tests for hemoglobin studies include cellulose acetate 
electrophoresis, microcolumn chromatography, alkaline denaturation test, 
cation-exchange high performance liquid chromatography (HPLC) [17–19], 
cation-exchange low pressure liquid chromatography (LPLC) [20–22], capil-
lary zone electrophoresis (CZE) [23–27], sandwich enzyme linked immu-
nosorbent assay (ELISA) for Hb F [28], Hb Bart’s [29] and Hb A2 [30], flow 
cytometric analysis of F cells [31], and immunochromatographic strip (IC 
strip) test for Hb Bart’s [32].
• DNA analysis: Tests for analysis of β-globin gene mutations include multiplex 
allele-specific polymerase chain reaction (MAS-PCR) [29], amplification 
refractory mutation system (ARMS)-PCR [33], mutagenically separated (MS)-
PCR [34–36], and high resolution melting curve (HRM) analysis [37–39].
2. Screening laboratory tests for β-thalassemia and HbE carriers
Two laboratory tests are usually performed for screening of the β-thalassemia 
carriers: automated red cell indices (mean corpuscular volume; MCV, mean cor-
puscular hemoglobin; MCH, and red cell distribution width; RDW) and one-tube 
osmotic fragility test (OFT). The screening tests for HbE carrier comprise those 
performed for the β-thalassemia screen plus the tests used for HbE screen. These 
tests include dichlorophenolindophenol precipitation (DCIP) test [40], HbE-tube 
test [15], and hemoglobin E test [16]. The results of these screening tests indicate 
chance that the blood samples are carriers of either β-thalassemia or HbE.
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2.1 Red blood cell indices
Red blood cells or erythrocyte indices used for screening for β-thalassemia carri-
ers and HbE carriers conventionally included mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH). These red cell indices must be obtained by 
automated blood cell analyzers. Normal ranges of MCV and MCH are 85.5 ± 6.8 fL 
and 27.1 ± 3.1 pg, respectively. Cut-off points of MCV and MCH are 80 fL and 27 pg, 
respectively.
MCV and MCH in β-thalassemia carriers are 68.7 ± 5.4 fL and 20.6 ± 2.1 pg. In 
HbE carriers, MCV and MCH values are 76.3 ± 4.6 fL and 24.2 ± 1.5 pg [41]. We 
found that the MCV and MCH in normal individuals, β-thalassemia carriers, and 
HbE carriers were significantly different [41]. With the cut-off points of 80 fL, 
MCV has been shown to be effective in screening for the β-thalassemia carriers 
with sensitivity and specificity of 92.9 and 83.9%, respectively [42, 43]. At 26.5 pg 
cut-off point of MCH, Pranpanus and co-workers found 92.5% sensitivity and 
83.2% specificity of MCH in screening for the β-thalassemia carriers. At the cut-off 
point of 80 fL for MCV and 27 pg for MCH, Karimi and co-workers found 98.5% 
sensitivity of MCH, which was more than that of MCV (97.6% sensitivity) in 
screening for β-thalassemia carriers. They concluded that the MCH was better than 
MCH [44].
MCV and MCH are not effective in screening for HbE carriers since mean 
levels in HbE carriers are just slightly lower than those in normal individu-
als, but the distribution overlaps substantially. Yeo et al. showed that the use 
of 80 fL cut-off point could miss cases of HbE carriers [45]. Ittarat et al. 
showed that 5% of HbE carriers would be missed in 80-fL cut-off points of 
MCV was used [46]. This group suggested the use of some discriminant func-
tions, F1 = 0.01 × MCH × (MCV) or F2 = RDW × MCH × 2(MCV)/Hb × 100 or 
F3 = MCV/RBC, to increase effectiveness of using red cell indices for screening 
for HbE carriers. Our unpublished data showed that using 80-fL and 27 pg cut-off 
points of MCV and MCH, respectively, did not miss cases HbE carriers regardless 
of hemoglobin levels (4.2–15.1 g/dL).
2.2 One-tube osmotic fragility test (OFT)
This simple test utilizes osmosis, the movement of water from lower to higher 
salt concentration region, to test for the osmotic resistance of the red blood cells. In 
a hypotonic condition, the fixed concentration of salt on the outside is lower than 
that on the inside of red blood cell, resulting in net water movement into the red 
blood cell. Normal red blood cells are then lysed and the mixture then turns red-
dish and clear. Red blood cells of the β-thalassemia and HbE carriers have higher 
osmotic resistance and thus have slower rupture rate, and the mixture remains 
turbid. Different laboratories may be using slightly different recipes for preparation 
of hypotonic salt solution such as 0.36% NaCl in distilled water (DW), 0.36% NaCl 
in phosphate buffer or buffered saline solution (BSS), and 0.45% NaCl in glycerine 
or glycerine saline solution (GSS). All of these solutions are normally based on the 
same concept of kinetic osmotic fragility.
2.2.1 0.36% NaCl-based and BSS-based one-tube osmotic fragility test
By mixing the 20 μL of red blood cells of normal and β-thalassemia carriers in 
2 mL of 0.36% NaCl in DW (0.36 g NaCl dissolved in 100 mL DW) or BSS (0.32 g 
NaCl, 0.05 g Na2HPO4, 0.01 g NaH2PO4 dissolved in 100 mL DW) and leave 
for 5 min, the normal red blood cells will completely lyse and the mixture turns 
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reddish-clear and reported as OFT-Negative. In contrast, the mixture of blood 
samples of β-thalassemia carriers and 0.36% NaCl remains turbid at 5 min and 
reported as OFT-Positive. In case that the appearance of the mixture is between 
positive and negative OFT-results, it is reported as OFT-suspicious (Figure 1). 
Chow et al. showed that this test has 95% sensitivity and 86% specificity for screen-
ing the β-thalassemia carrier [47]. Bobhate et al. demonstrated 97.1% sensitivity 
and 100% specificity of this test, which they called NESTROFT, in screening for 
β-thalassemia carriers [48], while Mamtani et al. showed 93.4% and 97.2% sensi-
tivity and specificity of this test for screening of the β-thalassemia carriers [49]. 
For HbE carriers, Fucharoen et al. showed 37.7% false negative OFT result in HbE 
carriers [50], which was closed to our unpublished data that showed approximately 
29.4% false negative results.
2.2.2  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test
This test was established by Prof. Dr. Torpong Sa-nguansermsri of Thalassemia 
Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai University and 
named this test “Erythrocyte Osmotic Fragility Test” (EOFT) [51]. In this platform, 
the influx of water into the erythrocyte is slow and hemolysis can be measured at 
any points of time after mixing blood with 0.45% GSS [1.424 g Na2HPO4.2H2O, 
0.262 g NaH2PO4.2H2O, 2.812 g NaCl, 19.27 g glycerine (87%), and DW to make 
1000 mL]. Technically, 10 μL of EDTA blood is mixed with 10 mL of 0.45% GSS 
and read 620-nm absorbance at 15, 30, 45, 60, and 120 s, before calculating hemoly-
sis rate at every time point.
The cut-off point of hemolysis rate is 60%. Positive blood samples have hemo-
lysis rate <60%, while the blood samples having hemolysis rate ≥60% is judged as 
negative. The β-thalassemia carriers have hemolysis rate of 17.6 ± 8.1%. Hemolysis 
rate of 32.6 ± 13.2% is observed in HbE carriers [52, 53].
2.2.3  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test expressed in “hemolysis area”
The portable spectrophotometer was invented and capable of reading absor-
bance and transmission of red light through the red blood cell suspension inside 
Figure 1. 
0.36% NaCl-based and BSS-based one-tube osmotic fragility test for screening of β-thalassemia and HbE 
carriers. The β-thalassemia carriers all have the positive OFT results, while HbE carriers have either positive, 
negative, and suspicious OFT results (see the text for detail).
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cuvette [54]. To perform this test, 20 μL of EDTA blood is mixed with 5 mL of 
GSS in 12 × 75 polypropylene cuvette. Then place the cuvette inside the cuvette 
holder of the portable spectrophotometer (red dots in Figure 2(A)) and start the 
machine. Light transmission (red line in Figure 2(B)), light absorbance (black line 
in Figure 2(B)), and HemeArea or hemolysis area (green line in Figure 2(B)) are 
generated simultaneously in real-time manner. At 120 s, the numeric HemeArea 
(or hemolysis area) is shown in green alphabets (Figure 2(B)).
Cut-off point of the hemolysis area is 52.4 unit. Blood samples having the hemo-
lysis area less than these cut-off values are judged as “positive samples,” while those 
samples having the hemolysis area ≥ 52.4 units are classified as “negative sample.” 
The hemolysis area of normal individuals was 67.1 ± 12.6 units. In contrast, the 
hemolysis area of HbE carriers, β-thalassemia carriers were found to be 36.4 ± 13.9, 
18.6 ± 1.1, respectively [54].
2.3 Dichlorophenolindophenol precipitation (DCIP) test
In dichlorophenolindophenol precipitation (DCIP) test, 2,6-dichiorophenol 
indophenol (DCIP) were oxidizing chemicals and used as indicator of ascorbic 
acid measurement. Hemoglobin E is resulted from amino acid change at codon 
26 of β-globin chain from glutamic acid to lysine. This change makes contact of 
α-globin chain and βE-globin chain less stable. Thus, in DCIP solution, molecule of 
HbE changes from tetramer to monomer, freeing sulfhydryl group of amino acid, 
oxidized by the DCIP, denatured, and precipitated [55].
The 500-mL DCIP reagent is composed of 4.36 g Trizma base, 2.68 g EDTA-
Na2.2H2O, 0.0276 g of DCIP, and 0.05 g of saponin. The pH of reagent is adjusted 
to 7.5 by using 6 N HCl. To perform test, 20 μL of EDTA blood is mixed with 5 mL 
DCIP reagent. The mixture is incubated in 37°C-water bath for 1 h before precipita-
tion occurs in case of HbE carriers. To enhance visualization, 20 μL of 6% (w/v) 
ascorbic acid is dropped into the mixture and the color of mixture turns from deep 
blue to pale red (Figure 3).
This test is now commercially available in Thailand. The commercial DCIP 
reagent has the same ingredient and incubation condition as the original test, 
except the volume of reagent is scaled down to 2 mL. The examples of commercially 
DCIP reagent presently distributed in Thailand are THALCON™ and KKU-DCIP™ 
reagent (Figure 4).
Figure 2. 
Portable spectrophotometer (A) and on-screen GSS-based OFT result with the hemolysis area (HemeArea in 
the screen) shown in the screen (B).
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reddish-clear and reported as OFT-Negative. In contrast, the mixture of blood 
samples of β-thalassemia carriers and 0.36% NaCl remains turbid at 5 min and 
reported as OFT-Positive. In case that the appearance of the mixture is between 
positive and negative OFT-results, it is reported as OFT-suspicious (Figure 1). 
Chow et al. showed that this test has 95% sensitivity and 86% specificity for screen-
ing the β-thalassemia carrier [47]. Bobhate et al. demonstrated 97.1% sensitivity 
and 100% specificity of this test, which they called NESTROFT, in screening for 
β-thalassemia carriers [48], while Mamtani et al. showed 93.4% and 97.2% sensi-
tivity and specificity of this test for screening of the β-thalassemia carriers [49]. 
For HbE carriers, Fucharoen et al. showed 37.7% false negative OFT result in HbE 
carriers [50], which was closed to our unpublished data that showed approximately 
29.4% false negative results.
2.2.2  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test
This test was established by Prof. Dr. Torpong Sa-nguansermsri of Thalassemia 
Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai University and 
named this test “Erythrocyte Osmotic Fragility Test” (EOFT) [51]. In this platform, 
the influx of water into the erythrocyte is slow and hemolysis can be measured at 
any points of time after mixing blood with 0.45% GSS [1.424 g Na2HPO4.2H2O, 
0.262 g NaH2PO4.2H2O, 2.812 g NaCl, 19.27 g glycerine (87%), and DW to make 
1000 mL]. Technically, 10 μL of EDTA blood is mixed with 10 mL of 0.45% GSS 
and read 620-nm absorbance at 15, 30, 45, 60, and 120 s, before calculating hemoly-
sis rate at every time point.
The cut-off point of hemolysis rate is 60%. Positive blood samples have hemo-
lysis rate <60%, while the blood samples having hemolysis rate ≥60% is judged as 
negative. The β-thalassemia carriers have hemolysis rate of 17.6 ± 8.1%. Hemolysis 
rate of 32.6 ± 13.2% is observed in HbE carriers [52, 53].
2.2.3  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test expressed in “hemolysis area”
The portable spectrophotometer was invented and capable of reading absor-
bance and transmission of red light through the red blood cell suspension inside 
Figure 1. 
0.36% NaCl-based and BSS-based one-tube osmotic fragility test for screening of β-thalassemia and HbE 
carriers. The β-thalassemia carriers all have the positive OFT results, while HbE carriers have either positive, 
negative, and suspicious OFT results (see the text for detail).
129
Laboratory Diagnosis of β-Thalassemia and HbE
DOI: http://dx.doi.org/10.5772/intechopen.90317
cuvette [54]. To perform this test, 20 μL of EDTA blood is mixed with 5 mL of 
GSS in 12 × 75 polypropylene cuvette. Then place the cuvette inside the cuvette 
holder of the portable spectrophotometer (red dots in Figure 2(A)) and start the 
machine. Light transmission (red line in Figure 2(B)), light absorbance (black line 
in Figure 2(B)), and HemeArea or hemolysis area (green line in Figure 2(B)) are 
generated simultaneously in real-time manner. At 120 s, the numeric HemeArea 
(or hemolysis area) is shown in green alphabets (Figure 2(B)).
Cut-off point of the hemolysis area is 52.4 unit. Blood samples having the hemo-
lysis area less than these cut-off values are judged as “positive samples,” while those 
samples having the hemolysis area ≥ 52.4 units are classified as “negative sample.” 
The hemolysis area of normal individuals was 67.1 ± 12.6 units. In contrast, the 
hemolysis area of HbE carriers, β-thalassemia carriers were found to be 36.4 ± 13.9, 
18.6 ± 1.1, respectively [54].
2.3 Dichlorophenolindophenol precipitation (DCIP) test
In dichlorophenolindophenol precipitation (DCIP) test, 2,6-dichiorophenol 
indophenol (DCIP) were oxidizing chemicals and used as indicator of ascorbic 
acid measurement. Hemoglobin E is resulted from amino acid change at codon 
26 of β-globin chain from glutamic acid to lysine. This change makes contact of 
α-globin chain and βE-globin chain less stable. Thus, in DCIP solution, molecule of 
HbE changes from tetramer to monomer, freeing sulfhydryl group of amino acid, 
oxidized by the DCIP, denatured, and precipitated [55].
The 500-mL DCIP reagent is composed of 4.36 g Trizma base, 2.68 g EDTA-
Na2.2H2O, 0.0276 g of DCIP, and 0.05 g of saponin. The pH of reagent is adjusted 
to 7.5 by using 6 N HCl. To perform test, 20 μL of EDTA blood is mixed with 5 mL 
DCIP reagent. The mixture is incubated in 37°C-water bath for 1 h before precipita-
tion occurs in case of HbE carriers. To enhance visualization, 20 μL of 6% (w/v) 
ascorbic acid is dropped into the mixture and the color of mixture turns from deep 
blue to pale red (Figure 3).
This test is now commercially available in Thailand. The commercial DCIP 
reagent has the same ingredient and incubation condition as the original test, 
except the volume of reagent is scaled down to 2 mL. The examples of commercially 
DCIP reagent presently distributed in Thailand are THALCON™ and KKU-DCIP™ 
reagent (Figure 4).
Figure 2. 
Portable spectrophotometer (A) and on-screen GSS-based OFT result with the hemolysis area (HemeArea in 
the screen) shown in the screen (B).
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This test has been validated and shown to be effective in screening for HbE car-
riers. Analysis in the author’s laboratory showed that this test had 100% sensitivity 
and 98.4% specificity in screening for HbE carriers [56]. Wiwanitkit et al. found 
almost the same effectiveness of this test in HbE screen; 100% sensitivity and 97.2% 
specificity [14]. Chapple et al. re-evaluated the KKU-DCIP reagent kit and found 
100% sensitivity and 92% specificity for screening for HbE carriers [55].
2.4 HbE-tube test
This test was invented by the author in 2012 [15]. It is based on the principle of 
anion-exchange liquid chromatography. The diethyl aminoethyl (DEAE)-cellulose 
having positive charge in buffer having fixed amount of NaCl is placed in the 
test tube. This condition allows all hemoglobins to bind DEAE-cellulose, except 
HbE and HbA2. Then these two hemoglobins will still dissolve in the supernatant. 
However, since HbE quantity is more than 10% in HbE carriers, then in case of 
HbE carrier, the supernatant color is red. In contrast, in non HbE, that is, no HbE 
in blood, the supernatant is colorless (Figure 5). This test is simple, requiring no 
incubation and centrifugation. Standing the test tube after mixing the blood for 
about 10 min is enough for visualizing the supernatant color.
Figure 4. 
DCIP test results obtained by commercial DCIP kit. The black lines placed behind the tube aid the result 
reading. If we cannot see the black lines, the result is positive. If the black lines are clearly seen, the result is 
negative. DCIP test produces turbid solution.
Figure 3. 
Dichlorophenolindophenol precipitation (DCIP) test. The DCIP results before adding ascorbic acid have 
deeply blue color, but after ascorbic acid addition, the color turns to pale red. The amount of precipitation is 
increased in homozygous HbE (EE), compared to HbE carrier (AE). No precipitation is seen for non-HbE 
(A2A). Modified from Ref. [53].
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To perform the test, 15 μL packed red cell (PRC) is added to pre-prepared 
DEAE-cellulose suspension in the transparent test tube (0.5 mL DEAE-cellulose 
suspension in 1.0 mL glycine-NaCl buffer containing 0.2 M glycine–0.01% KCN–
7.5 mM NaCl). The tube is shaken briefly, left for 5 min at room temperature, and 
spun at 3500 round per minute for 5 min before reading the results by visualizing 
the color of supernatant as shown in Figure 5.
This test was simple and effective in screening of HbE carriers. Its sensitiv-
ity and specificity for HbE screen are 100%. The reagent can be kept in the cold 
(2–8°C) for 5 months [15].
2.5 HbE screen test
This test was initially invented by Prof. Dr. Torpong Sa-nguansermsri of The 
Thalassemia Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai 
University, Thailand [57] and adopted for HbE screen in pregnant women by 
Sirichotiyakul et al. [58]. This test was also established in author’s laboratory 
(Unpublished data). This test works under the principle of anion-exchange column 
chromatography, modified from microcolumn chromatography for HbA2 quantifi-
cation [59, 60].
The test comprises small syringe packed inside with anion-coated resin such 
as diethylaminoethyl (DEAE)-Sephadex A50 suspended in Tris-HCl-KCN (THK) 
buffer (6.057 g tris hydroxymethyl aminomethane, 0.1 g KCN, 4 N HCl to adjust 
pH), pH 8.5. On passing hemolysate through this microcolumn, all hemoglobins 
bind to the resin. However, passing the eluting buffer (THK buffer, pH 8.2), only 
HbE and HbA2 are eluted. If the patients have HbE, the color of entire length of the 
microcolumn will be red. If the patients do not have HbE, the color of this point will 
be colorless (Figure 6).
To perform this test invented by Prof. Dr. Torpong Sanguansermsri, 10 mL hemo-
globin solution (40 μL hemolysate mixed in 5 mL THK buffer pH 8.5) is dropped into 
microcolumn prepacked with DEAE-Sephadex A 50 to the height of 5.0 cm in pasture 
pipette. The solution is allowed to flow through the microcolumn which is subse-
quently equilibrated with 10 mL THK buffer pH 8.5. Finally, HbE and HbA2 are eluted 
out of the microcolumn after poring 10 mL of THK buffer, pH 8.2. At the end, the red 
color of the column is observed. If almost the entire length of microcolumn is red, 
Figure 5. 
HbE tube test for screening of HbE carriers. The positive tube (Pos) is the result of HbE carrier having Hb type 
AE and red supernatant is seen. The negative tube (Neg) is the result of normal individual having Hb type 
A2A and colorless supernatant is seen.
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This test has been validated and shown to be effective in screening for HbE car-
riers. Analysis in the author’s laboratory showed that this test had 100% sensitivity 
and 98.4% specificity in screening for HbE carriers [56]. Wiwanitkit et al. found 
almost the same effectiveness of this test in HbE screen; 100% sensitivity and 97.2% 
specificity [14]. Chapple et al. re-evaluated the KKU-DCIP reagent kit and found 
100% sensitivity and 92% specificity for screening for HbE carriers [55].
2.4 HbE-tube test
This test was invented by the author in 2012 [15]. It is based on the principle of 
anion-exchange liquid chromatography. The diethyl aminoethyl (DEAE)-cellulose 
having positive charge in buffer having fixed amount of NaCl is placed in the 
test tube. This condition allows all hemoglobins to bind DEAE-cellulose, except 
HbE and HbA2. Then these two hemoglobins will still dissolve in the supernatant. 
However, since HbE quantity is more than 10% in HbE carriers, then in case of 
HbE carrier, the supernatant color is red. In contrast, in non HbE, that is, no HbE 
in blood, the supernatant is colorless (Figure 5). This test is simple, requiring no 
incubation and centrifugation. Standing the test tube after mixing the blood for 
about 10 min is enough for visualizing the supernatant color.
Figure 4. 
DCIP test results obtained by commercial DCIP kit. The black lines placed behind the tube aid the result 
reading. If we cannot see the black lines, the result is positive. If the black lines are clearly seen, the result is 
negative. DCIP test produces turbid solution.
Figure 3. 
Dichlorophenolindophenol precipitation (DCIP) test. The DCIP results before adding ascorbic acid have 
deeply blue color, but after ascorbic acid addition, the color turns to pale red. The amount of precipitation is 
increased in homozygous HbE (EE), compared to HbE carrier (AE). No precipitation is seen for non-HbE 
(A2A). Modified from Ref. [53].
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To perform the test, 15 μL packed red cell (PRC) is added to pre-prepared 
DEAE-cellulose suspension in the transparent test tube (0.5 mL DEAE-cellulose 
suspension in 1.0 mL glycine-NaCl buffer containing 0.2 M glycine–0.01% KCN–
7.5 mM NaCl). The tube is shaken briefly, left for 5 min at room temperature, and 
spun at 3500 round per minute for 5 min before reading the results by visualizing 
the color of supernatant as shown in Figure 5.
This test was simple and effective in screening of HbE carriers. Its sensitiv-
ity and specificity for HbE screen are 100%. The reagent can be kept in the cold 
(2–8°C) for 5 months [15].
2.5 HbE screen test
This test was initially invented by Prof. Dr. Torpong Sa-nguansermsri of The 
Thalassemia Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai 
University, Thailand [57] and adopted for HbE screen in pregnant women by 
Sirichotiyakul et al. [58]. This test was also established in author’s laboratory 
(Unpublished data). This test works under the principle of anion-exchange column 
chromatography, modified from microcolumn chromatography for HbA2 quantifi-
cation [59, 60].
The test comprises small syringe packed inside with anion-coated resin such 
as diethylaminoethyl (DEAE)-Sephadex A50 suspended in Tris-HCl-KCN (THK) 
buffer (6.057 g tris hydroxymethyl aminomethane, 0.1 g KCN, 4 N HCl to adjust 
pH), pH 8.5. On passing hemolysate through this microcolumn, all hemoglobins 
bind to the resin. However, passing the eluting buffer (THK buffer, pH 8.2), only 
HbE and HbA2 are eluted. If the patients have HbE, the color of entire length of the 
microcolumn will be red. If the patients do not have HbE, the color of this point will 
be colorless (Figure 6).
To perform this test invented by Prof. Dr. Torpong Sanguansermsri, 10 mL hemo-
globin solution (40 μL hemolysate mixed in 5 mL THK buffer pH 8.5) is dropped into 
microcolumn prepacked with DEAE-Sephadex A 50 to the height of 5.0 cm in pasture 
pipette. The solution is allowed to flow through the microcolumn which is subse-
quently equilibrated with 10 mL THK buffer pH 8.5. Finally, HbE and HbA2 are eluted 
out of the microcolumn after poring 10 mL of THK buffer, pH 8.2. At the end, the red 
color of the column is observed. If almost the entire length of microcolumn is red, 
Figure 5. 
HbE tube test for screening of HbE carriers. The positive tube (Pos) is the result of HbE carrier having Hb type 
AE and red supernatant is seen. The negative tube (Neg) is the result of normal individual having Hb type 
A2A and colorless supernatant is seen.
Beta Thalassemia
132
the result is “Positive.” However, if the red color sticks to only at the top layer of the 
packed resin, the result is “Negative” [57]. This test was evaluated by Sirichotiyakul 
et al. and found to have 100% sensitivity and 100% specificity for HbE screen [58].
Alternatively, the test was modified in author’s laboratory. In this modification, 
DEAE-cellulose was used as the pre-packed resin, and glycine-NaCl buffer was 
equilibrating and eluting buffer. To prepare microcolumn, DEAE-cellulose resin 
suspended in equilibrating buffer (0.2 M glycine + 0.01% KCN) is pre-packed to the 
height of 2.5 cm in 3-mL plastic syringe with 1-cm diameter. To perform the test, 
150 μL hemolysate is dropped into the microcolumn and allowed to pass through 
the resin before eluting HbE with 4 mL eluting buffer (0.2 M glycine + 0.01% 
KCN + 0.005 M NaCl). The red color of the resin packed in column is observed 
in the way resemble that mentioned above (Figure 6). The protocol was named 
“Naked-EyE-Microcolumn-HbE-Screen or NEMES” [61]. This test was found to 
have 100% sensitivity and 100% specificity for screening of HbE carriers.
3. Interpretation of the screening tests
The β-thalassemia carriers always have positive OFT, MCV less than 80 fL, MCH 
less than 27 pg, and negative HbE. In contrast, HbE carriers may have MCV: more or 
less than 80 fL, MCH: more or less than 27 pg, OFT: positive or suspicious or nega-
tive, and hemolysis area: more or less than 52.4 unit. However, all cases of HbE carri-
ers certainly have positive HbE screening tests performed by all mentioned tests.
The MCV, MCH, and OFT are all positive in β-thalassemia diseases such as 
homozygous βO-thalassemia, homozygous β+-thalassemia, compound heterozygous 
βO/β+-thalassemia, compound heterozygous HbE/βO-thalassemia, compound 
heterozygous HbE/β+-thalassemia, and homozygous HbE. However, the DCIP test, 
HbE tube test, and HbE screen test are positive in all cases having HbE in blood.
4. Usefulness of screening tests
In financially burden countries that have considerably high prevalence of thalas-
semia and hemoglobinopathies, initial screen of the carriers in population is essen-
tial. This approach helps to decrease the number of cases seeking further for more 
Figure 6. 
HbE screening test in a modified protocol so-called naked eye microcolumn for HbE screen (NEMES). The AE 
sample shows red color in the resin along entire length of the resin, but not for the A2A sample.
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expensive confirmatory tests. Normally, the sophisticated laboratory tests for conform-
ing the diagnosis of thalassemia and hemoglobinopathies are set up in big centers 
which are mostly located in the city. Thus, selected cases that are screened in for the 
definite diagnosis of thalassemia and hemoglobinopathies have to travel a long distance 
to the city. This would not consume much money for traveling and for laboratory tests.
4.1 Confirmatory method for thalassemia and hemoglobinopathies
Aims of confirmatory tests are to make the definite diagnosis of β-thalassemia 
and HbE. These tests generally performed only in blood samples having positive 
results of screening tests. Two sets of confirmatory tests are generally performed; 
hemoglobin studies and DNA analysis.
4.1.1  Hemoglobin studies by cellulose acetate electrophoresis (CAE) at alkaline 
condition
This test separates hemoglobins in blood by their negatively molecular net 
charge. Hemoglobins are allowed to dissolve in Tris-EDTA-Borate (TBE) buffer 
pH 8.6. This pH is more than isoelectric points (pI) of all hemoglobins (approxi-
mately 6.5–7.5) [62, 63]. At this pH, all hemoglobins have negative charge and 
migrate from cathodic part toward anodic end of the electrophoretic chamber.
In 1 L of TBE buffer, it is composed of 12.0 g tris-hydroxymethyl aminomethane 
(Tris), 1.22 g ethylenediaminetetraacetic acid (EDTA), and 1.5 g boric acid.
The electrophoresis is performed at a constant voltage of 250–300 volts for 
15–20 minutes or until HbA and HbE bands are clearly separated. At the end of 
electrophoresis, the hemoglobin bands on cellulose acetate plate are stained for 
5 minutes with Ponceau S stain (2 g of Ponceau S powder, 30 g of trichloroacetic 
acid, and 30 g of sulfosalicylic acid in 1 L of distilled water) and destained for 
5 minutes in destaining solution (5% acetic acid in distilled water). Finally, the 
cellulose acetate plate is made clear for permanent record by immersing for 5 min-
utes in clearing solution (4 volume of methanol +1 volume of glacial acetic acid) 
and dried by using hair dryer. Hemoglobin pattern from cathodic to anodic ends is 
Constant Spring-A2/E/C/O-S/D/Lepore/G-F-A-Portland-Bart’s-H [64] (Figure 7). 
Hemoglobin patterns on CAE at alkaline condition are shown in Table 1. In the past, 
densitometer was used to determine quantities of hemoglobins in blood samples. 
However, this technique is not conventionally performed presently because it may 
give falsely high levels of hemoglobins if the background is not completely cleared. 
However, CAE results can still give types of hemoglobins in blood samples. Thus, by 
Figure 7. 
(A) Hemoglobin patterns on cellulose acetate electrophoresis (CAE) at pH 8.6. (B) Example of hemoglobin 
pattern on CAE at pH 8.6 stained with Ponceau S stain.
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the result is “Positive.” However, if the red color sticks to only at the top layer of the 
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KCN + 0.005 M NaCl). The red color of the resin packed in column is observed 
in the way resemble that mentioned above (Figure 6). The protocol was named 
“Naked-EyE-Microcolumn-HbE-Screen or NEMES” [61]. This test was found to 
have 100% sensitivity and 100% specificity for screening of HbE carriers.
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less than 27 pg, and negative HbE. In contrast, HbE carriers may have MCV: more or 
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tive, and hemolysis area: more or less than 52.4 unit. However, all cases of HbE carri-
ers certainly have positive HbE screening tests performed by all mentioned tests.
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βO/β+-thalassemia, compound heterozygous HbE/βO-thalassemia, compound 
heterozygous HbE/β+-thalassemia, and homozygous HbE. However, the DCIP test, 
HbE tube test, and HbE screen test are positive in all cases having HbE in blood.
4. Usefulness of screening tests
In financially burden countries that have considerably high prevalence of thalas-
semia and hemoglobinopathies, initial screen of the carriers in population is essen-
tial. This approach helps to decrease the number of cases seeking further for more 
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expensive confirmatory tests. Normally, the sophisticated laboratory tests for conform-
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which are mostly located in the city. Thus, selected cases that are screened in for the 
definite diagnosis of thalassemia and hemoglobinopathies have to travel a long distance 
to the city. This would not consume much money for traveling and for laboratory tests.
4.1 Confirmatory method for thalassemia and hemoglobinopathies
Aims of confirmatory tests are to make the definite diagnosis of β-thalassemia 
and HbE. These tests generally performed only in blood samples having positive 
results of screening tests. Two sets of confirmatory tests are generally performed; 
hemoglobin studies and DNA analysis.
4.1.1  Hemoglobin studies by cellulose acetate electrophoresis (CAE) at alkaline 
condition
This test separates hemoglobins in blood by their negatively molecular net 
charge. Hemoglobins are allowed to dissolve in Tris-EDTA-Borate (TBE) buffer 
pH 8.6. This pH is more than isoelectric points (pI) of all hemoglobins (approxi-
mately 6.5–7.5) [62, 63]. At this pH, all hemoglobins have negative charge and 
migrate from cathodic part toward anodic end of the electrophoretic chamber.
In 1 L of TBE buffer, it is composed of 12.0 g tris-hydroxymethyl aminomethane 
(Tris), 1.22 g ethylenediaminetetraacetic acid (EDTA), and 1.5 g boric acid.
The electrophoresis is performed at a constant voltage of 250–300 volts for 
15–20 minutes or until HbA and HbE bands are clearly separated. At the end of 
electrophoresis, the hemoglobin bands on cellulose acetate plate are stained for 
5 minutes with Ponceau S stain (2 g of Ponceau S powder, 30 g of trichloroacetic 
acid, and 30 g of sulfosalicylic acid in 1 L of distilled water) and destained for 
5 minutes in destaining solution (5% acetic acid in distilled water). Finally, the 
cellulose acetate plate is made clear for permanent record by immersing for 5 min-
utes in clearing solution (4 volume of methanol +1 volume of glacial acetic acid) 
and dried by using hair dryer. Hemoglobin pattern from cathodic to anodic ends is 
Constant Spring-A2/E/C/O-S/D/Lepore/G-F-A-Portland-Bart’s-H [64] (Figure 7). 
Hemoglobin patterns on CAE at alkaline condition are shown in Table 1. In the past, 
densitometer was used to determine quantities of hemoglobins in blood samples. 
However, this technique is not conventionally performed presently because it may 
give falsely high levels of hemoglobins if the background is not completely cleared. 
However, CAE results can still give types of hemoglobins in blood samples. Thus, by 
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(A) Hemoglobin patterns on cellulose acetate electrophoresis (CAE) at pH 8.6. (B) Example of hemoglobin 
pattern on CAE at pH 8.6 stained with Ponceau S stain.
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using this technique, further tests must be done in order to determine the level of 
HbA2 and HbF. Raised level of HbA2 beyond normal range is the diagnostic marker 
for β-thalassemia carriers, while elevated level of HbF helps identify the high HbF 
condition found in the hereditary persistence of fetal hemoglobin (HPFH).
4.1.2 Hemoglobin study by microcolumn chromatography
This test is preliminarily aimed to quantify HbA2 levels that help diagnosis of 
the β-thalassemia carrier. However, HbE has the same pI as HbA2, thus these two 
hemoglobins are co-eluted. Microcolumn chromatography is an anion-exchange 
chromatography-based method. Anion-resin such as DEAE-cellulose or DEAE-
Sephadex A50 suspended in appropriate buffer is packed in the microcolumn. On 
passing hemolysate through the packed resin, negatively charged hemoglobins 
binds to the resin at different binding affinity. HbA2 and HbE bind to the resin at 
the weakest strength (if there is no Hb Constant Spring) and are eluted out easily 
with small amount of external anion such as CL−.
There are two types of microcolumn chromatography, based on the anion-resin 
and buffers used. These include (1) DEAE-Sephadex A50 plus Tris-HCl-KCN buf-
fer, and (2) DEAE-cellulose plus glycine-NaCl buffer.
4.1.2.1 Microcolumn chromatography using DEAE-Sephadex A50 resin
DEAE-Sephadex A 50 resin suspended in Tris-HCl-KCN buffer (0.05 M Tris 
plus 0.1 g KCN/1 L, adjust pH with 4 N HCl) pH 8.5 is packed in pasture pipette to 
the height of 8–9 cm [52]. Then, the microcolumn is applied with 100 μL hemoly-
sate, equilibrated with 10 mL THK buffer pH 8.5. Finally, 10 mL THK buffer pH 8.2 
is applied to the microcolumn to elute HbA2 and/or HbE before 10 mL eluate is 
collected for measuring light absorbance (A) or optical density (OD) at 415 nm. 
This is then called A415-A2 or OD415-A2. For measuring OD415 of total hemoglobin or 
OD415-Total Hb, 100 μL hemolysate is mixed with 10 mL DW before measuring the 
absorbance. The level of HbA2 or HbE is calculated by the Eq. 1 shown below.
  HbA 2 or HbE  (%) =  [ OD 415 −  A 2 / OD 415 − total Hb] × 100 (1)
If percent is less than 10, it is HbA2.
If percent is 10 up, it is HbE.
Normal range of HbA2 by this protocol is 2.62 ± 0.87% [52].
Hb patterns on CAE at pH 8.6 of adult
HbE heterozygote (carriers) EA
HbE homozygote EE (only 1 band of HbE)
βO-thalassemia heterozygote (carriers) A2A
β+-thalassemia heterozygote (carriers) A2A
βO-thalassemia homozygote (βO/βO) A2F
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4.1.2.2 Microcolumn chromatography using DEAE-cellulose
This protocol was described by Wood [64] and modified in the author’s labora-
tory in 2007 [65].
In modified protocol, DEAE-cellulose resin suspended in equilibrating buffer 
(0.2 M glycine + 0.01% KCN) is packed to the height of 2 cm in plastic microcol-
umn with 1.0-cm diameter. Then the microcolumn is applied by 50 μL hemolysate 
(prepared by mixing 1 part of PRC and 6 parts of 0.05% Triton X-100 as hemolysis 
buffer) and flushed with 5 mL eluting buffer (0.2 M glycine +0.01% KCN + 0.005 M 
NaCl). The 5-mL eluate is then collected and measured for absorbance or optical den-
sity at 415 nm (A415-A2 or OD415-A2). OD415 of total hemoglobin is measured in diluted 
hemolysate (50 μL hemolysate mixed with DW to 15 mL) and called OD415-Total.
Calculation of levels of HbA2 or HbE must follow the Eq. 2 shown below.
  HbA 2 or HbE  (%) =  [ OD 415 −  A 2 / OD 415 –total × 3] × 100 (2)
If percent is less than 10, it is HbA2.
If percent is 10 up, it is HbE.
Normal range of HbA2 by this protocol is 1.3–3.7% (mean 2.5%) [64].
For both protocols, if HbA2 level is less than 3.5%, the chance of β-thalassemia 
carrier is excluded. Instead, the cases may be either normal of α-thalassemia carriers. 
However, if HbA2 level is between 3.5 and 10.0%, the case is definitely β-thalassemia 
carrier. In β-thalassemia carriers, mean HbA2 is 4.8% with the range 3.7–7.0% [64].
4.1.2.3 Hemoglobin study by alkaline denaturation test of Betke
This test works under the principle that HbF is resistant to alkaline treatment, 
while other hemoglobins are not [66]. Therefore, if hemoglobin solution of normal 
adult is mixed with alkaline solution, HbA, HbA2 is denatured, leaving only HbF 
dissolved in the solution. The dissolved HbF can be determined for its level by 
measuring optical density at 540 nm.
The reagents that are required for this test comprise Drabkin’s solution (0.20 g 
of K3Fe(CN)6, 0.05 g of KCN, DW to 1 L), 1.2 N NaOH, and saturated ammonium 
sulphate.
To perform the test, 200 μL hemolysate is mixed in 3.8 mL of Drabkin’s solution 
to prepare cyanmethemoglobin. Thereafter, 2.8 mL of cyanmethemoglobin solution 
is mixed with 200 μL of 1.2 N NaCl and shaked vigorously for 2 min exactly before 
adding 2.0 mL of saturated ammonium sulphate. Then, the precipitated hemoglo-
bins are filtered out, and the OD540 of filtrate is measured and named OD540-filtrate. 
OD540 of total hemoglobin is measured in a mixture of 400 μL of hemolysate and 
6.75 mL of Drabkin’s solution and named OD540-Total.
The percentage of HbF is calculated by the following Eq. 3:
  HbF or Alk F  (%) =  ( OD 540 − filtrate / OD 540 − total) × 10 (3)
Since HbF is determined by alkaline treatment, its level is then named Alkaline F 
or, simply, Alk F. Besides HbF, Hb Bart’s (γ4) is also resistant to alkaline treatment. This 
protocol has maximum detection limit at only 50% of HbF. If the alkaline denaturation 
test is performed in fetal blood sample, the Alk F will not be more than 50%. Therefore, 
other techniques such as HPLC, CZE should be used to measure HbF in fetal blood.
Alk F is not diagnostic marker for both β-thalassemia carriers and HbE car-
riers. However, increased HbF level presently is considered advantageous in 
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This test works under the principle that HbF is resistant to alkaline treatment, 
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test is performed in fetal blood sample, the Alk F will not be more than 50%. Therefore, 
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Alk F is not diagnostic marker for both β-thalassemia carriers and HbE car-
riers. However, increased HbF level presently is considered advantageous in 
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β-thalassemia and β-hemoglobinopathies [6]. Patients with β-thalassemia disease 
who also inherit high HbF gene or quantitative trait loci (QTLs) will have mild 
clinical symptoms. Parents having high HbF gene can pass this gene to their 
β-thalassemia offspring. Thus, determining HbF in parents is useful in this way.
4.1.2.4  Hemoglobin study by cation-exchange high performance liquid 
chromatography (HPLC)
Cation-exchange HPLC has become the reference method for typing and quan-
titating hemoglobins in blood samples [19, 67, 68]. In this system, hemoglobins are 
dissolved in buffer having a pH of 6.4 that is less than pI of hemoglobins (6.5–7.5) 
and molecular net charge then is converted to be positive. Different hemoglobins 
then have different amount of positive charge which determines binding strength of 
hemoglobins to negatively charged resin. Hb Bart’s has the weakest binding affinity, 
while Hb Constant Spring has the strongest binding affinity. Therefore, on passing 
external cation, the order of hemoglobins that are eluted fast to slowly should be as 
follows: Hb Bart’s-HbH-HbF-HbAo-HbA2/E-Hb Constant Spring (Figure 8).
Figure 8. 
Hemoglobin pattern of cation-exchange HPLC of normal human adult: A2A. As shown in the figure, major 
hemoglobin is HbAo which accounts for 82.4%, while the minor HbA2 accounts for 2.6%. Other minor hemoglobins 
are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is negligible and reported as 0.0%. 
This HPLC result may be that of normal individuals or α-thalassemia carriers. It is noted that this kind of cation-
exchange HPLC pattern may be also observed in carriers of α-thalassemia 1 and carriers of α-thalassemia 2.
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HbA is normally derivatized to several fractions including the minor Hbs A1a, 
A1b, A1c, and major HbAo. The minor Hbs A1a, A1b, and A1c are eluted just after 
HbF. For routine Hb typing work, only the major HbAo is usually reported to clini-
cians. This makes sum of hemoglobin peaks does not equal to 100%.
HbE, which is common in Southeastern part of the world, is co-eluted with 
HbA2. However, most of the manufacturers design program to read hemoglobin 
peak at the A2 region as only HbA2. Therefore, the operator must be aware that if 
the percentage of A2-peak is more than 10, it is HbE plus HbA2 and indicates that 
the sample has HbE. The operator must report HbE or HbE plus HbA2, instead of 
reporting HbA2 as reported by the machine.
There are several manufacturers producing the HPLC machine in the world 
and the operating procedures as well as quality control protocols are established 
specifically for each brand. Most importantly, all of these brands generate identical 
separation peaks of hemoglobins. Figure 8 shows example of hemoglobin pattern 
obtained from Variant™ Hemoglobin Analysis System, the widely used HPLC 
machine in Thailand. In this protocol, the hemoglobin types in normal human 
adults are A2A with HbA2 of 2.6 ± 0.38% [19].
Contrast to the CAE at pH 8.6, hemoglobins separated by the cation-exchange 
HPLC are automatically calculated for their proportions in blood. Therefore, 
both types and quantities of hemoglobins are usually obtained when run in this 
platform.
Figure 9. 
Hemoglobin pattern of cation-exchange HPLC of β-thalassemia carrier in human adult: A2A. As shown in the 
figure, major hemoglobin is HbAo which accounts for 78.6%, while the minor HbA2 accounts for 5.9%. Other 
minor hemoglobins are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is negligible 
and reported as 0.0%.
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cians. This makes sum of hemoglobin peaks does not equal to 100%.
HbE, which is common in Southeastern part of the world, is co-eluted with 
HbA2. However, most of the manufacturers design program to read hemoglobin 
peak at the A2 region as only HbA2. Therefore, the operator must be aware that if 
the percentage of A2-peak is more than 10, it is HbE plus HbA2 and indicates that 
the sample has HbE. The operator must report HbE or HbE plus HbA2, instead of 
reporting HbA2 as reported by the machine.
There are several manufacturers producing the HPLC machine in the world 
and the operating procedures as well as quality control protocols are established 
specifically for each brand. Most importantly, all of these brands generate identical 
separation peaks of hemoglobins. Figure 8 shows example of hemoglobin pattern 
obtained from Variant™ Hemoglobin Analysis System, the widely used HPLC 
machine in Thailand. In this protocol, the hemoglobin types in normal human 
adults are A2A with HbA2 of 2.6 ± 0.38% [19].
Contrast to the CAE at pH 8.6, hemoglobins separated by the cation-exchange 
HPLC are automatically calculated for their proportions in blood. Therefore, 
both types and quantities of hemoglobins are usually obtained when run in this 
platform.
Figure 9. 
Hemoglobin pattern of cation-exchange HPLC of β-thalassemia carrier in human adult: A2A. As shown in the 
figure, major hemoglobin is HbAo which accounts for 78.6%, while the minor HbA2 accounts for 5.9%. Other 
minor hemoglobins are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is negligible 
and reported as 0.0%.
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4.2  Cation-exchange HPLC hemoglobin patterns of β-thalassemia carriers and 
HbE carriers in human adults
Hemoglobin patterns obtained from the cation-exchange HPLC of β-thalassemia 
and HbE are totally different. In carrier state, β-thalassemia carriers in adult life 
have normal Hb types for adult which is A2A, but HbA2 levels is increased to the 
levels of 5.9 ± 1.35% (Figure 9) [19]. HbE carriers in adult life have abnormal Hb 
typing by the cation-exchange HPLC which is AE with HbE (plus A2) of 27 ± 3.93% 
[19], as shown in Figure 10.
4.3  Cation-exchange HPLC hemoglobin patterns of β-thalassemia diseases and 
HbE disease in human adults
Hemoglobin patterns by the cation-exchange HPLC of adult β-thalassemia 
disease consist of several patterns depending on the combination of the abnormal 
β-thalassemia mutations.
4.3.1 Homozygous βO-thalassemia
Individuals of homozygous βO-thalassemia (βO/βO) are usually affected by the 
severe thalassemia disease and require regular blood transfusion. This group of patients 
Figure 10. 
Hemoglobin pattern of cation-exchange HPLC of HbE carrier in human adults: EA. As shown in the figure, 
major hemoglobin is HbAo which accounts for 59.2%, while the minor HbE (plus A2) accounts for 24.9%. 
Other minor hemoglobins are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is 
negligible and reported as 0.0%.
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is previously classified as thalassemia major, but now as transfusion dependent thalas-
semia [69]. Hence, hemoglobin patterns of homozygous βO-thalassemia in adult life of 
human should consist of HbF and HbA2 with no HbA prior to blood transfusion, that 
is, A2F (Figure 11). However, after recent blood transfusion, the hemoglobin types of 
A2FA are shown. HbA is certainly from the transfused blood ( Figure 12).
4.3.2 Homozygous β+-thalassemia
Individuals of homozygous β+-thalassemia always have mild clinical symptoms 
and previously are classified as β-thalassemia intermedia. The β-thalassemia 
intermedia cases usually require no blood transfusion. Thus, now this group of 
patients is newly classified as non-transfusion dependent thalassemia (NTDT) 
[69]. Hemoglobin pattern on cation-exchange HPLC of homozygous β+-thalassemia 
is quite resembling to that of transfused homozygous βO-thalassemia, that is, 
A2FA. However, single population of red blood cells on blood smear is also revealed 
in this homozygous β+-thalassemia, in contrast for dimorphic population in case of 
transfused homozygous βO-thalassemia. Figure 12 shows hemoglobin pattern by 
cation-exchange HPLC of the homozygous β+-thalassemia.
Figure 11. 
Cation-exchange HPLC pattern of homozygous βO-thalassemia prior to blood transfusion, which is read as 
A2F (F: 97.8%, A2: 2.2%) (credit to Eaktong Limveeraprajak of Sawan Pracharak Hospital).
Figure 12. 
Cation-exchange HPLC hemoglobin pattern A2FA seen in homozygous β+-thalassemia and compound 
heterozygous β+/βO-thalassemia (HbAo: 24.6%, HbF: 68.5%, HbA2: 3.9%).
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4.3.3 Compound heterozygous βO/β+-thalassemia
Patients with compound heterozygous βO/β+-thalassemia always have 
severe disease and may require blood transfusion. Thus, they are classified as 
TDT. Hemoglobin patterns by cation-exchange HPLC of transfused and non-
transfused cases is A2FA, being similar to homozygous β+-thalassemia (Figure 12). 
However, the compound heterozygous βO/β+-thalassemia has thalassemic red 
blood cell morphology like homozygous βO-thalassemia. In contrast, red blood cell 
morphology of homozygous β+-thalassemia is less abnormal than the other two 
β-thalassemia mentioned above.
Hb patterns by the cation-exchange HPLC of adult HbE disease also comprise 
several varieties depending on combination of βE mutation.
4.3.4 Homozygous HbE
Homozygous HbE (βE/βE) is the mild form of β-thalassemia disease. The 
patients usually have good clinical symptom with only mild anemia with no need 
of blood transfusion. Thus, cation-exchange HPLC always shows HbE as major 
hemoglobin and HbF as the minor hemoglobin; that is, EF (Figure 13). Sometime, 
this hemoglobin type of EF may be confused with that of HbE/βO-thalassemia 
as HbF in some cases of the later condition may be as low as 4.5% [70] and 2.1% 
[19]. This low level of HbF may overlap with that seen in homozygous HbE 
(4.3 ± 2.66%) [19]. Again, red blood cell morphology will help identify if the case 
is homozygous HbE or the HbE/βO-thalassemia. Red blood cell morphology on 
Figure 13. 
Hemoglobin pattern by cation-exchange HPLC of homozygous HbE in adults. The major peak contains HbE 
plus HbA2, but it is labeled A2 by software. Thus, level of HbE plus HbA2 in this case is 77.3, and that of HbF is 
1.7%. This case has no HbA, but the software mislabeled the HbA1 fraction as Ao.
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blood smear stained with Wright-Giemsa stain is totally different between homo-
zygous HbE and HbE/βO-thalassemia. In homozygous HbE, mild change of red 
blood cell morphology with considerable amount of target cells is usually observed. 
In contrast, thalassemia type of red blood cell morphology is typical for the HbE/
βO-thalassemia.
4.3.5 Compound heterozygous βE and βO-thalassemia
Individuals with compound heterozygote of βE and βO-thalassemia are always 
affected by the thalassemia disease and some require blood transfusion. Therefore, 
the hemoglobin patterns by cation-exchange HPLC of this case will be EF 
(61.2 ± 13.6% HbE, 31.1 ± 14.5% HbF) prior to blood transfusion [19] and EFA after 
recent blood transfusion (Figure 14).
4.3.6 Compound heterozygous βE and β+-thalassemia
Individuals with compound heterozygote of βE and β+-thalassemia have mild 
clinical symptoms and classified as NTDT. Therefore, interference of transfused 
blood is not possible. The cation-exchange HPLC pattern of hemoglobin in this case 
should be EFA. This is because some β-globin chains are still produced.
4.3.7 Double form of HbE carrier and HbH disease
This thalassemia syndrome is conventionally termed AEBart’s disease. This is 
a mild form of α-thalassemia syndrome, and blood transfusion is not required. 
Thus, transfused blood would not also interfere result reading in this situation. 
Hemoglobins A, E (with A2), Bart’s are always seen under the cation-exchange 
HPLC (Figure 15). This is why it is called AEBart’s disease.
4.3.8 Double form of HbE homozygote and HbH disease
This is also a mild form of α-thalassemia disease that shows hemoglobins 
E, F, and Bart’s in the cation-exchange HPLC. It is thus called EFBart’s disease. 
By running the cation-exchange HPLC, Hbs E, F, and Bart’s are always seen in 
the  chromatogram.
Figure 14. 
Hemoglobin pattern in cation-exchange HPLC of cases with HbE/βO-thalassemia (F 53.1%, E 35.8%).
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This is also a mild form of α-thalassemia disease that shows hemoglobins 
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4.3.9 Double form of HbE/βO-thalassemia and HbH disease
This is a rare form of thalassemia syndrome. On running in the cation-exchange 
HPLC, EFBart’s pattern of hemoglobin is also seen, being similar to the double form 
of homozygous HbE and HbH disease. Red blood cell morphology on blood smear 
may help differentiate these two conditions, but skillful personnels are needed to 
examine red blood cell morphology. However, DNA analysis in the only technique 
that can correctly differentiate this EFBart’s syndrome.
5. Hemoglobin study by capillary zone electrophoresis (CZE)
Capillary zone electrophoresis (CZE) has been introduced for use as a tool for 
analysis of hemoglobin variants [23–27, 71]. Conventionally, separation of hemo-
globin is performed in alkaline condition, in which HbH has the maximum molecu-
lar negative charge, followed, respectively, by Hb Bart’s, HbA, HbF, HbsA2/E, 
and Hb Constant Spring. The separation is based on high voltage (7500 V) and 
electro-endo-osmotic force (EOF). Hemoglobins are forced in the system to move 
from anode to cathode with the cuvette placed at the cathodic end. Once hemoglo-
bin band moves into the cuvette, the 415-nm absorbance is measured and the light 
signals are converted by the software to electropherogram. Each hemoglobin has 
its own location or zone in the electropherogram, HbCS-zone 2: Z(C), HbA2-zone 
3: Z(A2), HbE-zone 4: Z(E), HbF-zone 7: Z(F), HbA-zone 9: Z (A), Hb Bart’s – 
zone 12, and Hb H – zone 15. HbE and HbA2 are clearly separated by this system 
(Figures 16 and 17).
5.1 The CZE pattern of β-thalassemia carriers and HbE carriers
In β-thalassemia carrier at adult life, the CZE pattern of hemoglobin is similar to 
that obtained from cation-exchange HPLC. The normal hemoglobin typing result 
of A2A or A2FA with HbA2 levels of more than 3.5% (5.4 ± 0.5%) and HbF levels of 
less than 2% (0.9 ± 1.4%) are always observed [27] (Figure 18).
In HbE carrier of adult life, the hemoglobin pattern of CZE is different from 
that of cation-exchange HPLC. HbE and HbA2 co-eluted in the cation-exchange 
HPLC. In CZE, HbE moves behind HbA2. Thus, hemoglobin pattern of HbE carrier 
Figure 15. 
Cation-exchange HPLC of hemoglobin component in AEBart’s disease. HbE: 13.5%, HbA0: 71.8%, Hb Bart’s 
(no numeric proportion as the analysis software was not designed for Hb Bart’s quantification).
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in CZE should be A2EFA. The percentage of these hemoglobins is as follows: HbA2: 
3.5 ± 0.4%, HbE: 25.6 ± 1.4%, and HbF: 0.4 ± 0.8% [27]. HbE level in the CZE sys-
tem is usually lower than that obtained from cation-exchange HPLC (27.8 ± 7.5%). 
This is due to the fact that the level of HbE from HPLC is the sum of HbE and HbA2 
that are co-eluted, while only HbE is reported in the CZE system. Thus, performers 
must be careful in reporting HbE. HbA2 level is slightly elevated. This confirms that 
HbE carrier also acts as mild β-thalassemia carrier (Figure 19).
5.2 The CZE pattern in β-thalassemia disease and HbE disease
CZE pattern of hemoglobins in β-thalassemia disease in adults depends on types of 
the disease. Although, principles of separation are different, the patterns of hemoglobin 
Figure 16. 
CZE electropherogram of normal human hemoglobins. HbA: 94.3%, HbF: 2.4%, HbA2: 3.3%.
Figure 17. 
CZE pattern of hemoglobins from zone (Z) 1 to zone (Z) 15.
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in CZE should be A2EFA. The percentage of these hemoglobins is as follows: HbA2: 
3.5 ± 0.4%, HbE: 25.6 ± 1.4%, and HbF: 0.4 ± 0.8% [27]. HbE level in the CZE sys-
tem is usually lower than that obtained from cation-exchange HPLC (27.8 ± 7.5%). 
This is due to the fact that the level of HbE from HPLC is the sum of HbE and HbA2 
that are co-eluted, while only HbE is reported in the CZE system. Thus, performers 
must be careful in reporting HbE. HbA2 level is slightly elevated. This confirms that 
HbE carrier also acts as mild β-thalassemia carrier (Figure 19).
5.2 The CZE pattern in β-thalassemia disease and HbE disease
CZE pattern of hemoglobins in β-thalassemia disease in adults depends on types of 
the disease. Although, principles of separation are different, the patterns of hemoglobin 
Figure 16. 
CZE electropherogram of normal human hemoglobins. HbA: 94.3%, HbF: 2.4%, HbA2: 3.3%.
Figure 17. 




CZE pattern of hemoglobin of HbE carrier.
Figure 18. 
CZE pattern of hemoglobins of β-thalassemia carrier.
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in β-thalassemia disease and HbE disease obtained from CZE are quite similar to those 
obtained from cation-exchange HPLC. For homozygous βO-thalassemia, A2F is the 
typical hemoglobin typing results. For homozygous β+-thalassemia and compound 
heterozygous β+/βO-thalassemia, the A2FA is generally seen in CZE platform.
CZE patterns of hemoglobins in HbE disease in adults also depend on types of 
the diseases. However, as HbE and HbA2 are clearly separated in the CZE platform, 
these two hemoglobins must be separately reported. For example, in HbE/βO-
thalassemia, for example, A2EF must be reported together with the proportion of 
each hemoglobin (Figure 20).
6. Hemoglobin study by monoclonal antibody
Thalassemia and hemoglobinopathies can be identified accurately by using 
monoclonal antibodies (mAbs) against human hemoglobins [72, 73]. Application 
of mAb-based protocols aims primarily to identify the carriers of thalassemia and 
hemoglobinopathies. For instance, α-thalassemia carrier can be detected by using 
mAbs against Hb Bart’s [29] and HbH [74]. Immunochromatographic strip test 
utilizing mAb to Hb Bart’s was produced and successfully applied for screening 
α-thalassemia carriers [32, 75].
Figure 20. 
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in β-thalassemia disease and HbE disease obtained from CZE are quite similar to those 
obtained from cation-exchange HPLC. For homozygous βO-thalassemia, A2F is the 
typical hemoglobin typing results. For homozygous β+-thalassemia and compound 
heterozygous β+/βO-thalassemia, the A2FA is generally seen in CZE platform.
CZE patterns of hemoglobins in HbE disease in adults also depend on types of 
the diseases. However, as HbE and HbA2 are clearly separated in the CZE platform, 
these two hemoglobins must be separately reported. For example, in HbE/βO-
thalassemia, for example, A2EF must be reported together with the proportion of 
each hemoglobin (Figure 20).
6. Hemoglobin study by monoclonal antibody
Thalassemia and hemoglobinopathies can be identified accurately by using 
monoclonal antibodies (mAbs) against human hemoglobins [72, 73]. Application 
of mAb-based protocols aims primarily to identify the carriers of thalassemia and 
hemoglobinopathies. For instance, α-thalassemia carrier can be detected by using 
mAbs against Hb Bart’s [29] and HbH [74]. Immunochromatographic strip test 
utilizing mAb to Hb Bart’s was produced and successfully applied for screening 
α-thalassemia carriers [32, 75].
Figure 20. 




The β-thalassemia carrier can also be identified by using antigen-antibody 
reaction. Since elevated HbA2 level has been shown to be diagnostic marker of the 
β-thalassemia carrier, mAbs against δ-globin chain of HbA2 were produced and 
ELISA set up to quantify HbA2 levels by Shyamala et al. [76]. Using this ELISA, 
Shyamala found mean value of HbA2 in normal and β-thalassemia carrier to be 2.5 
and 5.4%, respectively. The mAb against HbA2 was also produced and sandwich 
ELISA developed in the author’s laboratory [30]. Under this developed sandwich 
ELISA, Kuntaruk found that the levels of HbA2 between normal and β-thalassemia 
carrier were also significantly different (Figure 21). Thus, the β-thalassemia car-
rier can be identified by the sandwich ELISA to quantify HbA2 level.
7. DNA analysis for β-thalassemia and HbE
Analysis of mutations in β-globin gene to identify β-thalassemia and HbE 
is now performed routinely in most laboratories. The finding of the causative 
point mutations in the β-globin gene provides definite diagnosis of these disor-
ders. More than 900 point mutations have been reported for β-thalassemia and 
β-hemoglobinopathies (Globin Gene Server: http://globin.cse.psu.edu/). Certain 
ethic groups have their own pattern of point mutations of β-globin gene [2, 4, 77, 78].
There are several allele-specific PCR protocols for detecting both carrier and 
disease state of β-thalassemia and HbE. These include mutagenically separated 
(MS)-PCR [35] and amplification refractory mutation system (ARMS)-PCR [79]. 
These two protocols were modified and adapted in author’s laboratory. Another 
allele-specific PCR protocol was established in the author’s laboratory and named 
“Multiplex Allele-Specific (MAS)-PCR” [29].
7.1 Identification of β-thalassemia and HbE by MS-PCR
The MS-PCR was used to detect β-globin gene mutations by several centers. 
In author’s laboratory, this PCR protocol was modified and adapted to identify 
Figure 21. 
HbA2 levels determined by sandwich ELISA set up in the author’s laboratory. Note that HbA2 levels in 
β-thalassemia trait are higher than those in normal, HbE trait, homozygous HbE, and suspected α-thalassemia 
trait (modified from [30]).
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the β-globin gene mutations commonly found in Thai individuals. These included 
TTCT deletion or 4 bp-deletion at codons 41/42 (β41/42) and A > T substitution 
at codon 17 (β17) of β-globin gene [80]. These two mutations have been shown to 
account for approximately 67.5% in Thais by author’s survey [29] and 83.9% by 
others’ studies [81]. The MS-PCR was performed in the author’s laboratory under 
the protocol described previously.
7.1.1 MS-PCR for β 41/42 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β41/42; 5′-TCA TTC GTC TGT CCA TTC TAA AC-3′, 150 ng of “Normal 
primer” for β41/42; 5′-TTC CCA CCA TTA GGC TGC TGG TGG TCT ACC CTT GGA 
CCC AGA GGT TCT T-3′, 250 ng of “Mutant primer” for β41/42; 5′-ACC CTT GGA 
CCC AGA GGT TGA G-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 324 and 351 bp indicate presence and 
absence of the β41/42 mutation, respectively (Figure 22).
Interpretation: Samples having only 324-bp amplified fragments are homozy-
gote for β41/42 with genotype β41/42/β41/42. Samples having only 351-bp fragments are 
negative for the β41/42 with genotype βA/βA or βT/βT (A represents HbA; T represents 
other types of β-globin gene mutation). Samples having both 324 and 351-bp 
amplified products are heterozygote for the β41/42 with genotype of either β41/42/βA or 
β41/42/βT (A represents HbA; T represents other types of β-globin gene mutation).
7.1.2 MS-PCR for β17 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β17; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 150 ng of “Normal 
Figure 22. 
MS-PCR for detecting β41/42 mutation. Lanes 1 and 3 are negative for the β41/42 mutations as only 351-bp 
amplified products are seen. Lanes 2, 4, and 5 are heterozygote for the β41/42 mutation as both 3510 and 324-bp 
amplified products are seen.
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The β-thalassemia carrier can also be identified by using antigen-antibody 
reaction. Since elevated HbA2 level has been shown to be diagnostic marker of the 
β-thalassemia carrier, mAbs against δ-globin chain of HbA2 were produced and 
ELISA set up to quantify HbA2 levels by Shyamala et al. [76]. Using this ELISA, 
Shyamala found mean value of HbA2 in normal and β-thalassemia carrier to be 2.5 
and 5.4%, respectively. The mAb against HbA2 was also produced and sandwich 
ELISA developed in the author’s laboratory [30]. Under this developed sandwich 
ELISA, Kuntaruk found that the levels of HbA2 between normal and β-thalassemia 
carrier were also significantly different (Figure 21). Thus, the β-thalassemia car-
rier can be identified by the sandwich ELISA to quantify HbA2 level.
7. DNA analysis for β-thalassemia and HbE
Analysis of mutations in β-globin gene to identify β-thalassemia and HbE 
is now performed routinely in most laboratories. The finding of the causative 
point mutations in the β-globin gene provides definite diagnosis of these disor-
ders. More than 900 point mutations have been reported for β-thalassemia and 
β-hemoglobinopathies (Globin Gene Server: http://globin.cse.psu.edu/). Certain 
ethic groups have their own pattern of point mutations of β-globin gene [2, 4, 77, 78].
There are several allele-specific PCR protocols for detecting both carrier and 
disease state of β-thalassemia and HbE. These include mutagenically separated 
(MS)-PCR [35] and amplification refractory mutation system (ARMS)-PCR [79]. 
These two protocols were modified and adapted in author’s laboratory. Another 
allele-specific PCR protocol was established in the author’s laboratory and named 
“Multiplex Allele-Specific (MAS)-PCR” [29].
7.1 Identification of β-thalassemia and HbE by MS-PCR
The MS-PCR was used to detect β-globin gene mutations by several centers. 
In author’s laboratory, this PCR protocol was modified and adapted to identify 
Figure 21. 
HbA2 levels determined by sandwich ELISA set up in the author’s laboratory. Note that HbA2 levels in 
β-thalassemia trait are higher than those in normal, HbE trait, homozygous HbE, and suspected α-thalassemia 
trait (modified from [30]).
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the β-globin gene mutations commonly found in Thai individuals. These included 
TTCT deletion or 4 bp-deletion at codons 41/42 (β41/42) and A > T substitution 
at codon 17 (β17) of β-globin gene [80]. These two mutations have been shown to 
account for approximately 67.5% in Thais by author’s survey [29] and 83.9% by 
others’ studies [81]. The MS-PCR was performed in the author’s laboratory under 
the protocol described previously.
7.1.1 MS-PCR for β 41/42 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β41/42; 5′-TCA TTC GTC TGT CCA TTC TAA AC-3′, 150 ng of “Normal 
primer” for β41/42; 5′-TTC CCA CCA TTA GGC TGC TGG TGG TCT ACC CTT GGA 
CCC AGA GGT TCT T-3′, 250 ng of “Mutant primer” for β41/42; 5′-ACC CTT GGA 
CCC AGA GGT TGA G-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 324 and 351 bp indicate presence and 
absence of the β41/42 mutation, respectively (Figure 22).
Interpretation: Samples having only 324-bp amplified fragments are homozy-
gote for β41/42 with genotype β41/42/β41/42. Samples having only 351-bp fragments are 
negative for the β41/42 with genotype βA/βA or βT/βT (A represents HbA; T represents 
other types of β-globin gene mutation). Samples having both 324 and 351-bp 
amplified products are heterozygote for the β41/42 with genotype of either β41/42/βA or 
β41/42/βT (A represents HbA; T represents other types of β-globin gene mutation).
7.1.2 MS-PCR for β17 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β17; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 150 ng of “Normal 
Figure 22. 
MS-PCR for detecting β41/42 mutation. Lanes 1 and 3 are negative for the β41/42 mutations as only 351-bp 
amplified products are seen. Lanes 2, 4, and 5 are heterozygote for the β41/42 mutation as both 3510 and 324-bp 
amplified products are seen.
Beta Thalassemia
148
primer” for β17; 5′-ACC TGA CTC CTG AGG AGA AGA CTG CCG TTA CTG CCC 
TGT GGG ACA-3′, 100 ng of “Mutant primer” for β17; 5′-TCT GCC GTT ACT GCC 
CTG TGG CAC-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 59°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 170 and 190 bp indicate presence and 
absence of the β17 mutation, respectively (Figure 23).
Interpretation: Samples having only 170-bp amplified fragments are homozy-
gote for β17 with genotype β17/β17. Samples having only 190-bp fragments are nega-
tive for the β17 with genotype βA/βA or βT/βT (A represents HbA; T represents other 
types of β-globin gene mutation). Samples having both 170 and 190-bp amplified 
products are heterozygote for the β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation).
7.1.3 MS-PCR for βE mutation or HbE
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common primer” 
for βE; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 100 ng of “Normal primer” for 
βE; 5′-CGT GGA TGA AGT TGG TGG AG-3′, 150 ng of “Mutant primer” for βE; 
5′-CTG CCC TGT GGG CAA GGT GAA CGT GGA TGA AGT TGG TGG AA-3′, 
10 mM Tris pH 8.8; 50 mM KCl and 1.25 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 160 and 138 bp indicate presence and 
absence of the βE mutation, respectively (Figure 24).
Interpretation: Samples having only 160-bp amplified fragments are homozy-
gote for βE with genotype βE/βE. Samples having only 138-bp fragments are negative 
for the βE with genotype βA/βA or βT/βT (A represents HbA; T represents other types 
Figure 23. 
MS-PCR for identifying β17 mutation. Lanes 4, 5, 6, and 8 are negative for the β17 mutation as only 190-bp 
amplified products are seen. Lanes 7 is homozygote for the β17 mutation as only 170-bp amplified products is seen. 
Lanes 1, 2, and 3 are heterozygote for the β17 mutation since both 170 and 190-bp amplified products are seen.
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of β-globin gene mutation). Samples having both 138 and 160-bp amplified prod-
ucts are heterozygote for the βE with genotype of either βE/βA or βE/βT (A represents 
HbA; T represents other types of β-globin gene mutation).
8. Identification of β-thalassemia and HbE by ARMS-PCR
ARMS-PCR was established by Old et al. [79]. This technique also uses three oli-
gonucleotide primers. However, the length of normal and mutant primers is similar. 
Therefore, size of normal and mutant amplified products is the same and cannot be 
separated in the agarose gel electrophoresis. Thus, two PCRs must be performed in 
the ARMS-PCR. Both PCRs have the same ingredients, except normal and mutant 
oligonucleotide primers are added in separated reaction tubes (M and N-tube). In 
addition, a pair of oligonucleotide primers specific to other gene must also be added 
into both PCRs. The amplified products obtained by this pair of primers are the 
internal control for the ARMS-PCR.
8.1 ARMS-PCR for β41/42
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. Both 
M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 0.6 units 
Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA GCC 
AC-3′, 0.15 μM of “M41/42 primer”; 5′-GAG TGG ACA GAT CCC CAA AGG ACT 
CAA CCT−3′ (for M-reaction only), 0.15 μM of “N41/42 primer”; 5′-GAG TGG ACA 
GAT CCC CAA AGG ACT CAA AGA-3′ (for N-reaction only), 0.2 μM of “P1 primer”; 
5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT CCC TGA 
GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated 
in 2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with 
a UV-transilluminator. The fragments sizing 439 bp is the specific amplified  products, 
and the PCR products sizing 314 bp are the control products (Figure 25).
Figure 24. 
MS-PCR for identifying βE mutation. Lane 1 is negative for the βE mutation as only 138-bp amplified products 
is seen. Lane 2 is heterozygote for βE mutation as both 138-bp and 160-bp amplified products are seen.
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primer” for β17; 5′-ACC TGA CTC CTG AGG AGA AGA CTG CCG TTA CTG CCC 
TGT GGG ACA-3′, 100 ng of “Mutant primer” for β17; 5′-TCT GCC GTT ACT GCC 
CTG TGG CAC-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 59°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 170 and 190 bp indicate presence and 
absence of the β17 mutation, respectively (Figure 23).
Interpretation: Samples having only 170-bp amplified fragments are homozy-
gote for β17 with genotype β17/β17. Samples having only 190-bp fragments are nega-
tive for the β17 with genotype βA/βA or βT/βT (A represents HbA; T represents other 
types of β-globin gene mutation). Samples having both 170 and 190-bp amplified 
products are heterozygote for the β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation).
7.1.3 MS-PCR for βE mutation or HbE
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common primer” 
for βE; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 100 ng of “Normal primer” for 
βE; 5′-CGT GGA TGA AGT TGG TGG AG-3′, 150 ng of “Mutant primer” for βE; 
5′-CTG CCC TGT GGG CAA GGT GAA CGT GGA TGA AGT TGG TGG AA-3′, 
10 mM Tris pH 8.8; 50 mM KCl and 1.25 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 160 and 138 bp indicate presence and 
absence of the βE mutation, respectively (Figure 24).
Interpretation: Samples having only 160-bp amplified fragments are homozy-
gote for βE with genotype βE/βE. Samples having only 138-bp fragments are negative 
for the βE with genotype βA/βA or βT/βT (A represents HbA; T represents other types 
Figure 23. 
MS-PCR for identifying β17 mutation. Lanes 4, 5, 6, and 8 are negative for the β17 mutation as only 190-bp 
amplified products are seen. Lanes 7 is homozygote for the β17 mutation as only 170-bp amplified products is seen. 
Lanes 1, 2, and 3 are heterozygote for the β17 mutation since both 170 and 190-bp amplified products are seen.
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of β-globin gene mutation). Samples having both 138 and 160-bp amplified prod-
ucts are heterozygote for the βE with genotype of either βE/βA or βE/βT (A represents 
HbA; T represents other types of β-globin gene mutation).
8. Identification of β-thalassemia and HbE by ARMS-PCR
ARMS-PCR was established by Old et al. [79]. This technique also uses three oli-
gonucleotide primers. However, the length of normal and mutant primers is similar. 
Therefore, size of normal and mutant amplified products is the same and cannot be 
separated in the agarose gel electrophoresis. Thus, two PCRs must be performed in 
the ARMS-PCR. Both PCRs have the same ingredients, except normal and mutant 
oligonucleotide primers are added in separated reaction tubes (M and N-tube). In 
addition, a pair of oligonucleotide primers specific to other gene must also be added 
into both PCRs. The amplified products obtained by this pair of primers are the 
internal control for the ARMS-PCR.
8.1 ARMS-PCR for β41/42
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. Both 
M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 0.6 units 
Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA GCC 
AC-3′, 0.15 μM of “M41/42 primer”; 5′-GAG TGG ACA GAT CCC CAA AGG ACT 
CAA CCT−3′ (for M-reaction only), 0.15 μM of “N41/42 primer”; 5′-GAG TGG ACA 
GAT CCC CAA AGG ACT CAA AGA-3′ (for N-reaction only), 0.2 μM of “P1 primer”; 
5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT CCC TGA 
GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated 
in 2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with 
a UV-transilluminator. The fragments sizing 439 bp is the specific amplified  products, 
and the PCR products sizing 314 bp are the control products (Figure 25).
Figure 24. 
MS-PCR for identifying βE mutation. Lane 1 is negative for the βE mutation as only 138-bp amplified products 
is seen. Lane 2 is heterozygote for βE mutation as both 138-bp and 160-bp amplified products are seen.
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Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. It both M and N-reactions have 439-bp PCR products, 
the samples are heterozygote for β41/42 with genotype of either β41/42/βA or β41/42/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 439-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β41/42 with 
genotype β41/42/β41/42. If samples have the 439-bp PCR products in only N-reaction, 
the samples are negative for the β41/42 with genotypes of either βA/βA or βT/βT (A 
represents HbA; T represents other types of β-globin gene mutation) (Figure 25).
8.2 ARMS-PCR for β17
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “M17 primer”; 5′-CTC ACC ACC AAC TCA GCC ACG 
TTC AGC ATA-3′ (for M-reaction only), 0.15 μM of “N17 primer”; 5′-CTC ACC 
ACC AAC TTC ATC CAC GTT CAC ATT-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM 
of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 239 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 26).
Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 239-bp PCR products, 
the samples are heterozygote for β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 239-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β17 with 
genotype β17/β17. If samples have the 239-bp PCR products in only N-reaction, the 
samples are negative for the β17 with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 26).
Figure 25. 
ARMS-PCR for identifying the β41/42 mutation. The 314-bp amplified products are internal control. The 
439-bp amplified products are the β41/42 specific products. Sample #1 is homozygote for β41/42 mutation as the 
439-pb amplified products are seen in only “M-reaction.” Sample #3 is negative for the β41/42 mutation since 
the 439-bp amplified products are seen in only “N-reaction.” Sample #2 is heterozygote for the β41/42 mutation 
since the 439-bp amplified products are seen in both “M-reaction” and “N-reaction.”
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8.3 ARMS-PCR for βE
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “HbE-M primer”; 5′-TAA CCT TGA TAC CAA CCT GCC 
CAG GGC GTT-3′ (for M-reaction only), 0.15 μM of “HbE-N primer”; 5′-TAA CCT 
TGA TAC CAA CCT GCC CAG GGC GTC-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of 
MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 260 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 27).
Figure 26. 
ARMS-PCR for identifying the β17 mutation. The 314-bp amplified products are internal control. The 239-bp 
amplified products are the β17 specific products. Sample #1 is homozygote for β17 mutation as the 239-pb amplified 
products are seen in only “M-reaction.” Sample #3 is negative for the β17 mutation since the 239-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the β17 mutation since the 239-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
Figure 27. 
ARMS-PCR for identifying βE mutation. The 314-bp amplified products are internal control. The 260-bp 
amplified products are the βE specific products. Sample #3 is homozygote for βE mutation as the 260-pb amplified 
products are seen in only “M-reaction.” Sample #1 is negative for the βE mutation since the 260-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the βE mutation since the 260-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
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Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. It both M and N-reactions have 439-bp PCR products, 
the samples are heterozygote for β41/42 with genotype of either β41/42/βA or β41/42/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 439-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β41/42 with 
genotype β41/42/β41/42. If samples have the 439-bp PCR products in only N-reaction, 
the samples are negative for the β41/42 with genotypes of either βA/βA or βT/βT (A 
represents HbA; T represents other types of β-globin gene mutation) (Figure 25).
8.2 ARMS-PCR for β17
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “M17 primer”; 5′-CTC ACC ACC AAC TCA GCC ACG 
TTC AGC ATA-3′ (for M-reaction only), 0.15 μM of “N17 primer”; 5′-CTC ACC 
ACC AAC TTC ATC CAC GTT CAC ATT-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM 
of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 239 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 26).
Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 239-bp PCR products, 
the samples are heterozygote for β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 239-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β17 with 
genotype β17/β17. If samples have the 239-bp PCR products in only N-reaction, the 
samples are negative for the β17 with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 26).
Figure 25. 
ARMS-PCR for identifying the β41/42 mutation. The 314-bp amplified products are internal control. The 
439-bp amplified products are the β41/42 specific products. Sample #1 is homozygote for β41/42 mutation as the 
439-pb amplified products are seen in only “M-reaction.” Sample #3 is negative for the β41/42 mutation since 
the 439-bp amplified products are seen in only “N-reaction.” Sample #2 is heterozygote for the β41/42 mutation 
since the 439-bp amplified products are seen in both “M-reaction” and “N-reaction.”
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8.3 ARMS-PCR for βE
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “HbE-M primer”; 5′-TAA CCT TGA TAC CAA CCT GCC 
CAG GGC GTT-3′ (for M-reaction only), 0.15 μM of “HbE-N primer”; 5′-TAA CCT 
TGA TAC CAA CCT GCC CAG GGC GTC-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of 
MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 260 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 27).
Figure 26. 
ARMS-PCR for identifying the β17 mutation. The 314-bp amplified products are internal control. The 239-bp 
amplified products are the β17 specific products. Sample #1 is homozygote for β17 mutation as the 239-pb amplified 
products are seen in only “M-reaction.” Sample #3 is negative for the β17 mutation since the 239-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the β17 mutation since the 239-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
Figure 27. 
ARMS-PCR for identifying βE mutation. The 314-bp amplified products are internal control. The 260-bp 
amplified products are the βE specific products. Sample #3 is homozygote for βE mutation as the 260-pb amplified 
products are seen in only “M-reaction.” Sample #1 is negative for the βE mutation since the 260-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the βE mutation since the 260-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
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Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 260-bp PCR products, 
the samples are heterozygote for βE with genotype of either βE/βA or βE/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 260-bp 
PCR products are seen in only M-reaction, the samples are homozygote for βE with 
genotype βE/βE. If samples have the 260-bp PCR products in only N-reaction, the 
samples are negative for the βE with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 27).
9. Identification of β-thalassemia and HbE by MAS-PCR
This PCR technique was established by author and named multiplex allele spe-
cific (MAS)-PCR [29]. MAS was intended to be used for identifying βThalassemia and 
βE-mutations in samples that have already been diagnosed to be β-thalassemia carrier, 
HbE carrier, and SEA-α thalassemia 1 carrier. Therefore, only mutant primers are put 
together in this MAS-PCR. However, the internal control of this PCR protocol is the 
amplified products generated by the normal pair of primers for α-globin gene cluster.
Procedure: The PCR was performed in a total volume of 25 μL containing 
1.1–1.4 ng genomic DNA, 140 μM dNTPs, 0.1 unit/μL of DNA polymerase, 0.25 ng/
μL “Beta-common-multiplex” primer (5′-AAG AGC CAA GGA CAG GTA CGG 
CTG T-3′), 0.125 ng/μL “Beta-17-multiplex” primer (5′-CCA ACT TCA TCC ACG 
TTC ACG TA-3′), 0.125 ng/μL “Beta cds-41/42-multiplex” primer (5′-AGA TCC 
CCA AAG GAC TCA ACC T-3′), 0.125 ng/μL “Beta-E-multiplex” primer (5′-CGT 
ACC AAC CTG CCC AGG GCC AT-3′), 25 ng/μL “SEA-1-multiplex” primer (5′-
TGA CTC CAA TAA ATG GAT GAG GA-3′), 0.25 ng/μL “SEA-2-multiplex” primer 
(5′-GCC TGC GCC GGG GAA CGT AAC CA-3′)and 0.5 ng/μL “SEA-3-multiplex” 
primer (5′-CGC CAA AGA TGG CTA CTC GGA GA-3′) in 10 mM Tris-HCl 
(pH 8.8), 50 mM KCl, 2.0% DMSO and 2.0 mM MgCl2.
Thermal cycles: A total of 37 thermal cycles were carried out with each cycle 
comprising denaturation at 95°C for 1 min, primer annealing at 62°C for 30 s, and 
primer extension at 72°C for 30 s. Initial denaturation was extended to 5 min and 
final extension was prolonged to 7 min.
Detection of amplified products: The PCR products were separated via 
2.0% agarose gel electrophoresis and visualized by the UV-transilluminator 
(Figure 28).
Figure 28. 
MAS-PCR for identifying β-thalassemia mutation, βE-mutation, and SEA-α thalassemia 1 mutation. The 
653-bp amplified products are the internal control generated by the α-globin gene cluster specific oligonucleotide 
primers. Lanes 1–5 are positive for βE mutation as the 293-bp amplified products are seen. Lane 6 is positive for 
both SEA-α thalassemia 1 and βE mutations as both 753-bp amplified products and 293-bp amplified products 
are seen. Lane 7 is positive for both SEA-α thalassemia 1 and β17 mutation as both 753-bp amplified products 
and 268-bp amplified products are seen. Finally, lane 8 is positive for SEA-α thalassemia 1 and β41/42 mutation 
as both 753-bp amplified products and 466-bp amplified products are seen (modified from [82]).
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Interpretation: All reactions must have the 653-bp control products. Presence of 753-
bp product indicates presence of the SEA-α thalassemia 1. Presence of the 466-bp, 293-
bp, and 268-bp products indicates presence of β41/42, βE, and β17, respectively (Figure 28).
10. Pitfalls in laboratory diagnosis of β-thalassemia and HbE
There are several pitfalls to be concerned when using laboratory data in diagno-
sis of β-thalassemia and HbE. The pitfalls are in both screening and confirmatory 
steps of laboratory diagnosis.
HbE tube test relies on concentration of NaCl. Therefore, exact amount of NaCl 
in the reagent must be prepared following the suggested ingredient. False positive 
results will be obtained if NaCl concentration is too high, and vice versa.
HbE screen test relies on pH-based microcolumn chromatography. Therefore, 
exact pH of buffer in the test kit must also be prepared. Too high pH causes falsely 
negative results and vice versa.
10.1 Pitfalls in screening tests for β-thalassemia and HbE carriers
1. Pitfalls in one-tube osmotic fragility test (OFT). The concentration of reagent 
must be exactly 0.36 and 0.45%, otherwise false positive results will be obtained 
if concentration is over 0.36 or over 0.45%. In contrast, false negative results 
will be obtained if concentration is less than 0.36 or 0.45%. Anemic blood sam-
ples will also give positive results. Therefore, Hb/Hct must also be checked if the 
results are positive. Not all HbE carriers have positive OFT results. Therefore, 
blood samples having negative OFT results must also be sent for HbE screen.
2. Pitfalls in MCV and MCH evaluation. MCV/MCH are the numeric data that 
must be obtained from automated blood cell counters that have good quality 
control. MCV must be obtained using fresh blood, but MCH may be obtained 
using 1 week-old blood. MCV is directly measured in automated blood coun-
ter, while MCH is generated by calculation. Thus, if blood samples have high 
degree of variation of red blood cell sizes or anisocytosis, false MCV values 
may be obtained. This situation may be found in β-thalassemia carriers or HbE 
carriers with co-existence iron deficiency anemia during treatment. Not all 
HbE carriers have MCV/MCH values below cutoff points. Therefore, all blood 
samples sent for MCV/MCH determination must also be sent for HbE screen. 
Most importantly, some blood samples may have discordant MCV-OFT results. 
It is then highly recommended to perform both OFT and MCV/MCH for 
screening for β-thalassemia and HbE carriers.
3. Pitfalls in HbE screening test. DCIP test is based on using the oxidizing re-
agent; dichlorophenolindophenol. This reagent can be reduced over long storage 
and the screening results will be falsely negative. Therefore, if color of the DCIP 
reagent turns deeply blue, it should not be used. HbH also denatured in the DCIP 
reagent. Therefore, positive samples must be checked if they are HbH disease.
10.2 Pitfalls in confirmatory tests for β-thalassemia and HbE
Normal hemoglobin type depends on age of the patients. Thus, reading and 
interpreting the hemoglobin typing results by all methodologies, age of the patients 
must be taken into account. In addition, transfused blood interferes the real 
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Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 260-bp PCR products, 
the samples are heterozygote for βE with genotype of either βE/βA or βE/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 260-bp 
PCR products are seen in only M-reaction, the samples are homozygote for βE with 
genotype βE/βE. If samples have the 260-bp PCR products in only N-reaction, the 
samples are negative for the βE with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 27).
9. Identification of β-thalassemia and HbE by MAS-PCR
This PCR technique was established by author and named multiplex allele spe-
cific (MAS)-PCR [29]. MAS was intended to be used for identifying βThalassemia and 
βE-mutations in samples that have already been diagnosed to be β-thalassemia carrier, 
HbE carrier, and SEA-α thalassemia 1 carrier. Therefore, only mutant primers are put 
together in this MAS-PCR. However, the internal control of this PCR protocol is the 
amplified products generated by the normal pair of primers for α-globin gene cluster.
Procedure: The PCR was performed in a total volume of 25 μL containing 
1.1–1.4 ng genomic DNA, 140 μM dNTPs, 0.1 unit/μL of DNA polymerase, 0.25 ng/
μL “Beta-common-multiplex” primer (5′-AAG AGC CAA GGA CAG GTA CGG 
CTG T-3′), 0.125 ng/μL “Beta-17-multiplex” primer (5′-CCA ACT TCA TCC ACG 
TTC ACG TA-3′), 0.125 ng/μL “Beta cds-41/42-multiplex” primer (5′-AGA TCC 
CCA AAG GAC TCA ACC T-3′), 0.125 ng/μL “Beta-E-multiplex” primer (5′-CGT 
ACC AAC CTG CCC AGG GCC AT-3′), 25 ng/μL “SEA-1-multiplex” primer (5′-
TGA CTC CAA TAA ATG GAT GAG GA-3′), 0.25 ng/μL “SEA-2-multiplex” primer 
(5′-GCC TGC GCC GGG GAA CGT AAC CA-3′)and 0.5 ng/μL “SEA-3-multiplex” 
primer (5′-CGC CAA AGA TGG CTA CTC GGA GA-3′) in 10 mM Tris-HCl 
(pH 8.8), 50 mM KCl, 2.0% DMSO and 2.0 mM MgCl2.
Thermal cycles: A total of 37 thermal cycles were carried out with each cycle 
comprising denaturation at 95°C for 1 min, primer annealing at 62°C for 30 s, and 
primer extension at 72°C for 30 s. Initial denaturation was extended to 5 min and 
final extension was prolonged to 7 min.
Detection of amplified products: The PCR products were separated via 
2.0% agarose gel electrophoresis and visualized by the UV-transilluminator 
(Figure 28).
Figure 28. 
MAS-PCR for identifying β-thalassemia mutation, βE-mutation, and SEA-α thalassemia 1 mutation. The 
653-bp amplified products are the internal control generated by the α-globin gene cluster specific oligonucleotide 
primers. Lanes 1–5 are positive for βE mutation as the 293-bp amplified products are seen. Lane 6 is positive for 
both SEA-α thalassemia 1 and βE mutations as both 753-bp amplified products and 293-bp amplified products 
are seen. Lane 7 is positive for both SEA-α thalassemia 1 and β17 mutation as both 753-bp amplified products 
and 268-bp amplified products are seen. Finally, lane 8 is positive for SEA-α thalassemia 1 and β41/42 mutation 
as both 753-bp amplified products and 466-bp amplified products are seen (modified from [82]).
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Interpretation: All reactions must have the 653-bp control products. Presence of 753-
bp product indicates presence of the SEA-α thalassemia 1. Presence of the 466-bp, 293-
bp, and 268-bp products indicates presence of β41/42, βE, and β17, respectively (Figure 28).
10. Pitfalls in laboratory diagnosis of β-thalassemia and HbE
There are several pitfalls to be concerned when using laboratory data in diagno-
sis of β-thalassemia and HbE. The pitfalls are in both screening and confirmatory 
steps of laboratory diagnosis.
HbE tube test relies on concentration of NaCl. Therefore, exact amount of NaCl 
in the reagent must be prepared following the suggested ingredient. False positive 
results will be obtained if NaCl concentration is too high, and vice versa.
HbE screen test relies on pH-based microcolumn chromatography. Therefore, 
exact pH of buffer in the test kit must also be prepared. Too high pH causes falsely 
negative results and vice versa.
10.1 Pitfalls in screening tests for β-thalassemia and HbE carriers
1. Pitfalls in one-tube osmotic fragility test (OFT). The concentration of reagent 
must be exactly 0.36 and 0.45%, otherwise false positive results will be obtained 
if concentration is over 0.36 or over 0.45%. In contrast, false negative results 
will be obtained if concentration is less than 0.36 or 0.45%. Anemic blood sam-
ples will also give positive results. Therefore, Hb/Hct must also be checked if the 
results are positive. Not all HbE carriers have positive OFT results. Therefore, 
blood samples having negative OFT results must also be sent for HbE screen.
2. Pitfalls in MCV and MCH evaluation. MCV/MCH are the numeric data that 
must be obtained from automated blood cell counters that have good quality 
control. MCV must be obtained using fresh blood, but MCH may be obtained 
using 1 week-old blood. MCV is directly measured in automated blood coun-
ter, while MCH is generated by calculation. Thus, if blood samples have high 
degree of variation of red blood cell sizes or anisocytosis, false MCV values 
may be obtained. This situation may be found in β-thalassemia carriers or HbE 
carriers with co-existence iron deficiency anemia during treatment. Not all 
HbE carriers have MCV/MCH values below cutoff points. Therefore, all blood 
samples sent for MCV/MCH determination must also be sent for HbE screen. 
Most importantly, some blood samples may have discordant MCV-OFT results. 
It is then highly recommended to perform both OFT and MCV/MCH for 
screening for β-thalassemia and HbE carriers.
3. Pitfalls in HbE screening test. DCIP test is based on using the oxidizing re-
agent; dichlorophenolindophenol. This reagent can be reduced over long storage 
and the screening results will be falsely negative. Therefore, if color of the DCIP 
reagent turns deeply blue, it should not be used. HbH also denatured in the DCIP 
reagent. Therefore, positive samples must be checked if they are HbH disease.
10.2 Pitfalls in confirmatory tests for β-thalassemia and HbE
Normal hemoglobin type depends on age of the patients. Thus, reading and 
interpreting the hemoglobin typing results by all methodologies, age of the patients 
must be taken into account. In addition, transfused blood interferes the real 
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hemoglobin typing results of the patients. If the patients of β-thalassemia disease 
(βO/βO) have just received blood transfusion, their hemoglobin types will be A2AF, 
instead of A2F which is the real hemoglobin type of the βO/βO. If patients of HbE/
βO-thalassemia (βE/βO) have recent blood transfusion, their hemoglobin types will 
be EFA, instead of EF which is the real hemoglobin type of βO/βE. Therefore, recent 
blood transfusion should always be taken into account when reading and interpret-
ing the hemoglobin typing results.
Co-existence of α-thalassemia 1 in β-thalassemia carrier and in HbE carrier can 
be found some regions. This is called double α-thalassemia 1/β-thalassemia carriers 
and double α-thalassemia 1 and HbE carriers. Results of one-tube osmotic fragility 
test are always positive in double α-thalassemia 1/β-thalassemia carriers, being the 
same as that of the single β-thalassemia carrier. However, MCV/MCH in double 
α-thalassemia 1/β-thalassemia carriers are slightly higher than those in the single 
β-thalassemia carriers (70.7 ± 2.6 vs. 68.4 ± 2.7 for MCV, 21.0 ± 1.2 vs. 20.7 ± 0.9 for 
MCH) [83]. HbA2 level in double α-thalassemia 1/β-thalassemia carriers is lower 
than that in single β-thalassemia carrier (5.27 ± 0.77% vs. 5.65 ± 0.78%) [29]. In 
contrast, the results of one-tube osmotic fragility test of double α-thalassemia 1/
HbE carrier are usually positive, being different from those of single HbE which 
can be either positive or negative. The MCV/MCH in double α-thalassemia 1/
HbE carrier are lower than those of the single HbE carrier (68.7 ± 8.9 fL vs. 
75.7 ± 7.5 fL for MCV, 22.5 ± 3.1 pg vs. 24.9 ± 2.8 pg for MCH). HbE level in double 
α-thalassemia 1/HbE carrier are lower than those of the single HbE carrier 
(22.8 ± 4.4% vs. 27.6 ± 3.3%) [84]. Therefore, if HbE carriers have low HbE levels 
as well as MCV/MCH, further identification of α-thalassemia 1 genotype must 
be done.
11. Conclusions
Diagnosis of β-thalassemia and HbE requires laboratory investigations. 
Screening tests are used to search for carriers, while confirmatory tests are carried 
out in those samples positive for screening tests with the aim to make the definite 
diagnosis. There are several pitfalls in these laboratory tests, both in screening tests 
and confirmatory tests that must not be overlooked, otherwise misdiagnosis will 
occur.
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hemoglobin typing results of the patients. If the patients of β-thalassemia disease 
(βO/βO) have just received blood transfusion, their hemoglobin types will be A2AF, 
instead of A2F which is the real hemoglobin type of the βO/βO. If patients of HbE/
βO-thalassemia (βE/βO) have recent blood transfusion, their hemoglobin types will 
be EFA, instead of EF which is the real hemoglobin type of βO/βE. Therefore, recent 
blood transfusion should always be taken into account when reading and interpret-
ing the hemoglobin typing results.
Co-existence of α-thalassemia 1 in β-thalassemia carrier and in HbE carrier can 
be found some regions. This is called double α-thalassemia 1/β-thalassemia carriers 
and double α-thalassemia 1 and HbE carriers. Results of one-tube osmotic fragility 
test are always positive in double α-thalassemia 1/β-thalassemia carriers, being the 
same as that of the single β-thalassemia carrier. However, MCV/MCH in double 
α-thalassemia 1/β-thalassemia carriers are slightly higher than those in the single 
β-thalassemia carriers (70.7 ± 2.6 vs. 68.4 ± 2.7 for MCV, 21.0 ± 1.2 vs. 20.7 ± 0.9 for 
MCH) [83]. HbA2 level in double α-thalassemia 1/β-thalassemia carriers is lower 
than that in single β-thalassemia carrier (5.27 ± 0.77% vs. 5.65 ± 0.78%) [29]. In 
contrast, the results of one-tube osmotic fragility test of double α-thalassemia 1/
HbE carrier are usually positive, being different from those of single HbE which 
can be either positive or negative. The MCV/MCH in double α-thalassemia 1/
HbE carrier are lower than those of the single HbE carrier (68.7 ± 8.9 fL vs. 
75.7 ± 7.5 fL for MCV, 22.5 ± 3.1 pg vs. 24.9 ± 2.8 pg for MCH). HbE level in double 
α-thalassemia 1/HbE carrier are lower than those of the single HbE carrier 
(22.8 ± 4.4% vs. 27.6 ± 3.3%) [84]. Therefore, if HbE carriers have low HbE levels 
as well as MCV/MCH, further identification of α-thalassemia 1 genotype must 
be done.
11. Conclusions
Diagnosis of β-thalassemia and HbE requires laboratory investigations. 
Screening tests are used to search for carriers, while confirmatory tests are carried 
out in those samples positive for screening tests with the aim to make the definite 
diagnosis. There are several pitfalls in these laboratory tests, both in screening tests 
and confirmatory tests that must not be overlooked, otherwise misdiagnosis will 
occur.
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